Report Catalog

BRAND MANAGEMENT AND PRODUCT LEADERSHIP click to expand contents

Building Winning Trademarks and Trade Name Operations in Biopharma (ID PSM-382)

This benchmarking report distills winning strategies, structures, and approaches to the overall trademark evaluation and registration process at pharmaceutical and biotech companies. It delivers benchmarks that can inform successful trademark naming operations, funding levels, cross-functional participation, global coordination, best structures, winning internal communication strategies, and superior regional understanding.

$3900

Establishing a Promotion Review Editor to Oversee Advertising and Promotion Review Process (ID PSM-373)

This benchmarking report examines the utilization of the Promotion Review Editor role within biopharmaceutical companies. It probes the collaboration approaches, roles and responsibilities, importance and effectiveness of Promotion Review Editor within the company, involvement of Promotion Review Editors in electronic submissions and review process of promotional materials, functional location and reporting of Promotion Review Editors, and number of products supported by them. The report also highlights the best practices and challenges of having the Promotion Review Editor position in a company.

$2000

Patent Protection: How AbbVie Builds Patent Fences to Extend Brand Life and Safeguard HUMIRA and Its Immunology Franchise (ID PSM-371)

Best Practices, LLC conducted extensive secondary research to review how HUMIRA used patent innovations as a source of competitive advantage to add value to its clinical assets and commercial operations. It highlights the lessons learned and winning strategies in HUMIRA’s journey to achieving blockbuster status.

$2500

Strategic Portfolio Planning for Successful New Product and Drug Platform Positioning (ID PSM-365)

Best Practices, LLC conducted “meta-analysis” of 22 of its primary and secondary benchmark studies to inform how drug platforms give rise to tech / MOA-enabled product portfolios and market leading franchises. This report also includes case studies of new product planning and market entry of many successful brands. It spotlights winning strategies, best practices and pitfalls to avoid for successful positioning of new products and drug platforms.

$7500

Maximizing Mature Brands & Assets: Successful Lifecycle Management Strategies, Tactics and Insights (ID PSM-352)

This Best Practices, LLC benchmarking report identifies effective lifecycle management strategies to maximize the potential of mature brands. It provides benchmarks around the time, cost, budget and effectiveness of different lifecycle management strategies. This report also highlights the success factors, lessons learned and barriers to maximizing the potential of a mature brand.

$7500

Best Practices in Global Branding for New Products: Creating an Effective Global Brand for New Products and Ensuring Alignment across Geographies and Affiliates (ID PSM-331)

This study benchmarks the important aspects of the global branding process, including activities, timing, positioning, key message development, regional alignment and the tradename process. It also provides benchmarks around agency utilization & cost, and alignment with affiliates.

$5000

Launching A Specialty-Care Blockbuster Franchise in Hepatitis C: How Sovaldi & Harvoni Rewrote New Product Launch History (ID PSM-322)

This study reviews key aspects of Sovaldi’s launch, including prevalence of Hep C, Sovaldi’s method of action, key aspects of its product launch, results of launch, payers’ reaction to pricing, Gilead’s response to pricing criticism, patent challenges and the entrance of Harvoni.

$2500

Best Practices in Building Your Corporate Value Proposition (ID POP-250)

This study helps corporate leadership understand the importance of a corporate brand. Branding is the strategic process of establishing both the tangible and intangible attributes to differentiate your company and give it focus to consumers and others.

$2900

Best Practices in Expanding a Product Portfolio Without Cannibalizing an Established Pharmaceutical Brand (ID PSM-298)

This study identifies successful strategies and tactics for marketing multiple brands for the same indication or area of use without cannibalizing an existing portfolio. Special attention was given to strategies for managing resources and for avoiding or controlling product cannibalization.

$4400

Best Practices in Expanding a Medical Device Product Portfolio Without Cannibalizing an Established Brand (ID PSM-301)

This study identifies successful strategies and tactics for marketing multiple brands for the same indication or area of use without cannibalizing an existing portfolio. Special attention was given to strategies for managing resources and for avoiding or controlling product cannibalization.

$3900

Best Practices in Launch Optimization: How Promotional Efficiency can be Leveraged to Support Multiple Products & Indications (ID PSM-293)

This study identifies evidence-based benchmarks on the pros and cons of managing multiple products via a franchise approach. The study focused on uncovering proven tactics for efficiently deploying Sales and Marketing resources to reduce the costliness of launching and promoting multiple products simultaneously.

$5260

Lifecycle Management Excellence: High-Performing Strategies Used to Maximize Potential Of Mature Brands (ID PSM-283)

This study is designed to help brand and marketing leaders identify winning lifecycle management (LCM) strategies they can use to extend the commercial life of bio-pharmaceutical products. The study examines ROI and future viability of 20 different LCM strategies. In addition, the research provides insights into which strategies will survive as they are faced with a changing pharmaceutical environment.

$5500

Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products (ID OP-106)

This study identifies the best practices of veteran pharmaceutical executives for all aspects of communicating disease state information within their companies. The study also gives particular attention to communication challenges around products that were first in class or that treat conditions that are largely unknown or stigmatized including HIV, erectile dysfunction, high cholesterol, overactive bladder, restless legs and others.

$7200

Winning Brand Team Management: Best Practices in Leadership, Work Practices, Structure and Performance Management (ID SM-177)

This report identifies how pharmaceutical and biotech companies structure and manage their cross-functional brand teams to facilitate brand performance. The study also examines how brand teams manage their stakeholder relationships and decision rights.

$4115

Brand Equity and Loyalty Through Oncology Marketing (ID PSM-218)

This benchmarking report identifies the key trends and best practices in using the internet as a marketing and value-added service tool for physicians, thought leaders and patients in the oncology marketplace. Specifically, this report will serve as a reference in effectively using websites to market oncology products.

$1185

Pharmaceutical Brand Leadership: Getting There and Staying on Top (ID PSM-210)

This report analyses the factors that enable pharmaceutical brands to reach and sustain brand leadership position. This report will provide marketing and brand leaders with the knowledge of the activities and skillsets that truly make a difference in the journey to market leader position.

$1840

Best Practices in Speaker Training and Development: Driving Pharmaceutical Brand Growth (ID SM-158)

This study reveals how leading companies design effective, competitive training programs, effectively identify potential speakers, optimize the use of speakers, and structure key stakeholder groups to have the greatest impact on speaker training.

$3163

Best Practices in Pharmaceutical Conventions Management (ID SM-159)

This report highlights the best practices of leading companies in optimizing their conventions management functions. In particular, it addresses the logistics of effectively managing conventions with limited budgets.

$1557

Managing Mature Product Promotion (ID PSM-204)

This benchmarking report highlights the best practices and key lessons learned in the management and promotion of mature products.

$908

Developing Trademarks for Brand Success (ID PSM-203)

This benchmarking report delivers successful strategies for pharmaceutical trademark development. In particular, this report highlights the advantages and disadvantages of a number of trademark strategies, meaningful names, use of suffixes and prefixes with names, registration of logos and other brand components, registration of domain names and use of multiple trademarks.

$908

Pharmaceutical Speaker Programs: Building the Business (ID SM-130)

Help sales reps develop strong, rewarding relationships through effective speaker program management. Impact doctor-rep relationships to build customer loyalty and drive market share.

$4219

Best Practices in Managing Public Relations (ID SM-154)

Manage staffing and budgets for your external affairs department, as well as assign proper roles and responsibilities.

$900

BUSINESS COMMUNICATIONS click to expand contents

Evolution of Technology Platforms during the Global COVID-19 Pandemic and Beyond (ID CM-4)

This benchmarking report examines the changes in streamlined virtual technology functionalities and platforms within life sciences companies due to the emergence of the global COVID-19 pandemic. It probes the use of digital communicative and collaborative platforms, frequency and effectiveness of various modes of technology used to support external and internal stakeholder communication, use of new technologies, duration of technology changes, and approach towards dealing with technology changes post COVID-19 crisis.

$995

Changes in Outreach and Communications with Stakeholders during the Global COVID-19 Pandemic (ID CM-1)

This benchmarking report explores how companies are approaching external engagements with stakeholders following the global COVID-19 pandemic. In particular, this report spotlights the implementation of global COVID-19 pandemic task force, external engagement policies and limitations, necessary resources, challenges and issues prevalent due to the global COVID-19 pandemic, response to constraints in travel and visitation, and performance tracking during the global COVID-19 pandemic.

$995

Identifying Superior Corporate Affairs and Corporate Communications Capabilities (ID PSM-347)

This report delivers insights around the capabilities, structures, outsourcing, budgets, effectiveness and key activities for the effective functioning of the Corporate Affairs / Communications function. Additionally, the report identifies the trends or initiatives expected to have a positive impact on the Corporate Affairs / Communications group.

$2400

Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizing Competitive Assessment & Data Disclosure Summaries (ID PSM-318)

This study provides insights into creating effective Market Landscape Summaries, Clinical Development Profile Maps, and other critical executive briefs. It will aid Market Intelligence & Analytics leaders in crafting high-impact landscape assessments that meet the needs of senior leadership.

$3900

Internal Communication Excellence: Engaging Middle Management to Align with Senior Leadership and Energize the Front Line (ID POP-243)

This study highlights the winning approaches, tools, and technologies that help leadership effectively communicate to and through middle management. Specifically, this study measures the effectiveness of different communication message types, channels used, and sending frequencies.

$1950

Internal Communication Success: Best Practices within the Pharmaceutical Industry to Ensure Organizational Effectiveness (ID PSM-277)

This study explores the most effective and preferred communication strategies for reaching internal executives. The study also seeks to help pharmaceutical and medical companies assess their current internal communication strategies with that of benchmark class companies.

$2500

Best Practices in Reaching Busy Executives: How Pharmaceutical and Medical Device Leaders Use and Respond to External Communications (ID PSM-276)

This study explores the most effective and preferred B-2-B channels & tools of communication, optimum communication frequencies for B-2-Bcommunications. Specifically, this study benchmarks the tools and usage frequency that pharmaceutical and medical executives are making use of for external communication.

$2500

Best Practices for Ensuring Internal Communication Excellence: Increase Organizational Effectiveness (ID PSM-275)

This study explores the most effective and preferred communication strategies for reaching internal executives. The study also seeks to help companies assess their current internal communication strategies with that of benchmark class companies.

$2500

Best Practices in B2B Communications: How to Effectively Reach Core Decision-Makers (ID PSM-274)

This study explores the most effective and preferred B-2-B channels & tools of communication, optimum communication frequencies for B-2-Bcommunications. Specifically, this new study benchmarks the tools and usage frequency executives are making use of for external communication.

$2500

Communication Excellence: Tactics Used by BioPharma Executives to Increase Organizational Effectiveness (ID PSM-273)

This study identifies the most effective external and internal communication strategies and tactics and how people best utilize various communication formats to achieve organizational objectives.

$4000

Internal Communications Excellence: Optimizing Group Structure & Operations (ID PSM-255)

This study understands how leading companies structure their internal communication groups to focus on the entire corporation or support their specific business units.

$4900

External Communications Excellence: Optimizing Group Structure & Operations (ID PSM-256)

This study understands how leading companies structure their external communication groups to focus on the entire corporation or support their specific business units. The study will help companies compare their current strategies with that of benchmark practices at leading companies.

$5100

Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products (ID OP-106)

This study identifies the best practices of veteran pharmaceutical executives for all aspects of communicating disease state information within their companies. The study also gives particular attention to communication challenges around products that were first in class or that treat conditions that are largely unknown or stigmatized including HIV, erectile dysfunction, high cholesterol, overactive bladder, restless legs and others.

$7200

Communications Excellence: Optimizing Group Structure & Operations (ID PSM-254)

This study identifies how leading companies structure their internal and external communication groups to focus on the entire corporation or support their specific business units. The best practices, current trends and insights in this study will help companies compare their current strategies with that of benchmark practices at leading companies.

$8000

Best Practices for Internal Communications Regarding Brands & Disease State (ID POP-229)

This benchmarking report is designed to help product teams at pharmaceutical, biotech and medical device companies avoid common pitfalls in internal communications that can hinder brand performance. Also, it details 10 best practices for internal brand and disease state communications. Additionally, the report covers the most effective tactics, strategies and channels for pre-launch disease state communication to employees across all job levels, corporate functions and therapeutic areas.

$7400

BUSINESS OPERATIONS click to expand contents

Benchmarking Library and Knowledge Management Services in the Biopharma Industry (ID POP-379)

This benchmarking report establishes key metrics, empowering leaders in biopharmaceutical corporate libraries to elevate their services, staffing, budget, and activity levels. Library and information center leaders can refer to this report to gauge the scope, volume, cost, and delivery of their services against industry counterparts in pharmaceuticals, biotech, and medical devices.

$5000

Library Services Benchmarks: Corporate Library Services in the Biopharmaceutical Industry (ID POP-354)

This benchmarking report establishes key metrics for comparing services, staffing, budget and activity levels in biopharmaceutical corporate library services organizations. Library and information center leaders can refer to this report to compare scope, volume, cost, and delivery of library services at their companies with those at other pharmaceutical, biotech and medical device organizations.

$4000

How Biopharma & Medical Device Companies are Pivoting to Support the Boom in Telehealth During the COVID-19 Pandemic and Beyond (ID CM-10)

This benchmarking report probes how biopharmaceutical and medical device companies are pivoting to support the rapidly emerging telehealth delivery channel. It delivers benchmarks around the impact of operational services delivered via telehealth channel, valuable telehealth services offered by various biopharma groups, key lessons learned in each operational area related to telehealth delivery channel during COVID-19, and telehealth change duration.

$995

Top Management Tactics & Long-Term Strategies for Senior Biopharma Executives Steering through COVID-19 and Beyond (ID CM-5)

This benchmarking report examines operational decisions, objectives, challenges, opportunities and effective day-to-day practices from functional as well as senior management perspective in response to COVID-19 pandemic.

$995

Evolution of Technology Platforms during the Global COVID-19 Pandemic and Beyond (ID CM-4)

This benchmarking report examines the changes in streamlined virtual technology functionalities and platforms within life sciences companies due to the emergence of the global COVID-19 pandemic. It probes the use of digital communicative and collaborative platforms, frequency and effectiveness of various modes of technology used to support external and internal stakeholder communication, use of new technologies, duration of technology changes, and approach towards dealing with technology changes post COVID-19 crisis.

$995

Changes in Outreach and Communications with Stakeholders during the Global COVID-19 Pandemic (ID CM-1)

This benchmarking report explores how companies are approaching external engagements with stakeholders following the global COVID-19 pandemic. In particular, this report spotlights the implementation of global COVID-19 pandemic task force, external engagement policies and limitations, necessary resources, challenges and issues prevalent due to the global COVID-19 pandemic, response to constraints in travel and visitation, and performance tracking during the global COVID-19 pandemic.

$995

Health Info System Excellence: How Top Biopharmas Build Integrated Data Systems to Fulfill Patient-Centric Clinical & Commercial Objectives (ID POP-324)

This Best Practices, LLC research probes how biopharma companies can work with vendors to develop fully integrated and accessible databases for aggregated health insights, often referred to as health information systems. It identifies the strengths and weaknesses of six health information vendors, including IQVIA, Symphony Health, Accenture, Corrona, Optum Health, and Digital Reasoning Systems. This report will give an understanding of how peer pharma companies utilize a mix of vendors and data types when creating and maintaining their health information systems. It also provides insights into the typical roles of each function relative to data collection, storage, and analysis.

$3900

Telepsychiatry: Understanding the Opportunity & Evolution of Telehealth in Behavioral Sciences (ID POP-314)

This report was collated by interviewing several telepsychiatry platform leaders and practicing tele-psychiatrists to understand the market evolution, emerging business models and opportunities in telepsychiatry. This report also looks at the impact of telepsychiatry on the practice of behavioral health, patient and psychiatrists’ experience within the telepsychiatry channel, payer reactions, and biopharma collaboration.

$4000

Library Services Benchmarks 2018: Corporate Library Services in the Biopharmaceutical Industry (ID POP-295)

This report provides 2018 benchmarks around the services, staffing, budget and activity levels within pharmaceutical and medical device corporate libraries. Library and information center leaders can refer to this report to compare their scope, volume, cost and delivery of services with those of other leading organizations.

$2900

Library Services Benchmarks 2017: Corporate Library Services in the Pharmaceutical Industry (ID POP-281)

This report delivers 2017 benchmarks for key services and resources provided by libraries and information centers within the biopharmaceutical industry. Library and information center leaders can utilize this report to compare their potential user base penetration, cost recovery practices, chargeback policies, service offerings, recent innovations, staffing, outsourcing, and budget levels with those of other library and information services organizations across the biopharmaceutical industry.

$2000

Best Practices in Managing Board Meetings in the Global Market (ID PSM-338)

This study provides insights into conducting advisory boards and utilizing advisory board feedback to add value across the development and marketing process at bio-pharmaceutical companies. In particular, it provides benchmarks around the structure, planning, execution and utilization of advisory board feedback.

$4000

Library Services Benchmarks 2016: Corporate Library Services in the Pharmaceutical Industry (ID POP-273)

This study provides 2016 benchmarks for selected services and resources provided by libraries and information centers within the biopharmaceutical industry. Library and information center leaders can use this study to compare the scope, cost, volume and delivery of library services at their organizations with those at other leading biopharmaceutical organizations.

$2750

Benchmarking Advisory Board Management At Small Pharmaceutical & Medical Device Organizations (ID PSM-321)

Best Practices, LLC undertook this research to identify best practices in advisory board management at small pharmaceutical and medical device organizations. The study delivers benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board members, advisory board operational and resource benchmarks.

$4400

Benchmarking Advisory Board Management At Mid-Sized Pharmaceutical & Medical Device Organizations (ID PSM-320)

This study was undertaken by Best Practices, LLC to identify the best practices in advisory board management at mid-sized biopharmaceutical and medical device companies. The study delivers benchmarks on the optimum structure for various types of advisory boards, recruitment of advisory board participants, advisory board operational and resource benchmarks.

$4400

Benchmarking Advisory Board Management At Large Pharmaceutical & Medical Device Organizations (ID PSM-319)

This study is designed to assist executives at large pharmaceutical and medical device organizations in identifying ways to best utilize the knowledge of advisory boards. It provides leading insights on the appropriate structure for different advisory boards, selection of advisory board participants, operational and cost benchmarks, top challenges and best practices for conducting advisory boards.

$4400

Pharmaceutical Library Services: Staffing, Resources and Activities Critical to Corporate Libraries (ID POP-248)

This study will help library and information center leaders compare scope, volume, cost, and delivery of library services at their companies with those at other organizations within the bio-pharmaceutical industry.

$1500

Best Practices in Crisis Management & Business Continuity for BioPharma Manufacturing and Supply Chain Operations (ID POP-244)

This study examines how world-class companies optimize their Business Continuity and Crisis Management groups and how their response plans fare when faced with major disasters or operating disruptions.

$6700

Pharmaceutical Science Excellence: CMC Activities, Resources, and Performance (ID POP-225)

This study helps to better understand resource and investment levels, expertise, and activities in global (pre-launch) Chemistry, Manufacturing and Control (CMC) operations in top pharmaceutical companies. The study also intended to provide executives with data to assess the effectiveness and efficiency of their CMC operations and provide insights to improve drug development programs.

$10500

M&A Integration Excellence: What Bio-Pharma Companies Need to Know (ID POP-224)

This report examines winning bio-pharmaceutical M&A integration strategies to provide field benchmarks, lessons learned insights and best practice observations regarding the strategic combination of biotechnology and pharmaceutical assets to optimize ROI.

$7000

Profitable Partnerships: Developing Excellence in Alliances (ID OP-98)

This benchmarking report probes how business development executives at pharmaceutical and biotechnology companies view success in alliance creation, development and execution. This report will serve as a reference for organizations in conducting a performance gap analysis, identifying potential areas for improvement, and closing these performance gaps.

$5776

Supply Chain Excellence Series: Improving the Bottom Line (ID POPS-217)

Developed from surveys and interviews of more than 100 supply chain and supply base executives from top-flight companies and containing more than 300 best practices, benchmarks, narratives, strategies and tactics for driving supply chain value, this series is a start-to-finish guide for supply chain excellence. Covered in granular detail, yet designed as a quick reference, this series can be customized to meet your supply chain needs.

$25000

Excellence in Pharmaceutical Contracting & Pricing (ID POP-209)

Insights revealed in this 63-slide presentation will guide development of cost-effective contracting centers with metrics for cycle time, volume and complexity of work, staffing, training and pricing and payment accuracy. The report also looks at impacts of health care legislation on contracting groups as well as risk mitigation methods and contract automation.

$1878

Driving Productivity and Minimizing Rework in the Quality Control Laboratory (ID OP-80)

The study examines staffing levels, structures, sample testing and documentation processes, performance indicators and innovative workflow technologies of leading pharmaceutical quality-control laboratories.

$1000

Pharmaceutical & Diagnostic Companies: Can They Work Together? (ID SM-160)

Genetic discoveries and regulatory concerns have created an environment where pharmaceutical companies need diagnostic industry partners to realize the full potential of a product. Likewise, diagnostic companies could potentially reap great benefits from partnerships in the form of increased development and marketing support for a new test. This Best Practices Benchmarking® Report will help your organization understand the various nuances involved in creating those successful partnerships.

$2709

Merger & Acquisition Integration Excellence (ID OP-73)

Create superior business growth and value for stakeholders by mastering the five key areas of integration.

$4000

Driving Growth through New Product Planning and Strategic Alliances (ID SM-135)

Drive overall growth through a well-managed portfolio by addressing current and long-term needs in your company’s new product planning and strategic alliance systems.

$5622

CLINICAL OPERATIONS click to expand contents

Building a Competitive IIT Program: Best Practices to Support Better Funding, Resourcing, and Approval Policies (ID POP-408)

This benchmarking report provides actionable insights into optimizing Investigator-Initiated Trials (IIT) management within biopharma organizations. It covers critical aspects like IIT funding strategies, key policies, approval processes, and efficiency-enhancing best practices. The research also segments data by geography (US, EU, Global) and company size (Large vs. Mid/Small Pharma), offering detailed comparisons to help you improve your IIT program’s performance. Additionally, it incorporates proprietary data on IIT program FTEs, phase intervals, and submission review approaches.

$4500

KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History (ID PSM-392)

This case study reveals how Merck turned a near-failure into a cornerstone of cancer treatment through extensive clinical trials, innovative marketing, strategic collaborations, and unwavering investment. Despite entering the immuno-oncology market as a second-to-market product, KEYTRUDA not only caught up with its competitors but also became a dominant force in the field. The analysis provides insights into how Merck's efforts collectively propelled KEYTRUDA to the forefront of cancer treatment, establishing it as a blockbuster drug and a cornerstone of Merck’s oncology portfolio.

$3000

Benchmarking IIS Strategy: Maximizing Investigator-Initiated and Collaborative Study Capabilities (ID POP-355)

This benchmarking report probes the strategies, resources and activities surrounding investigator-initiated studies (IISs) and collaborative studies which are needed to help Medical Affairs and Clinical Development groups gain support for IIS programs and maximize the potential of their drug portfolios.

$3500

Best Practices in the Oversight and Management of Investigator-Initiated Trials in Oncology (ID POP-341)

This benchmarking report provides a detailed roadmap for improving IIT management within oncology companies, capturing critical metrics and insights on IIT management team structure, staffing, budget, and performance metrics.

$5800

Best Practices in the Oversight and Management of Investigator Initiated Trials in CNS Therapeutic Area (ID POP-340)

This benchmarking report provides a detailed roadmap for improving IIT management within CNS companies, capturing critical metrics and insights on IIT management team structure, staffing, budget and performance metrics.

$5800

Pharma’s Digital Transformation Turning Point: Disruption, Challenges and Recommendations for Medical and Commercial Leaders (ID PSM-367)

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic. It probes the various approaches towards digital transformation adopted by forward-looking biopharma companies spanning critical areas including HCP and external engagement, advisory boards and speaker programs management, clinical trials management, patient engagement, performance measurement, and others.

$5500

Best Practices for Managing Clinical Trials During and Beyond the COVID-19 Pandemic (ID CM-9)

This benchmarking report identifies best-in-class practices of leading pharmaceutical companies in managing clinical trials during and beyond the COVID-19 pandemic. The report examines the impact of COVID-19 pandemic on trials timeline, finances, data collection protocols, and staffing levels. It also probes the management of virtual clinical trials, benefits of virtual clinical trials, and key learnings from industry leaders in managing clinical trials during and beyond the COVID-19 pandemic.

$995

Best Practices in the Oversight and Management of Investigator Initiated Trials (ID POP-327)

This benchmarking report provides a detailed roadmap for improving IIT management at bio-pharmaceutical companies, providing critical metrics and insights on IIT management team structure, staffing, budget and performance metrics.

$5800

Innovation in Combo Product Clinical Development – Harnessing Patient Insights from Reported Usability Outcomes (ID POP-308)

This benchmarking research provides current insights into how companies are integrating patient feedback into their clinical data and leveraging this data to address adherence and utilization issues. In particular, this report establishes benchmarks around clinical development team structure, roles, and operational standards. It also identifies the optimal measure targets, utilization, and deployment of patient and observer usability measures.

$2400

Benchmarking R&D and Clinical Talent Development Initiatives (ID PHR-215)

This benchmarking report examines how leading pharma and tech companies align their Learning and Development function within R&D with corporate objectives, measure the success of their talent development initiatives, and identify ways to improve talent retention and development. It also explores current and future challenges for talent development.

$2100

Investigator Initiated Trials Management (ID POP-282)

This benchmarking report provides a detailed roadmap for pharmaceutical and medical device companies to improve their investigator-initiated trial (IIT) management. In particular, this report delivers insights on IIT management team structure, staffing, budget, IIT proposal evaluation, performance improvement, publication metrics and communication channels.

$5500

Best Practices in Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance (ID POP-277)

This study provides benchmarks around the core aspects of the scientific publication function including the structure and leadership of publication groups; publication strategy creation and data delivery; publication channel utilization across product lifecycle; publication effectiveness and transparency; and publication staffing and budget.

$4900

Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals (ID PSM-323)

This study evaluates how biopharmaceutical companies involved in specialty therapeutic areas and rare diseases manage the market research approval process. It provides insights, metrics and best practices around the management of roles and responsibilities, cycle times, honoraria requirements, non-conforming requests and vendors.

$7000

Clinical Affairs Excellence: Benchmarking Clinical Trial Strategies for Pharmaceutical Success in a Global Marketplace (ID POP-239)

This study will inform clinical affairs leaders at pharmaceutical companies on emerging approaches to staffing, outsourcing and managing clinical trials outside of the European and U.S. regions.

$6000

Clinical Affairs Excellence: Benchmarking Clinical Trial Strategies To Ensure Medical Device Success in a Global Marketplace (ID POP-238)

This study will inform clinical affairs leaders at medical device companies on emerging approaches to staffing, outsourcing and managing clinical trials outside of the European and U.S. regions.

$6000

CRO Bioequivalence Strategies: Performance Metrics, Processes & Trends (ID POP-233)

This study aims to identify key cost, quality and productivity metrics for the process of conducting bioequivalence studies required to bring a new generic drug to market.

$3500

Pharma Bioequivalence Strategies: Performance Metrics, Processes & Trends (ID POP-234)

This study identifies key cost, quality and productivity metrics for the process of conducting bioequivalence studies required to bring a new generic drug to market. Specifically, the study looks at the growing trend in outsourcing for bioequivalence studies.

$3900

Clinical Trial Excellence: Toolkit for Winning Investigators in a Competitive Marketplace (ID OP-105)

This report integrates best practices in winning clinical investigators in a competitive marketplace into an easy-to-follow format. The toolkit is designed to aid managers in their efforts to identify, select and recruit top investigators in their therapeutic areas.

$4254

Clinical Trial Excellence: The Science & Art of Winning Investigators in a Competitive Marketplace (ID OP-94)

This 129-page Best Practices Benchmarking™ report covers how companies can: 1) increase the attractiveness and credibility of their studies through effective positioning; 2) identify KOLs and investigators for protocol design input and clinical trials; 3) evaluate the commitment and qualifications of these investigators; 4) create effective structures for both internal and external accountability; and 5) partner to leverage CRO expertise.

$6500

Finding and Keeping Top Investigators: Best Practices in Investigator Recruitment and Retention (ID OP-85)

Leading pharmaceutical companies have sought ways to improve the communication of the clinical trial benefits to potential investigators and patients. From motivating investigators to participate in the research to driving patients into the study, leading companies employ best practices to achieve these objectives through excellent clinical communications.

$4962

COMPETITIVE AND BUSINESS INTELLIGENCE click to expand contents

Utilizing Advanced Analytics and AI/ML for Competitive Intelligence Excellence (ID PSM-394)

This report delivers actionable insights into how Competitive Intelligence (CI) functions are evolving with the use of AI and advanced analytics. It examines key structural trends, staffing needs, and strategic practices that enhance stakeholder value. The study also explores the challenges of AI implementation and offers a comparative analysis of previous benchmarking studies, shedding light on the future of the CI function in the biopharma industry.

$4000

Strategic Operations in Competitive Intelligence: Current and Future Trends Transforming CI (ID PSM-390)

This benchmarking report, conducted by Best Practices, LLC, explores the dynamic Competitive Intelligence (CI) landscape. Empower your organization with actionable insights, setting benchmarks for CI structures, resources, reporting, metrics, and training needs. Delve into crucial benchmarks on key activities, Centers of Excellence utilization, and strategic AI implementation in the realm of CI.

$4000

Maximizing the Impact of US and Global Analytics and Insights Teams across the Biopharma Organization (ID PSM-386)

This benchmarking report examines how leading US and global biopharma companies leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$6600

Maximizing the Impact of CNS Analytics and Insights Teams across the Biopharma Organization (ID PSM-385)

This benchmarking report examines how leading CNS companies leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$6600

Maximizing the Impact of Oncology Analytics and Insights Teams across the Biopharma Organization (ID PSM-384)

This benchmarking report examines how leading oncology manufacturers leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$5900

Optimizing the Structure and Efficiency of the Competitive Intelligence Function (ID PSM-383)

This report identifies how leading pharmaceutical and biotech companies are improving the efficiency of their Competitive Intelligence function. It establishes benchmarks around the structures, budget, roles and responsibilities of the Competitive Intelligence function. Additionally, this report delivers critical Competitive Intelligence benchmarks around vendor management, capabilities, key activities, technology advancement, and use of Centers of Excellence.

$4999

Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization (ID PSM-366)

This benchmarking report examines how leading biopharma companies leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$6600

Health Info System Excellence: How Top Biopharmas Build Integrated Data Systems to Fulfill Patient-Centric Clinical & Commercial Objectives (ID POP-324)

This Best Practices, LLC research probes how biopharma companies can work with vendors to develop fully integrated and accessible databases for aggregated health insights, often referred to as health information systems. It identifies the strengths and weaknesses of six health information vendors, including IQVIA, Symphony Health, Accenture, Corrona, Optum Health, and Digital Reasoning Systems. This report will give an understanding of how peer pharma companies utilize a mix of vendors and data types when creating and maintaining their health information systems. It also provides insights into the typical roles of each function relative to data collection, storage, and analysis.

$3900

Pharma Competitive Intelligence Landscape Assessment (ID PSM-351)

This landscape assessment was conducted using a meta-analysis approach to identify evolutionary insights for Competitive Intelligence structure, staffing and investment in the biopharmaceutical industry. Insights in this research have been distilled from ten of Best Practices, LLC’s existing benchmarking studies.

$6000

Market Research Vendor Excellence: Exclusive Vendor Management (ID PSM-340)

This Best Practices, LLC benchmarking report probes well-established and newly emergent models and trends in exclusive market research vendor management. Particularly, this report establishes benchmarks around exclusive vendor partnerships management, use and extent of outsourcing of exclusive vendors, evaluation and return on investment, automation in vendor management and key lessons learned in exclusive vendor management.

$3300

Competitive Intelligence Excellence Benchmark: Creating a High-Value CI Function to Drive Better Business Decisions (ID PSM-335)

This report identifies best practices and innovative approaches for enhancing the strategic role and impact of the competitive intelligence function within bio-pharmaceutical companies. In particular, it delivers industry benchmarks around the structure and leadership of the competitive intelligence function, key competitive intelligence sources and activities; resource levels, use of third party vendors and requisite employee competencies.

$6000

How Successful Companies Create and Develop a High-Value CI Function to Drive Better Business Decisions (ID PSM-302)

This study identifies best practices and innovative methods for improving the strategic role and impact of the Competitive Intelligence function within the pharmaceutical and related industries. The study provides health care industry and CI leaders with metrics and insights they can use to increase the value of their function and generate greater influence within the corporation.

$6000

Best Practices In Competitive Intelligence: Policies & Guidelines That Reduce Corporate Risks (ID PSM-260)

This study identifies the key benchmarks of world-class companies for optimizing CI operations and working with the Legal department to develop policies. CI leaders can use this research to help create or maintain policies and guidelines regarding CI operations as well as to compare their data collection practices and resource/structural benchmarks with those of leading organizations.

$4000

Competitive Intelligence Policies, Ethics and Data Collection: Navigating the Gray Zone (ID SM-179)

This study understands how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines. In addition, the study looked at how CI groups work with legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department’s ability to deliver results.

$5352

Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection within Approved Guidelines (ID PSM-226)

This report discusses how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines and also includes how CI groups work with legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department’s ability to deliver results.

$3995

CUSTOMER SERVICE click to expand contents

Automating Medical Information: Using New Tools and Systems To Scale and Optimize Medical Info and Call Center Operations (ID POP-393)

This benchmarking report will help Medical Information groups incorporate effective automation, innovative tools, optimal resources, and more efficient processes to handle Medical Information Requests. It will also provide best practices and lessons learned to upscale call center capacity and increase response rate, while maintaining a lean headcount.

$4600

Challenges and Effective Practices for Optimizing a Customer Relationship Management System for Field Medical Teams (ID POP-334)

This benchmarking report highlights the key challenges and effective practices for optimizing a customer relationship management system for field medical teams. It is designed to help Medical Affairs leaders understand the latest trends and applications around CRM utilization, support and management for field-based medical teams.

$4000

Building a World Class Medical Information and Patient Services Call Center (ID PCS-214)

This benchmarking report identifies performance benchmarks for building a world class medical information and patient services call center. It provides call center leaders with critical insights and metrics that can be used to evaluate and improve information and service call center effectiveness.

$3750

Best Practices in Postmarketing Surveillance and Complaint Resolution Management at Medical Device Firms (ID PCS-213)

This benchmarking report highlights the winning strategies used by top medical device companies to collect valuable insights from customer feedback and drive business improvements in the global marketplace, specifically the United States, European Union, Australia and Japan by streamlining their postmarketing surveillance and resolution systems.

$4800

Building a World-Class Call Center: Performance Metrics, Operations, Structures & Trends at Consumer/OTC Companies (ID PCS-212)

This study identify performance benchmarks for the size, cost, service delivery efficiency, structure, leadership, processes, technology, and operations of call center organizations for consumers/ OTC companies within pharmaceutical and related industries.

$4250

Creating a World-Class Call Center in North America’s Current Healthcare Environment: Performance Metrics, Operations, Structures and Trends (ID PCS-211)

This study provides participants with current metrics for call center performance in relation to new technology use. The study also examines future trends for call centers.

$5000

Managing Service to Sales Cultural Transformation (ID CS-64)

This report delivers benchmarks and insights on training, deploying and transforming call center representatives from being solely focused on customer service to achieving sales excellence – by providing tools and skills that enable service representatives to cross-sell and up-sell.

$4718

Contact Center Excellence: Developing & Maintaining a World-Class Contact Center (ID CSS-63)

A must-have for all contact center executives, this series is critical for driving call center success. Through extensive interviews, benchmark surveys and multiple site visits, this series highlights the tactics used by some of the world's top companies to develop and implement efficient and high-quality call centers as well as transition existing customer service centers into high-sales performers.

$25000

DIGITAL TECHNOLOGY click to expand contents

Interweaving Medical Strategy to Maximize New Treatment Success: Linking Launch Strategies with Medical Operations Excellence and Competitive Resourcing Decisions (ID POP-405)

This benchmarking report explores the evolving role of Medical Affairs in new biopharma product launches. It provides insights on resource allocation, strategic development, and operational execution, with a focus on leveraging data, analytics, and digital tools for launch success. The report covers critical success factors, common challenges, and effective strategies used by leading biopharma organizations.

$4500

Medical’s Road Map for Social Media Success in Rare Disease Segment (ID POP-361)

This benchmarking report examines current trends and future directions to construct the roadmap for Medical Affairs’ social media success in Rare Disease segment. The research explores current trends and success factors in harnessing the power of social media to effectively educate the rare disease market. It delivers benchmarks around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$5500

Medical’s Road Map for Social Media Success in Immunology (ID POP-360)

This Best Practices, LLC report investigates current trends and future directions to build the roadmap for Medical Affairs’ social media success in Immunology. The report delivers benchmarks around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$5500

Medical’s Road Map for Social Media Success in Oncology (ID POP-359)

This benchmarking report uncovers industry best practices and benchmarks to construct Medical’s road map for social media success in Oncology. It delivers insights around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$5500

Medical’s Road Map for Social Media Success (ID POP-358)

This benchmarking report examines current trends and future directions to construct the roadmap for Medical Affairs’ social media success. It delivers benchmarks around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$6490

Embracing Omnichannel Engagement in Medical Affairs (ID POP-357)

This benchmarking report probes the advances in omnichannel engagement approaches by Medical Affairs organizations. It examines current levels of omnichannel engagement in Medical Affairs, staffing and budget dedicated to omnichannel efforts, digital and in-person engagement activities, direct and indirect communication channels, and emerging KPIs for evaluation. The report further evaluates the challenges, benefits, and lessons learned in implementing omnichannel engagement programs.

$5490

Medical Affairs and Digital Opinion Leaders: Identifying, Engaging and Succeeding with Online Influencers (ID POP-347)

This benchmarking report examines how Medical Affairs teams can effectively identify, engage, and collaborate with Digital Online Influencers. The research benchmarks key aspects of a DOL engagement program, including DOL identification and engagement, DOL program structure and staffing, vendor management, and ensuring compliant DOL engagement. It also highlights key strategies, success stories, and lessons learned in the realm of DOL engagement.

$5000

Building More Effective Medical Affairs Product Launch Teams: Cardiology and Pulmonology Segment (ID POP-385)

This benchmarking report explores Medical’s role in cardiology and pulmonology product launches. The research probes digital tool utilization and launch tool deployment, roles and responsibilities, cross-functional alignment, and performance metrics. It further explores critical success factors for and major challenges to launch preparedness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Immunology Segment (ID POP-388)

This benchmarking report explores the critical role of Medical Affairs in launching immunology products. It analyzes the use of digital tools, role definitions, cross-functional alignment, and key performance indicators. Additionally, the report highlights success factors and major challenges impacting launch readiness.

$6000

Building More Effective Medical Affairs Product Launch Teams: CNS / Neurosciences Segment (ID POP-386)

This Best Practices, LLC report examines the role of Medical Affairs in CNS / Neurosciences product launches. The research investigates digital launch tool deployment, roles and responsibilities, cross-functional alignment, and performance metrics used to gauge success. Additionally, the report identifies key success factors and major challenges in achieving effective launch preparedness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Hematology Segment (ID POP-387)

This Best Practices, LLC report delves into the pivotal role of Medical Affairs in the launch of hematology products. It examines the deployment of digital tools, the delineation of roles and responsibilities, cross-functional collaboration, and key performance metrics. The report also identifies the success factors and significant challenges that influence launch readiness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Metabolic Diseases Segment (ID POP-390)

This Best Practices, LLC report offers an in-depth analysis of how Medical Affairs can transform the launch of products for metabolic diseases. It explores the integration of digital tools, clear definition of roles, effective cross-functional collaboration, and essential performance metrics. The report also examines success factors and critical challenges that impact launch preparedness, equipping teams with actionable insights for achieving superior results.

$6000

Building More Effective Medical Affairs Product Launch Teams: Oncology Segment (ID POP-391)

This Best Practices, LLC report delves into optimizing Medical Affairs teams for successful oncology product launches. It covers the strategic use of digital tools, defines roles and responsibilities, and explores effective cross-functional collaboration. The report also highlights key success factors and common obstacles, providing actionable insights to enhance launch readiness in the competitive oncology landscape.

$6000

Building More Effective Medical Affairs Product Launch Teams: Respiratory Segment (ID POP-392)

This Best Practices, LLC report explores the vital contributions of Medical Affairs teams in launching respiratory products. It examines the implementation of digital tools, role management, and cross-departmental collaboration. The report identifies key success factors and common challenges, providing strategic guidance for optimizing launch readiness and effectively meeting patient needs in the respiratory therapeutic area.

$6000

Building More Effective Medical Affairs Product Launch Teams: Infectious Diseases Segment (ID POP-389)

This Best Practices, LLC report focuses on optimizing Medical Affairs in the context of infectious disease product launches. It provides a thorough analysis of digital tool integration, role clarity, and collaborative efforts. The report identifies key success drivers and challenges that Medical Affairs teams must navigate to ensure launch readiness in the rapidly evolving infectious diseases space.

$6000

Building More Effective Medical Affairs Product Launch Teams (ID POP-342)

This benchmarking report explores Medical Affairs’ role in product launch. The research explores roles and responsibilities, cross-functional alignment, performance metrics, resourcing, activities effectiveness, launch timeline, and digital launch tools deployment. It further explores the success factors and major challenges to Medical Affairs’ launch preparedness.

$6500

Healthcare Innovation Using Artificial Intelligence and Data Analytics: How “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth (ID PSM-379)

This Best Practices, LLC case study reviews how artificial intelligence and data analytics are being utilized to drive innovation in healthcare. Specifically, this case study probes how Colgate-Palmolive’s “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth.

$2400

Omnichannel Marketing: Maximize your Digital Marketing Assets (ID PSM-378)

This benchmarking report examines how leading biopharma companies are adopting an integrated omnichannel marketing strategy by maximizing their digital assets. It establishes industry benchmarks around digital marketing service structure, digital marketing staffing and investment, digital operations, innovative tools, digitizing new product planning and launch, performance measurement, mobile engagement and digital health, and key channels and activities.

$6000

Digital Trends in Biopharma Launch Strategy and Investment (ID PSM-375)

This benchmarking report spotlights the secondary and tertiary drivers behind the accelerated pace of using digital strategies to drive innovative biopharma launches. The report identifies the high-value digital activities, spotlights investment trends, and captures key lessons learned. It also benchmarks the tools and techniques used to get the most out of digital launches.

$3750

Pure Play Digital Launch: Launching a New Blockbuster Migraine Drug During a Global Pandemic (ID PSM-374)

This Best Practices, LLC case study probes how Biohaven used modern digital tools and technologies to successfully launch its ‘one dose’ migraine drug, Nurtec during the global COVID-19 pandemic.

$2500

Best Practices in the Use of Digital Technologies and Artificial Intelligence within Medical Affairs (ID POP-331)

This benchmarking report probes the use of digital technologies and artificial intelligence within Medical Affairs. It delivers benchmarks around digital activities and capabilities in Medical Affairs, roles and reporting in Digital Medical Affairs, resourcing of digital initiatives, patient engagement through e-medical initiatives, and use of artificial intelligence in Medical Affairs. The report also highlights the key trends and emerging digital issues in Medical Affairs.

$7400

Addyi (flibanserin): How an upstart biopharma used social media and policy tools to support its NDA approval - and a $1 billion payday (ID PSM-368)

Best Practices, LLC conducted extensive secondary research of government and company information to review how Sprout Pharma used social media, active lobbying and policy levers to win approval for its controversial therapy, Addyi® (flibanserin) in female hypoactive sexual desire disorder (HSDD) category.

$2900

Pharma’s Digital Transformation Turning Point: Disruption, Challenges and Recommendations for Medical and Commercial Leaders (ID PSM-367)

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic. It probes the various approaches towards digital transformation adopted by forward-looking biopharma companies spanning critical areas including HCP and external engagement, advisory boards and speaker programs management, clinical trials management, patient engagement, performance measurement, and others.

$5500

How Biopharma & Medical Device Companies are Pivoting to Support the Boom in Telehealth During the COVID-19 Pandemic and Beyond (ID CM-10)

This benchmarking report probes how biopharmaceutical and medical device companies are pivoting to support the rapidly emerging telehealth delivery channel. It delivers benchmarks around the impact of operational services delivered via telehealth channel, valuable telehealth services offered by various biopharma groups, key lessons learned in each operational area related to telehealth delivery channel during COVID-19, and telehealth change duration.

$995

Patient Support Excellence: Critical Programs, Tactics & Tools to Ensure Strong Advocacy & Access to Medicine during COVID-19 and Beyond (ID CM-6)

This benchmarking report highlights the evolution of advocacy group relationships and patient support programs during and post the COVID-19 era. It specifically identifies the impact of COVID-19 on patient support programs, implications of digital technology implementation for patient engagement, usage and effectiveness of performance metrics, key patient support tools, communication frequency and staffing.

$995

Evolution of Technology Platforms during the Global COVID-19 Pandemic and Beyond (ID CM-4)

This benchmarking report examines the changes in streamlined virtual technology functionalities and platforms within life sciences companies due to the emergence of the global COVID-19 pandemic. It probes the use of digital communicative and collaborative platforms, frequency and effectiveness of various modes of technology used to support external and internal stakeholder communication, use of new technologies, duration of technology changes, and approach towards dealing with technology changes post COVID-19 crisis.

$995

Connected Health Excellence: Assessing the Development, Deployment, and Impact of Integrated Treatment Apps (ID PSM-364)

This benchmarking report is designed to help biopharma and medical device leaders make informed decisions about “connected healthcare applications” which enhance an existing device or drug delivery system by examining the benefits and business case for apps, data collection practices, product development and external partnership models, and prevailing regulatory approaches.

$5250

Connecting Pharma to Patients with Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets (ID PSM-354)

This benchmarking report probes the winning strategies, effective practices, and potential stumbling blocks encountered as a company shifts towards digital patient engagement in global, emerging and developed markets. Specifically, this report delivers digital patient engagement benchmarks around the tactics, tools and technologies employed for successful engagement; staffing drivers; investment trends; structure and reporting; processes and use of vendors; depth and scope of engagement; performance effectiveness; and critical lessons learned.

$5990

Driving the Value of Digital Initiatives in Medical Affairs (ID POP-296)

This benchmarking report explores how Medical Affairs can improve its digital capabilities to better serve internal and external stakeholders. It delivers benchmarks around enhancing Medical Affairs digital capabilities through operations, activities, channels, services, roles, reporting and resourcing. This report also highlights the top digital engagement trends that will greatly impact the Medical Affairs function.

$5900

Forge Top-Tier Biopharma Digital Strategy & Experience (ID PSM-343)

This benchmarking report explores how digital marketing leaders at pharmaceutical and medical device companies utilize new tools and tactics to educate key customers, enhance reach, increase speed, boost sales force effectiveness, measure and increase customer satisfaction, and offset declining HCP access.

$5500

Digital Innovation Path: Trends in Healthcare Digital Marketing Innovation, Customer Engagement, Investment and Approvals (ID PSM-337)

This research provides critical insights into how savvy bio-pharma digital marketers are expanding the reach and effectiveness of digital customer engagement through emerging channels, measuring ROI for innovative activities, right-sizing budget and staffing investment levels, and enhancing the digital content and program review and approval process.

$4400

Growing Biopharma Digital Marketing Impact: Digitizing Launch, Developing Talent and Optimizing Service Alignment (ID PSM-334)

This research identifies the critical drivers of digital marketing performance excellence in the healthcare industry. It probes how savvy biopharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs, and optimizing insource vs. outsource mix.

$4450

Optimizing Biopharma Digital Marketing: Insights to Improve Digital ROI, Performance Measurement, Field Force Support & Mobile Engagement (ID PSM-332)

This research provides a host of foundational benchmarks requisite to drive digital marketing performance excellence in the healthcare industry. It identifies how savvy digital marketers are utilizing new tools and tactics to reduce cost, enhance sales force effectiveness, measure performance and ROI for important channels, and key trends in mobile customer engagement.

$4400

Finding & Showcasing Digital Impact: ROI, Performance Metrics, Launch & Maximizing Digital Performance (ID PSM-327)

This study identifies a host of foundational benchmarks required to achieve best-in-class performance in digital marketing in the healthcare sector, and foster a robust digital culture throughout the organization. It examines the top operational areas for measuring and demonstrating return on digital investment, key drivers and timing factors for maximizing return on investment, program approval timeframes, cross-channel performance metrics for individual channels and regulatory impact.

$5000

Best-in-Class Pharma Digital Marketing Performance: Core Services, Speed, Spend & Structure (ID PSM-325)

This study examines the factors required to achieve performance excellence in digital marketing in the health care sector, and foster a robust digital culture throughout the organization. It provides benchmarks around structural, staffing & budget trends, achieving multichannel maturity, and speed to execute key digital tactics.

$5000

Key Trends & Innovative Activities in Biopharma Digital Marketing (ID PSM-324)

This study identifies the hotspots in digital and multichannel innovation and evaluates key trends in successful education and engagement of physicians, patients and other customer groups across online channels. It also assesses the impact, effectiveness, and ROI of leading digital marketing activities and programs.

$5000

Pharma Digital Marketing Innovation: Service, Measurement & Investment Trends to Maximize Customer Impact (ID PSM-309)

This study examines how leading organizations maximize the value provided by the Digital Marketing function through efficient service delivery to both internal and external customers, across different regions, business lines, and throughout the product lifecycle. Leading insights in the study will help biopharma digital leaders right-size their budgetary investments, optimize resource allocation to key channels, and evaluate productivity and performance for all programs to demonstrate premium value to senior leadership.

$6950

Pharma Social Media Listening: Benchmarking Innovative Practices in the Healthcare Industry (ID PSM-303)

This study helps healthcare companies improve their Social Media Listening (SML) programs to capture maximum patient and market insights while maintaining strict compliance. The study delivers crucial benchmarks from industry-leading companies on key Listening activities, platforms, websites monitored, data gathered, approval processes, and Adverse Events reporting and management.

$4150

Digital Marketing Excellence: Generating Top Value in an Emerging Healthcare Function (ID PSM-294)

This study helps healthcare companies measure and improve performance across a wide range of Digital Marketing (DM) functional areas and activities. Also, the study delivers insights on performance tracking, new tools and technologies, demonstrating value, better alignment with brand teams, talent acquisition and development, mitigating Regulatory risk, and investment trends.

$5500

Mastering Digital Marketing Structure & Strategy: Transforming Multi-Channel Marketing (ID PSM-285)

The study distills winning strategies for Digital Marketing activity management, staffing, and budget allocation to help executives manage their service costs and better serve their business units and their products.

$5175

Online Patient Support Excellence: Using Brand Website Services to Grow Loyal Customers (ID PSM-258)

This study examined 10 leading biopharmaceutical products that treat chronic conditions, such as rheumatoid arthritis, osteoporosis and cancer, for which treatment is often expensive and patient education and long-term support are essential.

$3929

Best Practices for Using Social Media To Drive Business Outcomes (ID PSM-259)

This study identifies how companies use Social Media tools in their business environment, the opportunities and risks associated with Social Media applications as well as requirements for managing their use.

$3500

HUMAN RESOURCES click to expand contents

Navigating KPI and Performance Measurement Challenges During the Global COVID-19 Pandemic (ID CM-2)

This benchmarking report explores how companies are approaching changes in key performance indicators (KPIs) during the COVID-19 pandemic. In particular, this report spotlights the changes in KPIs and performance measurement, measurement period, authority and duration over the course of the pandemic. It also examines the challenges encountered around performance measurement and suggestions from industry peers for best adapting KPIs and other measurements during the global pandemic to better reflect performance.

$995

Benchmarking R&D and Clinical Talent Development Initiatives (ID PHR-215)

This benchmarking report examines how leading pharma and tech companies align their Learning and Development function within R&D with corporate objectives, measure the success of their talent development initiatives, and identify ways to improve talent retention and development. It also explores current and future challenges for talent development.

$2100

Marketer Career Path Excellence: Best Practices for Training and Developing High-Impact Healthcare Marketers (ID PSM-339)

This benchmarking report identifies critical marketer training and development approaches and best practices to guide better marketing career path planning and execution at biopharmaceutical companies. It provides benchmarks around key skills, competencies, training curriculum and content, common language, role rotations, mentoring, external partnerships and career path development approaches for forging high-impact marketing professionals and future leaders.

$6500

Commercial On-Boarding Excellence: Bringing New Employees Up To Productivity Quickly and Effectively (ID PHR-213)

This study assesses how world-class companies optimize their Commercial On-boarding training and development in a way that is cost-conscious but can support the aggressive goals of the organization.

$5885

Driving Growth & Talent Retention through Pay for Performance (ID POP-245)

This study investigates how compensation organizations at leading global companies are structuring and implementing pay for performance annual bonus programs to reward top performers and retain talent in today's environment of shrinking resources and increasing talent competition.

$4500

From Classroom to Boardroom: Training Can Propel Market Researchers from Order-Takers to Trusted Business Advisers (ID PSM-284)

This study to probe critical experiences, winning strategies and important resource trends regarding how best to develop and deploy Market Research Training and Development in today’s increasingly complex global marketplace with ongoing resource constraints.

$6050

Best Practices in Building Global Capacity for Corporate Teams (ID POP-231)

Best Practices, LLC launched this timely study that uncovers the tools the techniques that top companies use to function effectively on a global basis and to improve the performance of their global teams and networks.

$4200

Effective Policies & Procedures for Managing the Workforce during a Flu-Like Pandemic (ID HRS-1)

This study was designed to gain insights into what policies or procedures that organizations in the U.S. have developed to manage their workforces during a flu-like pandemic. Disaster planning and personnel executives from all industries can use this research to compare - or begin creating - their own attendance and pay policies to address flu-like pandemic.

$1800

Achieving HR Administration Excellence – Shared Services, Outsourcing and Cost Reduction (ID HR-57)

This benchmarking report explores how leading organizations achieve excellence in Human Resources Administration. It delivers benchmarks around the organizational structure, staffing level, outsourcing, leave of absence (LOA) administration and vendor management. Human resources leaders can refer to this report to enhance the overall productivity of their organization.

$4182

Hiring Top Talent: Best Practices in University Recruiting (ID HR-59)

This benchmarking report highlights the best practices for recruiting top talent from colleges and universities. It contains benchmarks around program structure, scope, budgets, staffing levels, key activities, technology and tools. Human resources executives can refer to this report to assess their recruiting performance, identify and correct any resource and performance gaps within their university recruiting organizations and begin building a strategic path for program improvement in the future.

$3400

U.S. Pharmaceutical Budget and Staffing Excellence: Benchmarking the Resources Required to Drive Productivity and Growth (ID HR-60)

This report is designed to provide pharmaceutical and biotech companies with critical budget and staffing resource benchmarks to assess the efficiency of key business functions and enhance organizational efficiencies.

$5995

Achieving Excellence in University Recruiting (ID HRS-59)

In this environment, staffing executives who are responsible for university hiring need to understand their program position relative to other companies through comparing performance metrics, processes and best practices. This benchmark package is designed to meet that need. It includes: A rapid custom analysis of your university recruiting program data; Hiring Top Talent: Best Practices in University Recruiting; Features of Winning University Recruiting Websites.

$5500

Best Practices in Career Path Definition and Succession Planning (ID HR-50)

Manage your "corporate benches" to meet company needs with successful career path and succession planning systems.

$1994

Corporate University Excellence: Creating a Robust and Flexible Workforce (ID HR-61)

This 28-page report highlights corporate universities at six leading companies from six different industries. Specifically, this research uncovers best practices in building the business case for a corporate university, experiences in competency development, and best uses of technology and how to measure the effectiveness of a corporate university.

$825

MARKET ACCESS click to expand contents

KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History (ID PSM-392)

This case study reveals how Merck turned a near-failure into a cornerstone of cancer treatment through extensive clinical trials, innovative marketing, strategic collaborations, and unwavering investment. Despite entering the immuno-oncology market as a second-to-market product, KEYTRUDA not only caught up with its competitors but also became a dominant force in the field. The analysis provides insights into how Merck's efforts collectively propelled KEYTRUDA to the forefront of cancer treatment, establishing it as a blockbuster drug and a cornerstone of Merck’s oncology portfolio.

$3000

Meeting the Needs of Payers through the Market Access Function (ID PSM-391)

This benchmarking report delves into strategies for Market Access leaders to elevate payer engagement, emphasizing the adoption of best-in-class approaches. It offers insights on optimizing the structure, activities, staffing, and investment within the function for enhanced effectiveness.

$3000

Case Study: How argenx Broke into a Captive Market to Begin Dislodging an Entrenched Market Leader (ID PSM-388)

This case study reviews VYVGART’s trajectory to breaking into the captive generalized Myasthenia Gravis (gMG) market to begin dislodging an entrenched market leader. The study probes the development, launch, and market entry strategies executed by argenx to launch VYVGART as a first step in its rare disease franchise building.

$3900

Best Practices in Creating Efficient and Effective Medical Affairs and Market Access Teams in Medical Devices (ID POP-346)

This benchmarking report establishes staffing, resourcing, and operating benchmarks for Medical Affairs and Market Access teams within medical device companies. It will help Medical Affairs and Market Access leaders determine how to strategically adapt their own teams to current medical device industry standards.

$4500

Meeting the Challenge of Copay Accumulator Programs: Effective Pharma Strategies & Tactics for Ensuring Patient Access (ID PSM-359)

This benchmarking report highlights the impact of payer-imposed copay accumulator programs on specialty pharma manufacturers and their patients. The research also delves into effective tactics and strategies employed by organizations for mitigating the impact of copay accumulator programs. Research findings and insights will help Market Access leaders create and deploy an effective copay accumulator mitigation strategy that meets the full scope of the threat and ensure patient-centric treatment and reimbursement solutions.

$5500

Meeting the Challenge of Copay Accumulator Programs: Effective Oncology Manufacturer Strategies & Tactics for Ensuring Patient Access (ID PSM-361)

This benchmarking report highlights the impact of payer-imposed “copay accumulator” programs on oncology and other specialty manufacturers and their patients. The research delves into effective tactics and strategies employed by specialty biopharma companies for mitigating the impact of copay accumulator programs. Research findings and insights will help Market Access leaders create and deploy an effective copay accumulator mitigation strategy that meets the full scope of the threat and ensure patient-centric treatment and reimbursement solutions.

$5800

Best Practices in Formulary Success: Key Payer Responsibilities and the Information & Qualities they Seek from Field Medical Teams (ID PSM-350)

This benchmarking report explores what types of information managed care organizations find most important for their formulary decision-making and how they are using these information types for their formulary placement decisions. In addition, this report highlights payers’ perceptions and experiences with pharma organizations’ field medical representatives.

$6100

Benchmarking the Roles and Responsibilities for U.S.-Based Field Medical Team Interactions with Managed Care Customers (ID POP-283)

Best Practices, LLC undertook this benchmarking research to deliver insights around the roles, responsibilities, resources and activities for U.S.-based payer liaison medical teams. This report also contains qualitative information from study participants on the value, weaknesses and best practices surrounding the use of field medical roles to interact with the payer community.

$6000

Medical Affairs’ Critical Role in Payer Interactions (ID POP-271)

This study was undertaken to better understand the role of Medical Affairs in critical payer interactions and identify best practices in developing effective relationships with payers. This report also delivers benchmarks around the required resource levels, talent acquisition and training for maintaining effective payer relationships, and payer segmentation and prioritization.

$5500

Optimizing the Managed Markets Function: Roles, Structures, Resources and Activities (ID PSM-312)

This study assesses the operational performance of managed markets functions within small and mid-cap pharmaceutical companies. It benchmarks the budget and staffing levels, organizational models, role of clinical specialists, and compensation structure of managed markets functions.

$5100

Reshaping Commercial Models to Serve ACOs, IDNs & Emerging Provider Networks (ID PSM-314)

This study is designed to assist pharmaceutical and medical device companies in developing an effective strategy for serving Accountable Care Organizations and Integrated Delivery Networks in the rapidly changing U.S. healthcare marketplace. It assesses the relative impact and priority of key practices as well as the failure points that influence overall ACO/IDN service performance.

$7300

Deploying the iPad or Android-Based Tablet to Managed Markets Teams: Benchmarking Training and Effectiveness (ID PSM-305)

This study identifies the key challenges, lessons learned and best practices for deploying iPads or Android-Based tablets to large customer-facing commercial groups within BioPharma and Medical Device organizations.

$4500

Increasing Market Access through Innovative Payer Market Research: Assessing New Tools & Technologies to Gain Insight into Payer Decision Making (ID PSM-304)

This study probes how health care companies structure internal research groups conducting payer research, and it assesses what market research approaches are most effective and innovative for understanding diverse payer needs, preferences and decision-making.

$6500

Best Practices in Developing a Structured Career Path for the Managed Markets Professional (ID PHR-214)

This study depicts how the managed market sales function is organized, including possible career path progression models, performance measurements, promotion eligibility requirements, and trends around other factors that improve engagement and performance.

$2500

Resource Benchmarks for U.S. Pharmaceutical Managed Care Operations (ID PSM-282)

This study provides managed care leaders with important benchmarks on the optimal size of U.S. Managed Care groups linked to activities performed to allow managed care leaders to assess their efficiency level relative to peers.

$3400

Managed Care Pull-Through Excellence: From Formulary Access to Increased Market Share (ID SM-187)

This study encompasses current pull-through operating tactics and strategies used by account managers, sales leaders and brand executives, helpful for identification and closure of performance gaps in pull-through organizations’ processes, programs and activities.

$7000

Managed Markets Account Management: Assessing the Performance of Account Executives (ID PSM-240)

This study identifies common performance measurement practices across geographies and hierarchy, provide insight into effective evaluation of the function and determine measures that drive functional success.

$4210

Developing Managed Care Pull-Through Excellence (ID PSM-241)

This study will enable pharmaceutical, bio-pharma and medical device company leadership to identify program gaps, uncover insights and discover successful best practices to share with their employees.

$5200

Serving the Healthcare Needs of Employers: Employer Market Strategies and Tactics (ID PSM-237)

This report frames the current employer market landscape and analyzes how leading companies organize their employer groups, conceive of their efforts, and operate in the field. Managed Care, Managed Markets, and other Sales and Marketing heads can use the metrics and narrative insights contained in this report to compare their employer groups to those of other top companies, or to spearhead a new employer market effort within their own organization.

$3395

Managed Markets Market Research: Effective Structures & Activities for Gaining Maximum Payer Access & Insight (ID PSM-233)

This study examines the corporate structures and activities for Managed Markets market research (MMMR) that are most effective for gaining payer insights.

$3995

Pathways to Pharmacy Relations Excellence (ID PSM-202)

This benchmarking report reveals how leading pharmaceutical and biotechnology companies align strategies, structures, programs and resources to achieve performance excellence in pharmacy relations.

$1124

MARKET RESEARCH, ANALYTICS AND FORECASTING click to expand contents

Utilizing Advanced Analytics and AI/ML for Competitive Intelligence Excellence (ID PSM-394)

This report delivers actionable insights into how Competitive Intelligence (CI) functions are evolving with the use of AI and advanced analytics. It examines key structural trends, staffing needs, and strategic practices that enhance stakeholder value. The study also explores the challenges of AI implementation and offers a comparative analysis of previous benchmarking studies, shedding light on the future of the CI function in the biopharma industry.

$4000

Maximizing the Impact of US and Global Analytics and Insights Teams across the Biopharma Organization (ID PSM-386)

This benchmarking report examines how leading US and global biopharma companies leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$6600

Maximizing the Impact of CNS Analytics and Insights Teams across the Biopharma Organization (ID PSM-385)

This benchmarking report examines how leading CNS companies leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$6600

Maximizing the Impact of Oncology Analytics and Insights Teams across the Biopharma Organization (ID PSM-384)

This benchmarking report examines how leading oncology manufacturers leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$5900

Healthcare Innovation Using Artificial Intelligence and Data Analytics: How “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth (ID PSM-379)

This Best Practices, LLC case study reviews how artificial intelligence and data analytics are being utilized to drive innovation in healthcare. Specifically, this case study probes how Colgate-Palmolive’s “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth.

$2400

Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization (ID PSM-366)

This benchmarking report examines how leading biopharma companies leverage their Analytics & Insights teams to provide effective strategic consultation, focus resources, optimize analytics capabilities, grow service demand, drive innovation and scale successes.

$6600

Accelerating Growth and Performance through Superior Knowledge Management (ID KM-100)

This benchmarking report examines how leading companies across different industry sectors are managing their organizational knowledge to promote collaboration, generate deep market insights and support performance excellence of new and in-line products. In particular, this report probes the five “pillars” or critical dimensions of superior knowledge management including structure and leadership; culture and incentives; processes; technology; staffing and training.

$5400

Market Research Vendor Excellence: Exclusive Vendor Management (ID PSM-340)

This Best Practices, LLC benchmarking report probes well-established and newly emergent models and trends in exclusive market research vendor management. Particularly, this report establishes benchmarks around exclusive vendor partnerships management, use and extent of outsourcing of exclusive vendors, evaluation and return on investment, automation in vendor management and key lessons learned in exclusive vendor management.

$3300

Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals (ID PSM-323)

This study evaluates how biopharmaceutical companies involved in specialty therapeutic areas and rare diseases manage the market research approval process. It provides insights, metrics and best practices around the management of roles and responsibilities, cycle times, honoraria requirements, non-conforming requests and vendors.

$7000

Benchmarking Advisory Board Management At Large Pharmaceutical & Medical Device Organizations (ID PSM-319)

This study is designed to assist executives at large pharmaceutical and medical device organizations in identifying ways to best utilize the knowledge of advisory boards. It provides leading insights on the appropriate structure for different advisory boards, selection of advisory board participants, operational and cost benchmarks, top challenges and best practices for conducting advisory boards.

$4400

Big Data in Pharma: Current & Future Trends for Big Data Utilization Across Commercial Functions (ID PSM-315)

This study probes the current & future trends, winning strategies and best practices for Big Data utilization across the commercial function. It offers benchmarks around the most useful data types and sources for key commercial decisions; governance policies and leadership; and the most impactful data producers, dissemination channels and targets.

$5000

Big Data in Pharma: Current & Future Trends for Big Data Utilization Across the Health Outcomes Research Function (ID PSM-317)

This study probes the current & future trends, winning strategies and best practices for Big Data utilization across the Health Outcomes Research function. It investigates the most useful data types and sources for key HEOR decisions; governance policies and leadership and the most impactful data producers, dissemination channels and targets.

$5000

Big Data in Pharma: Current & Future Trends for Big Data Utilization Across Medical Affairs Functions (ID PSM-316)

This study probes the current & future trends and best practices for Big Data utilization across Medical Affairs functions. It investigates the types of big data projects used to inform key medical decisions; big data capabilities required; governance policies; types and value of data used for big data projects; data producers, dissemination & requestors; value rating of partnerships on big data projects; and policies & procedures governing big data activities.

$5000

Big Data in Pharma: Current & Future Trends for Big Data Utilization Across Medical, Commercial and HEOR Functions (ID PSM-311)

This study probes the current trends and best practices in utilizing Big Data across medical, commercial and HEOR segments. It investigates the most valuable big data projects, big data capabilities required, staffing and budget levels and governance policies.

$7500

Analytics Excellence: Current & Future Trends for Big Data Utilization in Pharma (ID PSM-310)

This study probes the current trends and best practices in utilizing Big Data in both medical and commercial settings in the pharmaceutical sector. It investigates the data types, data partnerships, and staffing/budget levels companies are using as they move to a more analytically based approach to commercial, HEOR & medical decisions.

$7000

Forging Deep Insights to Grow the Business: How Market Research Organizations Optimize the Mix of Tracking Research and Insight-Oriented Research (ID PSM-308)

This study shows the ideal allocation of market research resources to best serve internal customers. The study assessed the types of projects conducted and their respective values, as well as the internal structures and training needed to successfully manage the projects.

$3270

Innovation in the Pharma Industry: Market Research Tools, Technologies and Approaches to Improve Consumer Interactions (ID PSM-300)

This benchmarking study to identify current and evolving approaches for qualitative and quantitative consumer marketing research techniques and tools in pharmaceutical and medical device companies. This research examines the changing landscape for qualitative and quantitative research.

$6800

Best Practices in Innovating within Market Research to Reach Consumers: How New Tools, Technologies and Approaches Improve Understanding and Communicating with Consumers (ID PSM-299)

This cross-industry benchmarking study identifies current and evolving approaches for qualitative and quantitative consumer marketing research techniques and tools. It also reviews which quantitative research approaches market research leaders are currently utilizing most and why

$7600

Consumer Marketing Research Innovation: Assessing New Tools, Technologies and Approaches to Understand and Communicate with Consumers (ID PSM-296)

This study examines the changing landscape for qualitative and quantitative research. It also reviews which quantitative research approaches market research leaders are currently utilizing most and why.

$7400

Best Practices in Leveraging Employee Insights to Produce Cutting-Edge Market Research (ID PSM-295)

This study examines how leading global companies leverage their employees in conducting market research. The study provides Market Research executives, managers and supervisors with qualitative insights and quantitative metrics around the use of employees for Market Research.

$4500

Market Research Efficiency Benchmark: Using External Personnel and Automation to Maximize Effectiveness (ID PSM-288)

This study identify strategies, solutions, and the transition process Market Research groups are undergoing in the near future, this study seeks to help pharma and biotech executives and managers create more efficient groups and processes.

$5500

From Classroom to Boardroom: Training Can Propel Market Researchers from Order-Takers to Trusted Business Advisers (ID PSM-284)

This study to probe critical experiences, winning strategies and important resource trends regarding how best to develop and deploy Market Research Training and Development in today’s increasingly complex global marketplace with ongoing resource constraints.

$6050

Market Research: Impending Challenges And Changes To A Core Pharmaceutical Function (ID SM-189)

This study captures quantitative benchmarks and qualitative insights which provide companies with a deeper understanding of the future of market research. Specifically, the study covers the changing roles, responsibilities and trends in market research.

$4500

The Future of Market Research: Challenges And Changes In A Core Pharmaceutical Function (ID PSM-245)

This study reveals the future prospects of the market research function and its applications. By identifying recent trends, new directions, and best practices in Market Research, executives can aid and accelerate advancement of other business functions like Product Development.

$4100

Optimizing Oncology Market Research & Analytics (ID PSM-217)

This 40-slide presentation will help pharmaceutical and biotech companies evaluate and improve the effectiveness of their oncology market research and analytics (MR&A) programs.

$1391

MARKETING MANAGEMENT click to expand contents

KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History (ID PSM-392)

This case study reveals how Merck turned a near-failure into a cornerstone of cancer treatment through extensive clinical trials, innovative marketing, strategic collaborations, and unwavering investment. Despite entering the immuno-oncology market as a second-to-market product, KEYTRUDA not only caught up with its competitors but also became a dominant force in the field. The analysis provides insights into how Merck's efforts collectively propelled KEYTRUDA to the forefront of cancer treatment, establishing it as a blockbuster drug and a cornerstone of Merck’s oncology portfolio.

$3000

Medical-Commercial Collaboration and Growth Areas: Success Stories, Expanding Stakeholder Universe, Field Interactions, and the Future of Collaboration (ID POP-384)

The biopharma industry's digital transformation and demand for seamless customer experiences necessitate stronger collaboration between Medical Affairs and Commercial functions to leverage data-driven insights and improve patient outcomes. This Best Practices, LLC report highlights successful integration strategies and key collaboration opportunities to enhance impact and meet diverse customer needs.

$4500

Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease (ID PSM-389)

This case study reviews Tepezza’s trajectory to achieving blockbuster status in a rare disease autoimmune area for thyroid eye disease through Horizon Therapeutics’ launch and market entry strategies and execution.

$3900

Case Study: How argenx Broke into a Captive Market to Begin Dislodging an Entrenched Market Leader (ID PSM-388)

This case study reviews VYVGART’s trajectory to breaking into the captive generalized Myasthenia Gravis (gMG) market to begin dislodging an entrenched market leader. The study probes the development, launch, and market entry strategies executed by argenx to launch VYVGART as a first step in its rare disease franchise building.

$3900

Patient-Driven Growth: Maximizing Patient Journey Maps & Patient Co-Creation (ID POP-362)

This benchmarking report is designed to help biopharma leaders achieve patient-centric growth by examining innovative approaches, effective practices, and recommended vendors which are delivering high impact across patient journey mapping and patient co-creation. This research probes insights around patient journey mapping capabilities, structure, staffing, high-impact areas, sources, validation, updates, automation, vendors, innovation and KPIs – and overall leadership support of patient-centric initiatives. It also establishes benchmarks around patient co-creation programs, key design phases, engagement channels, high-impact areas, innovative trends.

$5900

Developing the Best Hybrid Work Model for Your Commercial Biopharma Organization (ID PSM-387)

This benchmarking report examines the changing forms, features, conditions, and triggers for hybrid work models that are best suited for a flexible and resilient Commercial organization.

$3900

Building Winning Trademarks and Trade Name Operations in Biopharma (ID PSM-382)

This benchmarking report distills winning strategies, structures, and approaches to the overall trademark evaluation and registration process at pharmaceutical and biotech companies. It delivers benchmarks that can inform successful trademark naming operations, funding levels, cross-functional participation, global coordination, best structures, winning internal communication strategies, and superior regional understanding.

$3900

Improving Patient Medication Adherence Metrics (ID PSM-381)

This report establishes industry benchmarks around patient medication adherence rates. It delivers benchmarks for basic metrics like Fill Rates, Time to Fill, and Reimbursement Rates as well as Complex Metrics like Adherence, Persistence, and Compliance Rates. The report also includes industry case studies around oral adherence.

$5000

Omnichannel Marketing: Maximize your Digital Marketing Assets (ID PSM-378)

This benchmarking report examines how leading biopharma companies are adopting an integrated omnichannel marketing strategy by maximizing their digital assets. It establishes industry benchmarks around digital marketing service structure, digital marketing staffing and investment, digital operations, innovative tools, digitizing new product planning and launch, performance measurement, mobile engagement and digital health, and key channels and activities.

$6000

Disease Awareness Program Excellence: Structure, Activities, and Resources Needed for Effective Pipeline Support (ID PSM-377)

This benchmarking report highlights effective practices around the timing, investment, and activities for disease awareness programs. It delivers insights, best practices, and pitfalls that participants have learned from many of their past disease awareness campaigns.

$5500

Digital Trends in Biopharma Launch Strategy and Investment (ID PSM-375)

This benchmarking report spotlights the secondary and tertiary drivers behind the accelerated pace of using digital strategies to drive innovative biopharma launches. The report identifies the high-value digital activities, spotlights investment trends, and captures key lessons learned. It also benchmarks the tools and techniques used to get the most out of digital launches.

$3750

Establishing a Promotion Review Editor to Oversee Advertising and Promotion Review Process (ID PSM-373)

This benchmarking report examines the utilization of the Promotion Review Editor role within biopharmaceutical companies. It probes the collaboration approaches, roles and responsibilities, importance and effectiveness of Promotion Review Editor within the company, involvement of Promotion Review Editors in electronic submissions and review process of promotional materials, functional location and reporting of Promotion Review Editors, and number of products supported by them. The report also highlights the best practices and challenges of having the Promotion Review Editor position in a company.

$2000

Pure Play Digital Launch: Launching a New Blockbuster Migraine Drug During a Global Pandemic (ID PSM-374)

This Best Practices, LLC case study probes how Biohaven used modern digital tools and technologies to successfully launch its ‘one dose’ migraine drug, Nurtec during the global COVID-19 pandemic.

$2500

Patient Advocacy Internal Collaboration to Raise Awareness, Guide Research, and Improve Access (ID PSM-370)

This benchmarking report probes how biopharma companies’ advocacy teams work to improve coordination efforts with internal groups such as Marketing, Medical Affairs, R&D, and Government Affairs. The report spotlights winning strategies, best practices and pitfalls to avoid when working with these groups.

$5000

Pharma’s Digital Transformation Turning Point: Disruption, Challenges and Recommendations for Medical and Commercial Leaders (ID PSM-367)

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic. It probes the various approaches towards digital transformation adopted by forward-looking biopharma companies spanning critical areas including HCP and external engagement, advisory boards and speaker programs management, clinical trials management, patient engagement, performance measurement, and others.

$5500

Effective Practices for Speaker Programs and Physician Advisory Boards during and after the COVID-19 Pandemic (ID CM-7)

This benchmarking report identifies effective practices for managing virtual speaker programs and physician advisory boards during the COVID-19 pandemic. It examines the key challenges with virtual speaker programs, approaches to addressing virtual program challenges, speaker program training formats for new and existing products, tactics to enhance virtual physician advisory boards, and managing virtual dinner programs and training during and post the COVID-19 pandemic.

$995

Changes in Outreach and Communications with Stakeholders during the Global COVID-19 Pandemic (ID CM-1)

This benchmarking report explores how companies are approaching external engagements with stakeholders following the global COVID-19 pandemic. In particular, this report spotlights the implementation of global COVID-19 pandemic task force, external engagement policies and limitations, necessary resources, challenges and issues prevalent due to the global COVID-19 pandemic, response to constraints in travel and visitation, and performance tracking during the global COVID-19 pandemic.

$995

Navigating KPI and Performance Measurement Challenges During the Global COVID-19 Pandemic (ID CM-2)

This benchmarking report explores how companies are approaching changes in key performance indicators (KPIs) during the COVID-19 pandemic. In particular, this report spotlights the changes in KPIs and performance measurement, measurement period, authority and duration over the course of the pandemic. It also examines the challenges encountered around performance measurement and suggestions from industry peers for best adapting KPIs and other measurements during the global pandemic to better reflect performance.

$995

Meeting the Challenge of Copay Accumulator Programs: Effective Pharma Strategies & Tactics for Ensuring Patient Access (ID PSM-359)

This benchmarking report highlights the impact of payer-imposed copay accumulator programs on specialty pharma manufacturers and their patients. The research also delves into effective tactics and strategies employed by organizations for mitigating the impact of copay accumulator programs. Research findings and insights will help Market Access leaders create and deploy an effective copay accumulator mitigation strategy that meets the full scope of the threat and ensure patient-centric treatment and reimbursement solutions.

$5500

Meeting the Challenge of Copay Accumulator Programs: Effective Oncology Manufacturer Strategies & Tactics for Ensuring Patient Access (ID PSM-361)

This benchmarking report highlights the impact of payer-imposed “copay accumulator” programs on oncology and other specialty manufacturers and their patients. The research delves into effective tactics and strategies employed by specialty biopharma companies for mitigating the impact of copay accumulator programs. Research findings and insights will help Market Access leaders create and deploy an effective copay accumulator mitigation strategy that meets the full scope of the threat and ensure patient-centric treatment and reimbursement solutions.

$5800

Value-Driven Patient Support Programs: How Top Companies Engage, Educate and Ensure the Adherence of their Patients (ID PSM-360)

This benchmarking research was undertaken to examine the growing importance of establishing a patient centric organization and how it can positively impact patient outcomes and commercial results. This benchmarking report probes current trends in patient support group structure, effectiveness, activities and staffing / budget levels within the biopharmaceutical sector. It also probes the utilization of patient hub services, and the best practices and pitfalls / stumbling blocks encountered as part of the patient support organization.

$3500

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice Outside of the United States (ID PSM-357)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management outside of the United States. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice (ID PSM-353)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice in the United States (ID PSM-356)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management in the United States. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Manufacturers Effectively Support Advocacy Groups Segmented by Reporting Function (ID PSM-358)

This benchmarking report highlights effective practices in patient advocacy group collaboration and relationship management. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy. Research insights are segmented on the basis of reporting structure to offer a clear understanding of the impact of organizational decisions on patient advocacy trends.

$6000

Connecting Pharma to Patients with Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets (ID PSM-354)

This benchmarking report probes the winning strategies, effective practices, and potential stumbling blocks encountered as a company shifts towards digital patient engagement in global, emerging and developed markets. Specifically, this report delivers digital patient engagement benchmarks around the tactics, tools and technologies employed for successful engagement; staffing drivers; investment trends; structure and reporting; processes and use of vendors; depth and scope of engagement; performance effectiveness; and critical lessons learned.

$5990

Gaining Support for Patient Adherence Programs and Effective Resource Allocation to Drive Adherence (ID PSM-349)

This benchmarking report delivers insights around the optimal resources and tactics for driving patient adherence. In particular, this report provides benchmarks around structure, staffing, vendor management, investment, leadership, process and program content for patient adherence programs. Additionally, this report highlights effective strategies for driving adherence.

$4000

Growing Your Medical Device Business in High-Potential Markets: Asia-Pacific & Latin America (ID PSM-346)

This report highlights the strategies and business models employed by medical device companies to capture market share and drive high revenue growth in key countries in Asia-Pacific and Latin America. In particular, this report delivers benchmarks around the structure, reporting, staffing and investment in high-potential emerging markets. The report also highlights the critical success factors and case studies of individual emerging markets.

$4900

Forge Top-Tier Biopharma Digital Strategy & Experience (ID PSM-343)

This benchmarking report explores how digital marketing leaders at pharmaceutical and medical device companies utilize new tools and tactics to educate key customers, enhance reach, increase speed, boost sales force effectiveness, measure and increase customer satisfaction, and offset declining HCP access.

$5500

Shaping an Impactful Global Marketing Organization in Measurement and Instrumentation Sector (ID PSM-345)

This report identifies the critical requirements for establishing an impactful global marketing organization in the measurement and instrumentation sector. It provides marketing leaders with insights regarding the activities falling under the purview of marketing function; optimal allocation of marketing resources across markets, products and services; effective relationships and governance models; and critical competencies requisite for an effective global marketing function.

$3000

Soliris: Translating Groundbreaking Science into a Successful Orphan Drug (ID PSM-342)

This case study reviews Soliris’ trajectory to achieving blockbuster orphan drug status – recording net product sales worth $2.8 billion in 2016 - through Alexion’s commercial expansion strategies, effective patient support programs and public relations campaigns. The study also highlights the numerous challenges encountered by the breakthrough therapy, most notably payer resistance to its hefty price tag and competition from upcoming biosimilars; and how Alexion is preparing to tackle these challenges.

$2500

Marketer Career Path Excellence: Best Practices for Training and Developing High-Impact Healthcare Marketers (ID PSM-339)

This benchmarking report identifies critical marketer training and development approaches and best practices to guide better marketing career path planning and execution at biopharmaceutical companies. It provides benchmarks around key skills, competencies, training curriculum and content, common language, role rotations, mentoring, external partnerships and career path development approaches for forging high-impact marketing professionals and future leaders.

$6500

Digital Innovation Path: Trends in Healthcare Digital Marketing Innovation, Customer Engagement, Investment and Approvals (ID PSM-337)

This research provides critical insights into how savvy bio-pharma digital marketers are expanding the reach and effectiveness of digital customer engagement through emerging channels, measuring ROI for innovative activities, right-sizing budget and staffing investment levels, and enhancing the digital content and program review and approval process.

$4400

Growing Biopharma Digital Marketing Impact: Digitizing Launch, Developing Talent and Optimizing Service Alignment (ID PSM-334)

This research identifies the critical drivers of digital marketing performance excellence in the healthcare industry. It probes how savvy biopharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs, and optimizing insource vs. outsource mix.

$4450

Optimizing Biopharma Digital Marketing: Insights to Improve Digital ROI, Performance Measurement, Field Force Support & Mobile Engagement (ID PSM-332)

This research provides a host of foundational benchmarks requisite to drive digital marketing performance excellence in the healthcare industry. It identifies how savvy digital marketers are utilizing new tools and tactics to reduce cost, enhance sales force effectiveness, measure performance and ROI for important channels, and key trends in mobile customer engagement.

$4400

REMS Excellence: Models & Trends in Supporting REMS Program Success (ID POP-270)

This study was conducted to identify how biopharmaceutical and medical device companies implement successful REMS plans for newly-approved products in the U.S. market. It provides insights around the structure and responsibilities of REMS teams, use of internal and external resources to support REMS programs, physician/ distributor compliance on ETASU, current challenges in REMS communication plans and innovative REMS approaches for new products.

$3000

Disease Awareness Program Excellence: Structure, Activities & Resources Needed for Effective Pipeline Support (ID PSM-328)

This study provides benchmarks on current disease state awareness program structure, spend, and activities that support pipeline products.

$6200

Finding & Showcasing Digital Impact: ROI, Performance Metrics, Launch & Maximizing Digital Performance (ID PSM-327)

This study identifies a host of foundational benchmarks required to achieve best-in-class performance in digital marketing in the healthcare sector, and foster a robust digital culture throughout the organization. It examines the top operational areas for measuring and demonstrating return on digital investment, key drivers and timing factors for maximizing return on investment, program approval timeframes, cross-channel performance metrics for individual channels and regulatory impact.

$5000

Best-in-Class Pharma Digital Marketing Performance: Core Services, Speed, Spend & Structure (ID PSM-325)

This study examines the factors required to achieve performance excellence in digital marketing in the health care sector, and foster a robust digital culture throughout the organization. It provides benchmarks around structural, staffing & budget trends, achieving multichannel maturity, and speed to execute key digital tactics.

$5000

Key Trends & Innovative Activities in Biopharma Digital Marketing (ID PSM-324)

This study identifies the hotspots in digital and multichannel innovation and evaluates key trends in successful education and engagement of physicians, patients and other customer groups across online channels. It also assesses the impact, effectiveness, and ROI of leading digital marketing activities and programs.

$5000

Patient Support Excellence: Structure, Activities and Resource Levels to Ensure Patient-Centric Products and Services (ID PSM-313)

This study explores the growing importance of establishing a patient centric organization and how it can positively impact patient outcomes and commercial results. It includes leading insights and metrics on current trends in Patient Support group structure, activities, alliances and resource/investment levels within the biopharmaceutical sector.

$7100

Pharma Digital Marketing Innovation: Service, Measurement & Investment Trends to Maximize Customer Impact (ID PSM-309)

This study examines how leading organizations maximize the value provided by the Digital Marketing function through efficient service delivery to both internal and external customers, across different regions, business lines, and throughout the product lifecycle. Leading insights in the study will help biopharma digital leaders right-size their budgetary investments, optimize resource allocation to key channels, and evaluate productivity and performance for all programs to demonstrate premium value to senior leadership.

$6950

Patient-Focused Marketing: Engagement Milestones Along the Patient Journey (ID PSM-306)

This study explores the growing influence of patients in the biopharmaceutical market and its impact on the activities and spends for marketing communications with patients.It also includes the current spending levels, key activities, and investment allocation patterns for marketing to and interacting with patients.

$8300

Pharma Social Media Listening: Benchmarking Innovative Practices in the Healthcare Industry (ID PSM-303)

This study helps healthcare companies improve their Social Media Listening (SML) programs to capture maximum patient and market insights while maintaining strict compliance. The study delivers crucial benchmarks from industry-leading companies on key Listening activities, platforms, websites monitored, data gathered, approval processes, and Adverse Events reporting and management.

$4150

Digital Marketing Excellence: Generating Top Value in an Emerging Healthcare Function (ID PSM-294)

This study helps healthcare companies measure and improve performance across a wide range of Digital Marketing (DM) functional areas and activities. Also, the study delivers insights on performance tracking, new tools and technologies, demonstrating value, better alignment with brand teams, talent acquisition and development, mitigating Regulatory risk, and investment trends.

$5500

Mastering Digital Marketing Structure & Strategy: Transforming Multi-Channel Marketing (ID PSM-285)

The study distills winning strategies for Digital Marketing activity management, staffing, and budget allocation to help executives manage their service costs and better serve their business units and their products.

$5175

Marketing Services Excellence: Driving Costs Down & Effectiveness Up (ID PSM-289)

This study investigates how companies are effectively structuring and operating the Marketing Services function within an environment that is characterized today by increasing globalization and shrinking resources.

$5750

Resource Benchmarks for Global Pharmaceutical Marketing Services (ID PSM-291)

This benchmarking report examines the staffing and resource investment levels for Marketing Services groups within global pharmaceutical, biotech and medical device companies.

$4400

Best Practices in Advancing Customer Marketing: Innovations in Engaging and Communicating with Health Care Providers, Patients, Payers and KOLs (ID PSM-280)

This study identifies how companies structure, staff and organize to find, use and quickly incorporate innovative practices to improve marketing across all customer groups.

$5000

Current and Future Trends in Physician E-Sampling: Managing for Superior Sales, Access, Service & Cost Benefits (ID PSM-278)

This study identifies and documents current practices and trends in physician e-sampling and explores the rationale for different tactical approaches to sampling and what constitutes success in physician e-sampling.

$3670

Medical Device Marketing Excellence: Optimizing Group Structure and Operations (ID PSM-272)

This study helps medical device marketing executives maximize their productivity and identify valuable insights critical to meet regulatory demands. The study also presents different organizational segments for medical device marketing activities and current trends in resource, structure and staffing levels. Also, the study also highlights future changes to be expected in medical device marketing.

$4500

Oncology Global Strategic Marketing: Benchmarking Budget Levels & Service Scope (ID PSM-271)

This study identifies valuable insights for Oncology-GSM leaders in budgeting and strategic planning. Specifically, this new study seeks to help GSM organizations understand the investment levels, marketing activities, timing and structures needed to successfully steer products and pipeline programs through the complex Oncology marketplace.

$6200

Online Patient Support Excellence: Using Brand Website Services to Grow Loyal Customers (ID PSM-258)

This study examined 10 leading biopharmaceutical products that treat chronic conditions, such as rheumatoid arthritis, osteoporosis and cancer, for which treatment is often expensive and patient education and long-term support are essential.

$3929

Best Practices for Using Social Media To Drive Business Outcomes (ID PSM-259)

This study identifies how companies use Social Media tools in their business environment, the opportunities and risks associated with Social Media applications as well as requirements for managing their use.

$3500

Performance Benchmark: Optimizing Staff Levels to Drive Growth in Medical Devices (ID PSM-244)

This study will aid organizations to benchmark strategic and tactical marketing activities with top companies in the medical device-healthcare sector, to support their product portfolio in driving corporate growth and profitability.

$2700

Innovations in Patient-Focused Initiatives: Case Studies in Reaching, Engaging and Supporting Patients (ID PSM-239)

As pharmaceutical, biotechnology and medical device companies seek new “go-to-market” strategies and tactics, they have explored new ways to approach and engage patient populations. This report examines the programs and initiatives aimed at directly affecting the lives and treatment of patients.

$4575

Performance Benchmark: Optimizing Marketing Staff Levels to Drive Growth (ID PSM-232)

This report examines Marketing Staffing and Activity versus growth and margin rates across three segments - Branded Bio-pharma Rx Products, Medical Devices, and Generic Products. The study would help to aid marketing organizations with direction for strategic and tactical marketing activities to support their product portfolios in optimizing growth and profitability rates.

$3500

Best Practices in Pharmaceutical Conventions Management (ID SM-159)

This report highlights the best practices of leading companies in optimizing their conventions management functions. In particular, it addresses the logistics of effectively managing conventions with limited budgets.

$1557

Using Institutional Patient Flow Maps to Optimize Psychiatric Treatment (ID SM-164)

This benchmarking report is designed to provide insights into the healthcare administered to psychiatric patients presenting with an episodic crisis. In particular, this report addresses issues such as communication gaps between patient and healthcare provider, patients more likely to fall through the cracks in the healthcare delivery process. Also, it looks at what decisions are made along the way and by whom and evaluates how healthcare could be improved for these critical patients.

$1892

Managing Market Planning for New Oncology Products (ID PSM-205)

This report shows how leading pharmaceutical companies successfully manage market planning for oncology products during Phase II and Phase III clinical trials.

$628

Mapping Patient Flow to Better Manage Severe Hospital Infections and Sepsis (ID SM-165)

This report provides insights into the management of patients with severe infections, and specifically the infection response known as sepsis at six leading academic medical centers through 19 interviews with expert physicians within the disciplines of emergency care, internal medicine, infectious disease and critical care. It includes an integrated patient flow map, showing an illustrated view of patient movements through the common pathways that exist across each of the medical centers for each phase of care: Emergency Department, General Inpatient and Intensive Care Unit. This map highlights common points of decision-making and disease onset or progression.

$1891

MEDICAL AFFAIRS click to expand contents

Building a Competitive IIT Program: Best Practices to Support Better Funding, Resourcing, and Approval Policies (ID POP-408)

This benchmarking report provides actionable insights into optimizing Investigator-Initiated Trials (IIT) management within biopharma organizations. It covers critical aspects like IIT funding strategies, key policies, approval processes, and efficiency-enhancing best practices. The research also segments data by geography (US, EU, Global) and company size (Large vs. Mid/Small Pharma), offering detailed comparisons to help you improve your IIT program’s performance. Additionally, it incorporates proprietary data on IIT program FTEs, phase intervals, and submission review approaches.

$4500

Interweaving Medical Strategy to Maximize New Treatment Success: Linking Launch Strategies with Medical Operations Excellence and Competitive Resourcing Decisions (ID POP-405)

This benchmarking report explores the evolving role of Medical Affairs in new biopharma product launches. It provides insights on resource allocation, strategic development, and operational execution, with a focus on leveraging data, analytics, and digital tools for launch success. The report covers critical success factors, common challenges, and effective strategies used by leading biopharma organizations.

$4500

Best Practices in Improving Medical Affairs Booth Impact at Critical Medical Congresses (ID POP-404)

This benchmarking report provides actionable insights into the types of medical content showcased by pharmaceutical companies in exhibit booths at key medical congresses. It also examines the methods used to engage healthcare professionals, focusing on display tactics, performance measurement, and the role of medical science liaisons. Additionally, the report explores best practices for poster and investigator events, offering a comprehensive view of how biopharma companies can optimize their booth strategies for greater impact.

$6000

Improving Medical Affairs Booth Impact at CNS Congresses (ID POP-406)

This benchmarking report provides key insights into optimizing Medical Affairs booths at CNS-focused congresses, including those in neurology and psychiatry. It examines best practices for displaying medical content, engaging HCPs, and measuring booth success. The research also explores how MSLs facilitate scientific exchange, the role of interactive displays, and effective poster/investigator events at CNS congresses. With tailored strategies, this report equips Medical Affairs teams with the tools to enhance CNS booth impact while ensuring compliance and scientific integrity.

$6000

Improving Medical Affairs Booth Impact at Oncology Congresses (ID POP-407)

This benchmarking report delivers in-depth insights into optimizing Medical Affairs booths at leading oncology congresses, where biopharma companies showcase cutting-edge cancer treatments and research. The research explores best practices for booth design, medical content sharing, and HCP engagement strategies tailored for oncology professionals. Additionally, it examines performance measurement tactics, innovative MSL content strategies, and the effectiveness of poster/investigator receptions at oncology events.

$6000

Assessing the Impact of Medical Affairs: Embrace New Measurement Strategies to Promote Your Value Story, Increase Impact, and Gain Resources (ID POP-394)

This benchmarking report explores the evolving metrics for evaluating Medical Affairs' value. By engaging 34 leaders from top biopharma organizations, it provides actionable insights into redefining and quantifying Medical impact, overcoming measurement hurdles, linking activities to real-world outcomes, and securing resources.

$4500

Automating Medical Information: Using New Tools and Systems To Scale and Optimize Medical Info and Call Center Operations (ID POP-393)

This benchmarking report will help Medical Information groups incorporate effective automation, innovative tools, optimal resources, and more efficient processes to handle Medical Information Requests. It will also provide best practices and lessons learned to upscale call center capacity and increase response rate, while maintaining a lean headcount.

$4600

Medical-Commercial Collaboration and Growth Areas: Success Stories, Expanding Stakeholder Universe, Field Interactions, and the Future of Collaboration (ID POP-384)

The biopharma industry's digital transformation and demand for seamless customer experiences necessitate stronger collaboration between Medical Affairs and Commercial functions to leverage data-driven insights and improve patient outcomes. This Best Practices, LLC report highlights successful integration strategies and key collaboration opportunities to enhance impact and meet diverse customer needs.

$4500

Global Medical Affairs Resourcing Benchmark for Med Planning Functions (ID POP-383)

Optimized resource allocation within the Medical Planning Function is vital for biopharma success. Best Practices, LLC's benchmarking study explores how top companies manage their Medical Planning resources for maximum impact. The report assesses productivity, outsourcing, spending, and staffing benchmarks at mid-sized to large biopharma firms.

$2100

Building a Foundational Global Function for Reviewing IME Grants (ID POP-382)

This operational benchmarking report explores the key roles and activities of global IME groups, focusing on structuring grant review processes to maximize IME budgets. It also investigates how these groups manage grant evaluation and selection, crucial for proactively identifying and addressing educational gaps at the provider level.

$4000

Global Medical Affairs Resourcing Benchmark for Med Communications & Content Development Functions (ID POP-381)

This benchmarking report provides an extensive analysis of resource allocation within Med Communications & Content Development functions. Through meticulous examination of productivity metrics, outsourcing benchmarks, spending patterns, and staffing dynamics across mid-sized and large biopharma organizations, this report equips Medical Publications leadership with strategic insights.

$3300

Global Medical Affairs Resourcing Benchmark for HEOR Functions (ID POP-380)

This benchmarking report delves into the intricate details of resource allocation within the Health Economics and Outcomes Research (HEOR) function. Through meticulous analysis of productivity, outsourcing benchmarks, expenditure patterns, and staffing dynamics within mid-sized and large biopharma organizations, this report offers invaluable insights for HEOR leadership.

$4000

Establishing LATAM Standards for Field Medical Performance Excellence (ID POP-377)

This benchmarking report aims to equip Field Medical Excellence leaders in the Latin America (LATAM) region with a comprehensive framework dedicated to fostering consistency and driving high impact. By providing key insights and benchmarks, this report assists field medical leaders in optimizing KOL interactions, evaluating MSL performance metrics, and strategically aligning staffing footprints.

$3000

Establishing MENA Standards for Field Medical Performance Excellence (ID POP-378)

This benchmarking report aims to equip Field Medical Excellence leaders in the Middle East - North Africa (MENA) region with a comprehensive framework dedicated to fostering consistency and driving high impact. The report provides benchmarks and insights aimed at optimizing KOL interactions, evaluating MSL performance metrics, and strategically aligning staffing footprints.

$3000

Establishing APAC Standards for Field Medical Performance Excellence (ID POP-376)

This benchmarking research was conducted by Best Practices, LLC to provide Field Medical Excellence leaders in the APAC region with a thorough framework dedicated to fostering consistency and achieving significant impact. Utilizing a comprehensive dataset meticulously organized at the country level, our report assists field medical leaders in enhancing KOL interactions, assessing MSL performance metrics, and strategically aligning staffing footprints.

$4000

Establishing EU Standards for Field Medical Performance Excellence (ID POP-375)

This benchmarking report is designed to provide Field Medical Excellence leaders in Europe with a comprehensive framework focused on fostering consistency and driving impactful outcomes. Drawing from an extensive dataset meticulously segmented at the country level, our report assists field medical leaders in optimizing KOL interactions, evaluating MSL performance metrics, and strategically aligning staffing footprints.

$4000

Establishing North America Standards for Field Medical Performance Excellence (ID POP-374)

This benchmarking report aims to equip Field Medical Excellence leaders in North America with a comprehensive framework dedicated to fostering consistency and driving high impact. Leveraging an extensive dataset thoughtfully segmented at the country level, our report aids field medical leaders in optimizing KOL interactions, evaluating MSL performance metrics, and strategically aligning staffing footprints.

$5000

Rare Disease Field Medical Excellence Benchmark of Top 12 Global Markets: Establishing Standards for High Performance & Impact (ID POP-373)

This benchmarking report is crafted to empower rare disease field medical excellence leaders in constructing a robust framework aimed at ensuring consistency and maximizing impact across five pivotal regions (North America, Europe, APAC, LATAM, and MENA), where medical science liaisons (MSLs) play a pivotal role. By leveraging an extensive and meticulously segmented dataset, this report equips rare disease field medical leaders with the insights needed to elevate KOL interactions, assess MSL performance metrics, and strategically align staffing footprints.

$6000

Field Medical Excellence Benchmark of Top 12 Global Markets: Establishing Standards for High Performance & Impact (ID POP-371)

This benchmarking report has been meticulously crafted to empower Global Field Medical Excellence leaders in shaping a comprehensive framework dedicated to fostering consistency and achieving high impact across five pivotal regions (North America, EU, APAC, LATAM, and MENA), each marked by active engagement of MSLs. Drawing from an extensive and nuanced dataset, thoughtfully segmented at regional, country, and therapeutic area levels, our report will help field medical leaders to optimize KOL interactions, assess MSL performance metrics, and strategically align their staffing footprints.

$6900

Oncology Field Medical Excellence Benchmark of Top 12 Global Markets: Establishing Standards for High Performance & Impact (ID POP-372)

This benchmarking report has been designed to help Oncology Field Medical Excellence leaders in developing a comprehensive framework dedicated to fostering consistency and driving high impact across five key regions (North America, Europe, APAC, LATAM, and MENA), characterized by the dynamic involvement of Medical Science Liaisons (MSLs). Leveraging an extensive and finely segmented dataset, the report serves as a valuable resource, enabling Oncology field medical leaders to enhance KOL interactions, evaluate MSL performance metrics, and strategically align staffing footprints for optimal operational efficiency.

$6000

Medical Affairs People Management Excellence: Maximizing Talent & Retention Through Better Training, Development and Career Path Leadership (ID POP-370)

This benchmarking report delves into the strategies employed by Medical Affairs groups to maximize their talent and retention through the implementation of superior training, development, and career path leadership. This report investigates key aspects of People Management within Medical Affairs, including onboarding, training protocols, ongoing development initiatives, retention strategies, hiring approaches, and performance assessments.

$4000

Rare Blood Disorders MSL Team Excellence: Benchmarking Staffing, Roles, Recruitment, Development, Retention, and Field Success (ID POP-367)

This benchmarking report delves into current and emerging trends around virtual and hybrid MSL management within the Rare Blood Disorders therapeutic area. The research will serve as a valuable resource for field medical groups specializing in Rare Blood Disorders, providing insights into enhancing MSL retention, competitive compensation structures, optimal staffing levels, impactful engagement strategies, access to key external experts, and the evaluation of field performance.

$5000

Leveraging Medical Analytics to Improve Strategy, Launch, Outcomes and Care Models (ID POP-369)

This benchmarking report explores how Medical Affairs groups are growing the use of analytics, gaining organizational support for higher investment, and achieving strategic goals by means of both big and small data analysis.

$4500

Oncology MSL Team Excellence: Benchmarking Staffing, Roles, Recruitment, Development, Retention, and Field Success (ID POP-366)

This benchmarking report delves into the management of virtual and hybrid Medical Science Liaisons (MSLs) within Oncology companies. It provides valuable insights into the evolving landscape of Oncology field medical teams, equipping leaders with the knowledge needed to enhance MSL retention, structure competitive compensation packages, optimize staffing levels, craft effective engagement strategies, facilitate access to critical external experts, and establish robust performance metrics.

$5000

Patient-Focused Medical Affairs Excellence: Building Medical Patient Teams and Engaging Stakeholders with Patient Experience Insights (ID POP-368)

This benchmarking report examines how top biopharma companies are developing efficient Medical patient teams and engaging influential stakeholders with rich patient experience insights. It delivers an array of insights, exploring high-value activities and engagement strategies; influence of patient insights on KOL engagement; direct patient interactions; and Medical’s utilization of patient-reported outcomes.

$3900

Rare Disease MSL Team Excellence: Benchmarking Staffing, Roles, Recruitment, Development, Retention, and Field Success (ID POP-365)

This benchmarking report establishes current and emerging trends around virtual and hybrid MSL management in the realm of rare diseases. Our research will assist rare disease field medical groups in better understanding how to increase MSL retention, provide competitive pay, optimize staffing, ensure effective engagement strategies and access to key external experts, and evaluate field performance and impact.

$5000

The Modern Field Medical Team: Benchmarking Hybrid vs. Traditional MSL Roles, Salary, Retention, Access and Engagement Levels (ID POP-364)

This benchmarking report establishes current and emerging trends around managing virtual and hybrid medical science liaisons. This study is designed to assist field medical groups in better understanding how to improve MSL retention, offer competitive salaries, optimize staffing, ensure effective engagement strategies and access to key external experts, and assess field performance and impact.

$5000

Quantifying Impact & Telling the Value Story in Medical Affairs (ID POP-363)

This benchmarking report examines how Medical Affairs groups assess their impact on external stakeholders and essentially communicate their value to the organization. It explores how the use of external metrics and value-based assessments affects Medical Affairs functions, allowing Medical Affairs professionals to create an engaging narrative for top-level management.

$7500

Medical’s Road Map for Social Media Success in Rare Disease Segment (ID POP-361)

This benchmarking report examines current trends and future directions to construct the roadmap for Medical Affairs’ social media success in Rare Disease segment. The research explores current trends and success factors in harnessing the power of social media to effectively educate the rare disease market. It delivers benchmarks around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$5500

Medical’s Road Map for Social Media Success in Immunology (ID POP-360)

This Best Practices, LLC report investigates current trends and future directions to build the roadmap for Medical Affairs’ social media success in Immunology. The report delivers benchmarks around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$5500

Medical’s Road Map for Social Media Success in Oncology (ID POP-359)

This benchmarking report uncovers industry best practices and benchmarks to construct Medical’s road map for social media success in Oncology. It delivers insights around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$5500

Patient-Driven Growth: Maximizing Patient Journey Maps & Patient Co-Creation (ID POP-362)

This benchmarking report is designed to help biopharma leaders achieve patient-centric growth by examining innovative approaches, effective practices, and recommended vendors which are delivering high impact across patient journey mapping and patient co-creation. This research probes insights around patient journey mapping capabilities, structure, staffing, high-impact areas, sources, validation, updates, automation, vendors, innovation and KPIs – and overall leadership support of patient-centric initiatives. It also establishes benchmarks around patient co-creation programs, key design phases, engagement channels, high-impact areas, innovative trends.

$5900

Medical’s Road Map for Social Media Success (ID POP-358)

This benchmarking report examines current trends and future directions to construct the roadmap for Medical Affairs’ social media success. It delivers benchmarks around the structure, activities, content sharing policies, stakeholder collaborations, content review committees, omnichannel integration, and key performance indicators.

$6490

Embracing Omnichannel Engagement in Medical Affairs (ID POP-357)

This benchmarking report probes the advances in omnichannel engagement approaches by Medical Affairs organizations. It examines current levels of omnichannel engagement in Medical Affairs, staffing and budget dedicated to omnichannel efforts, digital and in-person engagement activities, direct and indirect communication channels, and emerging KPIs for evaluation. The report further evaluates the challenges, benefits, and lessons learned in implementing omnichannel engagement programs.

$5490

Benchmarking Real-World Uses of Artificial Intelligence in Medical Affairs (ID POP-356)

This benchmarking report explores the real-world uses of artificial intelligence (AI) in Medical Affairs. The research probes how leading biopharma organizations are applying AI within Medical Affairs to enhance personalized engagement of stakeholders, improve data analysis and evidence generation, facilitate omnichannel implementation, modify medical strategy and operations, gather insights, and take critical actions. The report also highlights the key lessons learned for developing and deploying AI within a Medical Affairs organization.

$3900

Benchmarking IIS Strategy: Maximizing Investigator-Initiated and Collaborative Study Capabilities (ID POP-355)

This benchmarking report probes the strategies, resources and activities surrounding investigator-initiated studies (IISs) and collaborative studies which are needed to help Medical Affairs and Clinical Development groups gain support for IIS programs and maximize the potential of their drug portfolios.

$3500

Scientific Communication Platform Excellence (ID POP-353)

This benchmarking report examines current practices around the development, utilization, management, and evaluation of scientific communication platforms (SCPs). It also probes the top strategies and pitfalls observed by pharmaceutical and medical device companies during SCP initiation and development.

$4600

Building an Elite Medical Excellence Group (ID POP-352)

This benchmarking report examines how pharma and medical device companies are leveraging their Medical Excellence groups to raise efficiency and impact across their Medical organization. It delivers benchmarks around maturity, drivers, benefits, activities, staffing, investment, structure, and key performance measures. It also includes benchmark data from organizations planning to establish a Medical Excellence group in the near future.

$5900

Engaging Patients across Medical Affairs Activities and Functions (ID POP-351)

This benchmarking report highlights how Medical Affairs can amplify the patient voice within the biopharma organization. It delivers benchmarks around early-stage and late-stage patient support strategies, roles and responsibilities, and internal and external collaboration for patient engagement. The report also probes the critical lessons learned and pitfalls encountered in capturing and representing the patient voice through Medical Affairs.

$5700

Engaging Central Nervous System (CNS) Patients across Medical Affairs Activities and Functions (ID POP-402)

This benchmarking report delves into how Medical Affairs can amplify the voice of CNS patients within the biopharma industry. The report examines strategies for early-stage and late-stage patient support, roles and responsibilities, and effective internal and external collaboration with partners for CNS patient engagement. It also probes the critical lessons and pitfalls encountered in representing the patient voice in CNS segment.

$5700

Engaging Oncology Patients across Medical Affairs Activities and Functions (ID POP-403)

This benchmarking report focuses on how Medical Affairs can elevate the oncology patient voice within biopharma organizations. It examines early-stage and late-stage patient support strategies, roles and responsibilities, and the importance of internal and external collaboration to enhance oncology patient engagement. The report also delivers insights on critical lessons and challenges faced in representing the oncology patient voice.

$5700

Developing the Best Hybrid Work Model for Your Medical Affairs Organization (ID POP-350)

This benchmarking report examines the changing forms, features, conditions, and triggers for hybrid work models that are best suited for a flexible and resilient Medical Affairs organization.

$5100

HCP Engagement Excellence: Optimizing Contracting Processes, Resources and Internal Interactions for Engaging Physicians and other HCPs (ID POP-349)

This benchmarking report was undertaken to help pharma HCP contracting groups better understand the contracting process across different geographies. The research establishes benchmarks on HCP contracting process, effectiveness, timeline and staffing.

$4500

Medical HQ Excellence: Building a World-Class Medical Affairs Onboarding and Training Function (ID POP-348)

This benchmarking report explores how biopharma companies onboard and train key medical HQ personnel, including Associate Scientific Directors, Scientific Directors and Therapy Area leads. It delivers benchmarks on Medical Affairs onboarding and training program management, staffing, training formats, platforms, timelines, and performance assessment.

$4400

Medical Affairs and Digital Opinion Leaders: Identifying, Engaging and Succeeding with Online Influencers (ID POP-347)

This benchmarking report examines how Medical Affairs teams can effectively identify, engage, and collaborate with Digital Online Influencers. The research benchmarks key aspects of a DOL engagement program, including DOL identification and engagement, DOL program structure and staffing, vendor management, and ensuring compliant DOL engagement. It also highlights key strategies, success stories, and lessons learned in the realm of DOL engagement.

$5000

Best Practices in Creating Efficient and Effective Medical Affairs and Market Access Teams in Medical Devices (ID POP-346)

This benchmarking report establishes staffing, resourcing, and operating benchmarks for Medical Affairs and Market Access teams within medical device companies. It will help Medical Affairs and Market Access leaders determine how to strategically adapt their own teams to current medical device industry standards.

$4500

Current and Anticipated Applications of Artificial Intelligence (AI) in Medical Affairs (ID POP-344)

This report explores current and anticipated applications of artificial intelligence within Medical Affairs to determine how to deploy an AI strategy over the next 3 years. It probes key topics including business opportunities for Medical Affairs, working with consultancies and/or software vendors, measuring success, navigating regulations, structuring, staffing, and further opportunities for Medical Affairs using artificial intelligence.

$4800

How Pharma is Utilizing Social Media, Patient Groups and Virtual Formats for Delivering Medical Education (ID POP-343)

This benchmarking report is designed to help Medical Affairs leaders understand the latest medical education trends around use of social media platforms, patient programs, and sponsorships/corporate memberships.

$4900

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine (ID PSM-380)

This report probes successful practices for managing hostile stakeholders during the launch of a breakthrough new medicine. Best Practices, LLC engaged front-line executives at 11 companies across 9 therapeutic areas and conducted extensive secondary research on leading brand launches to identify winning strategies to soften stigma and hostile stakeholder responses during launch.

$3800

Building More Effective Medical Affairs Product Launch Teams: Cardiology and Pulmonology Segment (ID POP-385)

This benchmarking report explores Medical’s role in cardiology and pulmonology product launches. The research probes digital tool utilization and launch tool deployment, roles and responsibilities, cross-functional alignment, and performance metrics. It further explores critical success factors for and major challenges to launch preparedness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Immunology Segment (ID POP-388)

This benchmarking report explores the critical role of Medical Affairs in launching immunology products. It analyzes the use of digital tools, role definitions, cross-functional alignment, and key performance indicators. Additionally, the report highlights success factors and major challenges impacting launch readiness.

$6000

Building More Effective Medical Affairs Product Launch Teams: CNS / Neurosciences Segment (ID POP-386)

This Best Practices, LLC report examines the role of Medical Affairs in CNS / Neurosciences product launches. The research investigates digital launch tool deployment, roles and responsibilities, cross-functional alignment, and performance metrics used to gauge success. Additionally, the report identifies key success factors and major challenges in achieving effective launch preparedness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Hematology Segment (ID POP-387)

This Best Practices, LLC report delves into the pivotal role of Medical Affairs in the launch of hematology products. It examines the deployment of digital tools, the delineation of roles and responsibilities, cross-functional collaboration, and key performance metrics. The report also identifies the success factors and significant challenges that influence launch readiness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Metabolic Diseases Segment (ID POP-390)

This Best Practices, LLC report offers an in-depth analysis of how Medical Affairs can transform the launch of products for metabolic diseases. It explores the integration of digital tools, clear definition of roles, effective cross-functional collaboration, and essential performance metrics. The report also examines success factors and critical challenges that impact launch preparedness, equipping teams with actionable insights for achieving superior results.

$6000

Building More Effective Medical Affairs Product Launch Teams: Oncology Segment (ID POP-391)

This Best Practices, LLC report delves into optimizing Medical Affairs teams for successful oncology product launches. It covers the strategic use of digital tools, defines roles and responsibilities, and explores effective cross-functional collaboration. The report also highlights key success factors and common obstacles, providing actionable insights to enhance launch readiness in the competitive oncology landscape.

$6000

Building More Effective Medical Affairs Product Launch Teams: Respiratory Segment (ID POP-392)

This Best Practices, LLC report explores the vital contributions of Medical Affairs teams in launching respiratory products. It examines the implementation of digital tools, role management, and cross-departmental collaboration. The report identifies key success factors and common challenges, providing strategic guidance for optimizing launch readiness and effectively meeting patient needs in the respiratory therapeutic area.

$6000

Building More Effective Medical Affairs Product Launch Teams: Infectious Diseases Segment (ID POP-389)

This Best Practices, LLC report focuses on optimizing Medical Affairs in the context of infectious disease product launches. It provides a thorough analysis of digital tool integration, role clarity, and collaborative efforts. The report identifies key success drivers and challenges that Medical Affairs teams must navigate to ensure launch readiness in the rapidly evolving infectious diseases space.

$6000

Best Practices in the Oversight and Management of Investigator-Initiated Trials in Oncology (ID POP-341)

This benchmarking report provides a detailed roadmap for improving IIT management within oncology companies, capturing critical metrics and insights on IIT management team structure, staffing, budget, and performance metrics.

$5800

Building More Effective Medical Affairs Product Launch Teams (ID POP-342)

This benchmarking report explores Medical Affairs’ role in product launch. The research explores roles and responsibilities, cross-functional alignment, performance metrics, resourcing, activities effectiveness, launch timeline, and digital launch tools deployment. It further explores the success factors and major challenges to Medical Affairs’ launch preparedness.

$6500

Best Practices in the Oversight and Management of Investigator Initiated Trials in CNS Therapeutic Area (ID POP-340)

This benchmarking report provides a detailed roadmap for improving IIT management within CNS companies, capturing critical metrics and insights on IIT management team structure, staffing, budget and performance metrics.

$5800

Leveraging Outcomes Data - Operational Roles in Health Economics & Outcomes Research for CNS Products (ID POP-339)

This benchmarking report delivers insights around effective ways to develop successful Health Outcomes groups within companies offering CNS products. It illustrates how HEOR function is involved in decision-making and delivering value for medical activities. The report underlines strategies for effective health outcomes data communication and utilization, stakeholder collaboration, and launch investment timeline for new CNS therapies. It also outlines the advantages and challenges for a successful HEOR program.

$5900

Leveraging Outcomes Data - Operational Roles in Health Economics & Outcomes Research in Oncology Products (ID POP-338)

This benchmarking report delivers insights around effective ways to develop successful Health Outcomes groups within companies manufacturing oncology products. It illustrates how HEOR function is involved in decision-making and delivering value for medical activities. The report underlines strategies for effective health outcomes data communication and utilization, stakeholder collaboration, and launch investment timeline for new oncology therapies. It also outlines the advantages and challenges for a successful HEOR program.

$5900

Healthcare Innovation Using Artificial Intelligence and Data Analytics: How “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth (ID PSM-379)

This Best Practices, LLC case study reviews how artificial intelligence and data analytics are being utilized to drive innovation in healthcare. Specifically, this case study probes how Colgate-Palmolive’s “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth.

$2400

Field Medical Excellence: Optimizing Staffing, Structure and Performance (ID POP-337)

This benchmarking report highlights competitive field medical team staffing and resource levels, optimal field medical team structures, and performance metrics in key global markets. The research delivers a wide range of field-based benchmarks across staffing levels, resource allocations, productivity measures, efficiency indicators, frequency of thought leader interactions by tier, effective communication channels, and new approaches to measure field impact.

$4000

Medical Affairs 2025: Where Are We Going? How Do We Get There? (ID POP-336)

This research explores a four-year future horizon: What will the Medical Affairs organization look like in 2025? How will Medical Affairs leaders get there? The report examines evolving roles, stakeholder priorities, tools, technologies, capabilities, value fronts, and structures. It further explores the direction and velocity of change within Medical Affairs.

$5000

Disease Awareness Program Excellence: Structure, Activities, and Resources Needed for Effective Pipeline Support (ID PSM-377)

This benchmarking report highlights effective practices around the timing, investment, and activities for disease awareness programs. It delivers insights, best practices, and pitfalls that participants have learned from many of their past disease awareness campaigns.

$5500

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization (ID POP-333)

This benchmarking report probes best practices for gathering and disseminating insights within the Medical Affairs organization. It delivers benchmarks around the structure of Medical Insights and Dissemination group; coordination, activities, training techniques and tools required for gathering insights; activities and tools required for disseminating insights. It also highlights the innovative practices and key lessons learned in successfully gathering and distributing insights.

$6900

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization: Hematology Segment (ID POP-397)

This benchmarking report explores best practices for insight generation and distribution within Hematology Medical Affairs teams. It provides benchmarks on the structure of Hematology Medical Insights and Dissemination groups, focusing on coordination efforts, key activities, and effective tools and training techniques. The report also examines innovative practices for disseminating hematology insights and highlights valuable lessons learned to enhance performance across hematology-focused teams.

$6900

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization: Neurology Segment (ID POP-398)

This benchmarking report highlights best practices for gathering and distributing insights within Neurology Medical Affairs teams. It provides benchmarks on group structure, coordination, tools, and training techniques essential for effective insight management. The report also showcases innovative practices and key lessons learned, offering actionable strategies to enhance Neurology-focused Medical Affairs functions.

$6900

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization: Immunology Segment (ID POP-395)

This benchmarking report dives into best practices specifically for gathering and disseminating insights within Immunology Medical Affairs teams. It provides benchmarks on the structure of Immunology Medical Insights and Dissemination groups, highlighting key coordination efforts, activities, and the tools and training techniques essential for effective insights gathering. Additionally, it examines the tools and activities necessary for disseminating immunology insights and showcases innovative practices that drive success. The report also captures key lessons learned, offering valuable takeaways for elevating insight generation and distribution within immunology-focused teams.

$6900

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization: Endocrine and Metabolic Disorders Segment (ID POP-396)

This benchmarking report delves into best practices for gathering and disseminating insights within Endocrine and Metabolic Disorders-focused Medical Affairs teams. It provides benchmarks on the structure of insights dissemination groups, highlighting coordination efforts, activities, and the essential tools and training techniques for effective insight management. Additionally, the report examines the tools and activities necessary for disseminating insights, showcasing innovative practices that drive success. It also captures key lessons learned, offering valuable takeaways for elevating insight generation and distribution within teams focused on endocrine and metabolic disorders.

$6900

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization: Oncology (Hematologic Malignancies) Segment (ID POP-399)

This benchmarking report explores best practices for gathering and sharing insights within Oncology (Hematologic Malignancies) Medical Affairs teams. It provides benchmarks on team structure, coordination, and key tools for effective insight management. Discover innovative dissemination techniques, essential training methods, and expert-driven strategies to enhance insight generation and distribution. Gain actionable lessons to optimize your approach and drive Medical Affairs success in oncology.

$6900

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization: Oncology (Solid Tumors) Segment (ID POP-400)

This benchmarking report examines effective strategies for gathering, managing, and distributing insights within Medical Affairs teams focused on solid tumors. It establishes key benchmarks on team structure, coordination, and tools while exploring innovative dissemination techniques, essential training, and expert-driven strategies. By applying these insights, Medical Affairs teams can refine their approach to insight management, enhance decision-making, and contribute to advancing oncology care.

$6900

Best Practices for Gathering and Distributing Insights within Medical Affairs Organization: Psychiatry / CNS Segment (ID POP-401)

This benchmarking report explores best practices for gathering and sharing insights within Psychiatry and CNS-focused Medical Affairs teams. It provides key benchmarks on team structure, coordination, and essential tools for insight management. The report also examines innovative dissemination techniques, effective training programs, and expert-driven strategies that enhance insight generation and distribution. By leveraging these insights, Medical Affairs professionals can optimize their approach to insight management, strengthen cross-functional collaboration, and ensure critical scientific data informs clinical decision-making and therapeutic progress

$6900

Challenges and Effective Practices for Optimizing a Customer Relationship Management System for Field Medical Teams (ID POP-334)

This benchmarking report highlights the key challenges and effective practices for optimizing a customer relationship management system for field medical teams. It is designed to help Medical Affairs leaders understand the latest trends and applications around CRM utilization, support and management for field-based medical teams.

$4000

Benchmarking Thought-Leader Fair Market Value in the Healthcare Industries (ID POP-332)

This benchmarking report probes trends in fair market value (FMV) compensation rates for thought leaders across KOL tiers, therapeutic areas, countries, and activities. It also provides FMV compensation rates for event preparation and for non-specialists. The report also underlines the best practices and challenges encountered while determining fair market value for industry KOLs and thought leaders.

$4900

Best Practices in the Use of Digital Technologies and Artificial Intelligence within Medical Affairs (ID POP-331)

This benchmarking report probes the use of digital technologies and artificial intelligence within Medical Affairs. It delivers benchmarks around digital activities and capabilities in Medical Affairs, roles and reporting in Digital Medical Affairs, resourcing of digital initiatives, patient engagement through e-medical initiatives, and use of artificial intelligence in Medical Affairs. The report also highlights the key trends and emerging digital issues in Medical Affairs.

$7400

Pharma’s Digital Transformation Turning Point: Disruption, Challenges and Recommendations for Medical and Commercial Leaders (ID PSM-367)

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic. It probes the various approaches towards digital transformation adopted by forward-looking biopharma companies spanning critical areas including HCP and external engagement, advisory boards and speaker programs management, clinical trials management, patient engagement, performance measurement, and others.

$5500

How Strong Medical Affairs Teams Use RWE to Achieve Impact along Patient, Disease State, Clinical and Payer Fronts (ID POP-330)

This benchmarking report probes how Medical Affairs teams from leading pharmaceutical and medical device companies are using real world evidence to achieve impact along patient, disease state, clinical and payer fronts. It examines the role of Medical Affairs in RWE strategic decision making, oversight, evaluating evidence gaps, and interpreting the medical and clinical value of health outcomes. The report also delivers benchmarks around real world data sources, collection, evaluation, utilization, evidence generation, investment and key performance indicators.

$5400

Best Practices in Distributing Medical Info to Investigators and Physicians through Investigator Portals and Other Means (ID POP-329)

This benchmarking report examines the means used by pharma companies to distribute medical information to investigators and physicians.

$1500

Effective Practices for Speaker Programs and Physician Advisory Boards during and after the COVID-19 Pandemic (ID CM-7)

This benchmarking report identifies effective practices for managing virtual speaker programs and physician advisory boards during the COVID-19 pandemic. It examines the key challenges with virtual speaker programs, approaches to addressing virtual program challenges, speaker program training formats for new and existing products, tactics to enhance virtual physician advisory boards, and managing virtual dinner programs and training during and post the COVID-19 pandemic.

$995

Best Practices in the Oversight and Management of Investigator Initiated Trials (ID POP-327)

This benchmarking report provides a detailed roadmap for improving IIT management at bio-pharmaceutical companies, providing critical metrics and insights on IIT management team structure, staffing, budget and performance metrics.

$5800

Changes in Outreach and Communications with Stakeholders during the Global COVID-19 Pandemic (ID CM-1)

This benchmarking report explores how companies are approaching external engagements with stakeholders following the global COVID-19 pandemic. In particular, this report spotlights the implementation of global COVID-19 pandemic task force, external engagement policies and limitations, necessary resources, challenges and issues prevalent due to the global COVID-19 pandemic, response to constraints in travel and visitation, and performance tracking during the global COVID-19 pandemic.

$995

Navigating KPI and Performance Measurement Challenges During the Global COVID-19 Pandemic (ID CM-2)

This benchmarking report explores how companies are approaching changes in key performance indicators (KPIs) during the COVID-19 pandemic. In particular, this report spotlights the changes in KPIs and performance measurement, measurement period, authority and duration over the course of the pandemic. It also examines the challenges encountered around performance measurement and suggestions from industry peers for best adapting KPIs and other measurements during the global pandemic to better reflect performance.

$995

Thought-leader Management Excellence: Creating and Maintaining a High-performing External Stakeholder Engagement System (ID POP-326)

This benchmarking report is designed to help Medical Affairs leaders develop optimal thought-leader management systems across key dimensions. This report assesses the impact of structure, administration, internal communication, coordination, engagement, identification, technology enablement and performance measurement on thought-leader management systems.

$4400

Best Practices for Training & Developing High-Impact Medical Affairs Professionals (ID POP-325)

Best Practices, LLC conducted this study to uncover best-in-class practices that leading biopharmaceutical firms have adopted to design, oversee, deliver, and evaluate Medical Affairs training programs. This study will help leaders produce better strategic thinking, communication with internal and external stakeholders, thought leader management, and interactions with HCPs for their Medical Affairs group.

$4400

Maximizing the Impact of Medical Affairs in Hematology Product Launches (ID POP-323)

Best Practices, LLC undertook this benchmarking research to explore how Medical Affairs can maximize its hematology launch impact. This report provides insights and benchmarks around strategy planning, role, activities and timeline, cross-functional collaboration, staffing, budgeting, preparedness metrics, tools and technology for an effective Medical Affairs hematology launch. This report also highlights the critical success factors and pitfalls for Medical Affairs during hematology launch.

$6000

Global MSL Resourcing Excellence: Optimizing Resources, Alignment and Organizational Support for MENA Field Medical Operations (ID POP-318)

This benchmarking report examines how pharmaceutical companies structure and align their medical science liaison (MSL) teams in core markets in the Middle East/North Africa (MENA) region. The report also pinpoints competitive MSL staffing and resource levels – and probes how MSLs successfully support new product launches within MENA countries. It also reveals region and country-level field metrics on MSL productivity, efficiency, KOL and key account targeting, interaction frequency, communication and tools, skills and background, and other areas – all to enhance field medical impact across in the MENA region.

$3000

AMERICAS MSL Excellence: Optimizing Resources, Alignment and Organizational Support for Field Medical Operations in LATAM & Canada (ID POP-317)

This benchmarking report examines how pharmaceutical companies structure and align their medical science liaison (MSL) teams in core markets in Canada and Latin America. The report also pinpoints competitive MSL staffing and resource levels – and probes how MSLs successfully support new product launches within target countries. It also reveals region and country-level field metrics on MSL productivity, efficiency, KOL and key account targeting, interaction frequency, communication and tools, skills and background, and other areas – all to enhance field medical impact across Canada and Latin America.

$5000

Health Info System Excellence: How Top Biopharmas Build Integrated Data Systems to Fulfill Patient-Centric Clinical & Commercial Objectives (ID POP-324)

This Best Practices, LLC research probes how biopharma companies can work with vendors to develop fully integrated and accessible databases for aggregated health insights, often referred to as health information systems. It identifies the strengths and weaknesses of six health information vendors, including IQVIA, Symphony Health, Accenture, Corrona, Optum Health, and Digital Reasoning Systems. This report will give an understanding of how peer pharma companies utilize a mix of vendors and data types when creating and maintaining their health information systems. It also provides insights into the typical roles of each function relative to data collection, storage, and analysis.

$3900

Maximizing the Impact of Medical Affairs in Oncology Product Launches (ID POP-322)

Best Practices, LLC undertook this benchmarking research to explore how Medical Affairs can maximize its oncology launch impact. This report provides insights and benchmarks around strategy planning, role, activities and timeline, cross-functional collaboration, staffing, budgeting, preparedness metrics, tools and technology for an effective oncology launch. This report also highlights the critical success factors and pitfalls for Medical Affairs during oncology launch.

$6500

APAC MSL excellence: Optimizing resources, alignment and organizational support for field medical operations in Asia-Pacific (ID POP-316)

This benchmarking report probes how pharmaceutical companies structure and align their medical science liaison (MSL) teams in core APAC markets. The report also pinpoints competitive MSL staffing and resource levels – and examines how MSLs successfully support new product launches within APAC countries. It also delivers region and country-level field metrics on MSL productivity, efficiency, KOL and key account targeting, interaction frequency, communication and tools, skills and background, and other areas – all to enhance field medical impact across the APAC market.

$5000

Leveraging Outcomes Data: Operational Roles in Health Economics & Outcomes Research (ID POP-321)

This benchmarking report provides insights around effective ways to develop successful Health Outcomes groups. It demonstrates how HEOR function is involved in decision-making and delivering value for medical activities. It also highlights the strategies for effective health outcomes data communication and utilization, stakeholder collaboration, and launch investment timeline for new therapies. This report also outlines the advantages and challenges for a successful HEOR program.

$5900

Thought Leader Service Excellence: Establishing a Foundation for MSLs to Provide Proactive & Compliant Communication with KOLs (ID POP-320)

This benchmarking report analyzes how biopharmaceutical companies are developing integrated systems to provide proactive services to their most influential thought leaders. The research specifically delves into the creation and use of opt-in “standing order” systems – in which thought leaders signal their desire to receive scientific information on an ongoing basis. It also looks into proactive and reactive MSL interactions.

$2000

The Role of Medical Affairs in the Value-Based Healthcare Ecosystem (ID POP-319)

This benchmarking research examines the evolving role of Medical Affairs in the value-based healthcare ecosystem. It benchmarks the important activities, key facets of internal and external collaborations, value based contracts, healthcare economic information and FDAMA S114. This report also identifies the success factors and pitfalls for value-centric Medical Affairs operations.

$4000

EU MSL excellence: Optimizing resources, alignment and organizational support for European field medical operations (ID POP-315)

This benchmarking report probes how pharmaceutical companies structure and align their medical science liaison (MSL) teams in core markets in Europe. The report also pinpoints competitive MSL staffing and resource levels – and examines how MSLs successfully support new product launches within European countries. It also delivers region and country-level field metrics on MSL productivity, efficiency, KOL and key account targeting, interaction frequency, communication and tools, skills and background, and other areas – all to enhance field medical impact across the European market.

$5000

Raising Phase IV Performance & Value Through Optimal MSL Involvement (ID POP-312)

This benchmarking report examines how leading pharmaceutical and biotech companies are raising Phase IV performance and value through optimal involvement of medical science liaisons (MSLs). The report characterizes the MSL contributions most essential to Phase IV and spotlights Phase IV opportunity fronts for MSL deployment. It also provides insights around the field team structures, skills, and training that help maximize the impact of MSLs on Phase IV studies.

$4900

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice Outside of the United States (ID PSM-357)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management outside of the United States. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Maximizing the Impact of Medical Affairs in Product Launch (ID POP-311)

Best Practices, LLC undertook this benchmarking research to explore how Medical Affairs can maximize its launch impact. This report provides insights and benchmarks around strategy planning, role, activities and timeline, cross-functional collaboration, staffing, budgeting, preparedness metrics, tools and technology for an effective Medical Affairs launch. This report also highlights the critical success factors and pitfalls for Medical Affairs during launch.

$4900

Optimizing the Size and Improving the Impact of CNS Field-Based Medical Teams in Major Global Markets (ID POP-310)

Best Practices, LLC undertook this benchmarking research to help companies fill knowledge gaps around key CNS field-based medical team operational areas, including: staffing levels, resource allocations, productivity measures, efficiency (time spent on key external and internal activities), frequency of thought leader interactions by tier, effective communication channels, and tactics and tools for leveraging field insights across the organization. This report will serve as a reference for CNS field-based medical and other leadership teams in carving out a framework for expanding their CNS footprint in high-potential global markets.

$6000

Optimizing the Size and Improving the Impact of Field-Based Immunology Medical Teams in Major Global Markets (ID POP-309)

Best Practices, LLC undertook this benchmarking research to help companies fill knowledge gaps around key immunology field-based medical team operational areas, including: staffing levels, resource allocations, productivity measures, efficiency (time spent on key external and internal activities), frequency of thought leader interactions by tier, effective communication channels, and tactics and tools for leveraging field insights across the organization. This report will serve as a reference for immunology field-based medical and other leadership teams in carving out a framework for expanding their immunology footprint in high-potential global markets.

$6000

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice (ID PSM-353)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice in the United States (ID PSM-356)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management in the United States. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Manufacturers Effectively Support Advocacy Groups Segmented by Reporting Function (ID PSM-358)

This benchmarking report highlights effective practices in patient advocacy group collaboration and relationship management. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy. Research insights are segmented on the basis of reporting structure to offer a clear understanding of the impact of organizational decisions on patient advocacy trends.

$6000

Enhancing MSL Interactions with Non-US Healthcare Practitioners (ID POP-304)

This Best Practices, LLC report gathers insights on current MSL practices outside the US regarding HCP interactions and proactive disease presentations, unsolicited requests on clinical data and off-label uses, and group HCP presentations. This report also establishes benchmarks around the frequency, format, content and evaluators for recertification of MSLs.

$1300

Best Practices in Funding US Fellowships: Using Pharma Grants Effectively to Support Post-Graduate Education (ID POP-307)

Best Practices, LLC undertook benchmarking research to help companies better understand current practices around the funding and management of fellowship grants to support US post-graduate medical education.

$1200

Enhancing MSL Interactions with US Healthcare Practitioners (ID POP-302)

This Best Practices, LLC report gathers insights on current MSL practices in the US around HCP interactions and proactive disease presentations, unsolicited requests on clinical data and off-label uses, and group HCP presentations. This report also delves into the frequency, format, content and evaluators for recertification of MSLs.

$1300

How Medical Affairs Can Drive a Successful Medical Device Product Launch (ID POP-306)

This benchmarking report provides insights into how Medical Affairs operations, field teams, and call centers can provide high-value support for the launch of medical device products. This research will help Medical Affairs teams identify and implement more effective practices, pinpoint organizational gaps, and inform strategic planning for new medical device product launch.

$4600

Optimizing the Size and Improving the Impact of Oncology Field-Based Medical Teams in Major Global Markets (ID POP-305)

Best Practices, LLC undertook this benchmarking research to help companies fill knowledge gaps around key oncology field-based medical team operational areas, including: staffing levels, resource allocations, productivity measures, efficiency (time spent on key external and internal activities), frequency of thought leader interactions by tier, effective communication channels, and tactics and tools for leveraging field insights across the organization. This report will serve as a reference for oncology field-based medical and other leadership teams in carving out a framework for expanding their oncology footprint in high-potential global markets.

$6400

How Medical Affairs Can Deliver Value to Internal Stakeholders (ID POP-303)

This benchmarking research probes how Medical Affairs can improve the effectiveness of its internal collaborations by conducting the most valuable activities, improving its capabilities and evaluating performance through the use of KPIs and metrics. This study also identifies the challenges encountered by Medical Affairs in improving the perception of the value it brings to an organization and mitigation tactics to overcome these challenges.

$4000

Optimizing the Size and Improving the Impact of Field-Based Medical Teams in Major Global Markets (ID POP-301)

Best Practices, LLC conducted this benchmarking research to help organizations fill knowledge gaps around key field-based medical team operational areas, including: staffing levels, resource allocations, productivity measures, efficiency (time spent on key external and internal activities), frequency of thought leader interactions by tier, effective communication channels, and tactics and tools for leveraging field insights across the organization. This report will serve as a reference for field-based medical and other leadership teams in carving out a framework for expanding footprint in global markets.

$6400

Rare Diseases: What It Takes To Build Strong Field-based Medical Teams (ID POP-300)

Best Practices, LLC undertook this benchmarking research to identify top tactics for building strong field-based medical teams in support of rare diseases. In particular, this report establishes benchmarks around staffing and reporting level, time allocation for key responsibilities, number of products supported, outreach strategy, engagement frequency, proactive vs. reactive interactions, communication channels, performance effectiveness and use of technology.

$2990

Best Practices in Communicating and Disseminating Medical Information to External Stakeholders (ID POP-297)

This benchmarking report examines how the Medical Information function within leading companies communicates on and off-label information to stakeholders, and protects inadvertent use of information within slide decks and other medical information assets.

$4890

Driving the Value of Digital Initiatives in Medical Affairs (ID POP-296)

This benchmarking report explores how Medical Affairs can improve its digital capabilities to better serve internal and external stakeholders. It delivers benchmarks around enhancing Medical Affairs digital capabilities through operations, activities, channels, services, roles, reporting and resourcing. This report also highlights the top digital engagement trends that will greatly impact the Medical Affairs function.

$5900

Real World Evidence: Understand Trends & Seize Opportunities in the Changing Landscape of RWE Generation (ID POP-294)

This benchmarking report probes industry practices around the use of real world evidence (RWE), including current and future utilization of key RWE study methods, data collection methods, budget and outsourcing. It also examines the traits that are the best indicators for selecting a vendor for a particular RWE study method.

$7000

How Medical Affairs Creates Value & Relationships through Service to Critical External Groups (ID POP-293)

This benchmarking research probes Medical Affairs' roles, activities, services, tools, effectiveness and success metrics in serving key external groups including established groups such as payers, advocacy, guidelines organizations, government agencies and ACOs/IDNs/HCPs; and emerging groups such as specialty pharmacies, group purchasing organizations, large employer groups and pathway vendors.

$6000

Building Strong Field-Based Medical Teams to Support New Cardiovascular and Diabetes Products (ID POP-290)

This report highlights the winning strategies employed by leading biopharmaceutical companies to develop robust field-based medical teams for cardiovascular and diabetes therapeutic areas. In particular, this report delivers benchmarks around the deployment of MSLs and HOLs, associated value of field-based medical team responsibilities, key performance indicators, staffing and training.

$3950

Best Practices in Establishing Medical Affairs Capabilities in Emerging Countries: Using Structure, Staffing, and Responsibilities to Create an Effective Medical Affairs Group in TMEA (ID POP-289)

This report highlights the critical requirements for establishing effective Medical Affairs capabilities in the TMEA region, which encompasses Turkey, the Middle East and South Africa. Specifically, the report delivers benchmarks around Medical Affairs responsibilities; country-level structure, staffing and activities; field-based medical staff structure, staffing, responsibilities, compliance, performance and virtual meetings. Medical affairs leaders from the TMEA region can refer to this report to see how their regional and/or country-level groups compare with industry trends and averages.

$3700

Authorship Selection for Medical Publications at Pharmaceutical and Biotech Companies (ID POP-291)

This benchmarking report is designed to help medical publication leaders at pharmaceutical and biotechnology companies shape their publication policies. In particular, this report examines issues around authorship selection criteria, selection process and author transition to other organizations.

$3900

Investigator Initiated Trials Management (ID POP-282)

This benchmarking report provides a detailed roadmap for pharmaceutical and medical device companies to improve their investigator-initiated trial (IIT) management. In particular, this report delivers insights on IIT management team structure, staffing, budget, IIT proposal evaluation, performance improvement, publication metrics and communication channels.

$5500

Benchmarking Field Medical & Field Outcomes and Pricing KOL Engagement Strategies (ID POP-288)

This benchmarking research examines current industry trends and best practices for field-based medical and field-based outcomes and pricing teams in North America, Europe, APAC and Emerging Markets. Specifically, this report provides benchmarks around virtual HCP engagement; field medical team deployment and reporting relationships; and activity levels and product coverage.

$2200

Medical Affairs Strategies to Deliver Value to Payer Groups (ID POP-284)

This benchmarking report identifies leading Medical Affairs strategies for payer and Accountable Care Organization (ACO) / Integrated Delivery Network (IDN) engagement success. In particular, it delivers metrics and insights around payer and ACO/IDN segmenting and targeting; data presentation; field resource deployment; staff training; internal coordination; desired staff background; success factors and key challenges.

$5000

Real World Data and Medical Affairs: Best Practices in Maximizing its Use and Producing Results (ID POP-285)

Best Practices, LLC undertook this benchmarking research to understand Medical Affairs' role and responsibilities in the execution of Real World Data program. This report establishes benchmarks around the collection, generation, analysis and dissemination of Real World Data. Also, it provides insights around the publication strategies, key performance indicators and the pros and cons of various forms of Real World Data.

$6200

Benchmarking the Roles and Responsibilities for U.S.-Based Field Medical Team Interactions with Managed Care Customers (ID POP-283)

Best Practices, LLC undertook this benchmarking research to deliver insights around the roles, responsibilities, resources and activities for U.S.-based payer liaison medical teams. This report also contains qualitative information from study participants on the value, weaknesses and best practices surrounding the use of field medical roles to interact with the payer community.

$6000

Soliris: Translating Groundbreaking Science into a Successful Orphan Drug (ID PSM-342)

This case study reviews Soliris’ trajectory to achieving blockbuster orphan drug status – recording net product sales worth $2.8 billion in 2016 - through Alexion’s commercial expansion strategies, effective patient support programs and public relations campaigns. The study also highlights the numerous challenges encountered by the breakthrough therapy, most notably payer resistance to its hefty price tag and competition from upcoming biosimilars; and how Alexion is preparing to tackle these challenges.

$2500

Deploying the iPad or Android-Based Tablet to Medical Science Liaison Teams: Benchmarking Training and Effectiveness (ID POP-286)

Best Practices, LLC undertook this benchmarking research to identify the key challenges, lessons learned and best practices when deploying iPads or android-based tablets to MSL teams. Specifically, this report provides benchmarks around the extent of device implementation, training around tablet usage, content delivery and usage, tablets compliance with CRM systems, security concerns and measurement of key performance indicators.

$4000

Medical Affairs’ Role in Patient Engagement Activities (ID POP-280)

This benchmarking report delivers industry metrics and insights on key aspects of patient engagement programs including collaboration, activities, support, and involvement. Key benchmarks revolve around the role and responsibilities of the Medical Affairs function in different patient engagement activities like patient health outcomes, advocacy, education and medication adherence. Medical Affairs leaders can refer to this report to identify the patient engagement activities/strategies that work best for each group of stakeholders and gain insights into critical lessons learned and pitfalls.

$5800

Determining Best Practices for Data Dissemination Policies for Global Field Medical Teams (ID POP-279)

This study provides insights into formulating guidelines around on-label and off-label data discussions for global field medical teams to ensure compliance and consistency.

$1999

Best Practices in Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance (ID POP-277)

This study provides benchmarks around the core aspects of the scientific publication function including the structure and leadership of publication groups; publication strategy creation and data delivery; publication channel utilization across product lifecycle; publication effectiveness and transparency; and publication staffing and budget.

$4900

Strategies for Developing Strong Field-Based Medical Teams (ID POP-278)

This research provides insights into the deployment of medical science liaisons, health outcomes liaisons, nurse educators and their direct field-based supervisors.In particular, it delivers benchmarks around field-based medical team staffing, activity timing, and training.

$5500

Critical Strategies to Develop Strong Medical Information Groups (ID POP-276)

This research delivers critical benchmarks for the Medical Affairs function to develop strong Medical Information groups. It delivers benchmarks around leadership and structure of Medical Information groups, alignment of information activities with compliance requirements, tactics for efficient internal collaboration and resource levels required to create successful Medical Information groups.

$3900

Collaborating with Patient Advocacy Groups to Educate the Marketplace (ID PSM-330)

This benchmarking research identifies ways for bio-pharmaceutical companies to effectively collaborate and manage relationships with patient and professional advocacy groups. It also delivers benchmarks around the ideal structures and skill sets for pharma groups that deal with advocacy groups and evolving trends and challenges in patient advocacy.

$4000

Best Practices in Leading Medical Education Programs: Benchmarking Education Program Services, Trends & Effectiveness at Pharmaceutical Companies (ID POP-275)

This research was conducted to inform those who lead medical education programs at biopharmaceutical and medical device organizations regarding funding, staffing, program types and structure for this function or group. It reviews emerging Medical Education trends and explores how leading organizations deploy medical education programs and measure their effectiveness and value.

$5200

Medical Affairs Launch Excellence: Medical Affairs Role at Launch in Medical Device Companies (ID POP-274)

This study identifies the critical success factors for an effective medical affairs launch support, as well as highlights strategies for successful thought leader targeting and communication. Medical Affairs leaders at medical device companies can utilize this study to develop successful launch strategies.

$3900

Benchmarking Professional Medical Education Excellence: Structures, Resources and Activities to Optimize Large Biopharmaceutical Education Groups (ID POP-269)

This research was conducted to inform those who lead medical education programs at large biopharmaceutical companies about the proper size, structure and resourcing for the medical education function. It reviews emerging Medical Education trends at medical device and pharmaceutical organizations regarding funding and program types.

$6200

Medical Affairs’ Critical Role in Payer Interactions (ID POP-271)

This study was undertaken to better understand the role of Medical Affairs in critical payer interactions and identify best practices in developing effective relationships with payers. This report also delivers benchmarks around the required resource levels, talent acquisition and training for maintaining effective payer relationships, and payer segmentation and prioritization.

$5500

Disease Awareness Program Excellence: Structure, Activities & Resources Needed for Effective Pipeline Support (ID PSM-328)

This study provides benchmarks on current disease state awareness program structure, spend, and activities that support pipeline products.

$6200

Organizing and Aligning Medical Education Roles in the Medical Device Industry: Optimizing the Structure, Resources and Activities to Improve in Medical Education Delivery (ID POP-268)

This study explores emerging trends in Medical Education at medical device companies regarding funding and program types. It establishes benchmarks around the appropriate size, resources required and structure for Medical Education groups.

$3300

Developing Strong Internal Thought Leader Management Capabilities Inside Medical Affairs (ID POP-267)

This study explores how leading biopharmaceutical organizations structure and organize their Medical Affairs function and develop robust relationships with thought leaders. The study also benchmarks the resource levels, internal communication tactics and use of social media for effective thought leader management.

$5400

Best Practices in Medical Education Program Strategy: Establishing the Right Structures, Resources and Activities to Optimize Biopharmaceutical Education Groups (ID POP-266)

This study was undertaken to investigate evolving Medical Education trends at biopharmaceutical companies regarding program types and funding. The study also delivers benchmarks around the proper size, structure and resources for the Medical Education function.

$6200

Medical Affairs’ Role in Health Economics & Outcomes Research within Oncology (ID POP-264)

This study is designed to assist companies focused on oncology therapies find better ways to develop successful Health Outcomes groups. It delivers current data and best practices from Medical Affairs leaders with an oncology focus at leading biopharmaceutical companies.

$3800

Best Practices and the Role of Medical Affairs in Oncology Launch Excellence (ID POP-265)

This study is designed to help companies focused on oncology therapies find better ways to develop successful launch strategies. It delivers current data, insights and best practices in oncology launch excellence from Medical Affairs leaders at leading biopharmaceutical companies.

$4000

Best Practices in Globalizing MSL & Field-Based Medical Specialist Programs (ID POP-263)

This study is designed to assist Medical Affairs leaders achieve functional excellence in MSL globalization. It looks at the organizational models, resources, global standards, and internal communication processes that drive success in globalizing MSLs and other field-based medical specialists.

$6200

Best Practices in Developing Top-Tier Medical Affairs Capabilities within Medical Device Companies (ID POP-260)

This study delivers current data, insights and best practices from Medical Affairs leaders at top Medical Device companies. The benchmark data in this study will help companies find better ways to create strong performance metrics and successful global Medical Affairs organizations.

$5100

Medical Affairs’ Role in Health Economics & Outcomes Research (ID POP-259)

This study was undertaken by Best Practices, LLC to identify opportunity fronts and strategies to increase Medical Affair’s role in Health Outcomes data generation and utilization. It highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.

$5100

Benchmarking Advisory Board Management At Large Pharmaceutical & Medical Device Organizations (ID PSM-319)

This study is designed to assist executives at large pharmaceutical and medical device organizations in identifying ways to best utilize the knowledge of advisory boards. It provides leading insights on the appropriate structure for different advisory boards, selection of advisory board participants, operational and cost benchmarks, top challenges and best practices for conducting advisory boards.

$4400

Medical Affairs’ Role in Ensuring Excellence in Product Launch (ID POP-256)

This study seeks to identify the critical success factors for a strong Medical Affairs launch support. Research findings provide evidence based insights and metrics that will serve as a reference point for MA leaders to create value-based launch strategies.Survey responses are segmented on three criteria - Product’s Projected Peak Annual Revenue, Targeted Physicians and Product’s Launch Year.

$4500

Big Data in Pharma: Current & Future Trends for Big Data Utilization Across the Health Outcomes Research Function (ID PSM-317)

This study probes the current & future trends, winning strategies and best practices for Big Data utilization across the Health Outcomes Research function. It investigates the most useful data types and sources for key HEOR decisions; governance policies and leadership and the most impactful data producers, dissemination channels and targets.

$5000

Big Data in Pharma: Current & Future Trends for Big Data Utilization Across Medical Affairs Functions (ID PSM-316)

This study probes the current & future trends and best practices for Big Data utilization across Medical Affairs functions. It investigates the types of big data projects used to inform key medical decisions; big data capabilities required; governance policies; types and value of data used for big data projects; data producers, dissemination & requestors; value rating of partnerships on big data projects; and policies & procedures governing big data activities.

$5000

Best Practices in Developing Top-Tier Medical Affairs Capabilities, Creating Impact Measures and Improving Globalization (ID POP-255)

This study benchmarks the critical requirements for creating effective global Medical Affairs capabilities. It also identifies performance metrics to demonstrate the value of Medical Affairs to senior leadership. Leading insights in the study will help Medical Affairs leaders to develop a successful global Medical Affairs organization.

$4200

Best Practices In Aligning the Medical Affairs Function to Meet Its Role in a Changing Healthcare Environment (ID POP-251)

This study identifies the shifts in Medical Affairs structure, staffing and investment in Mature and Emerging Markets. Leaders in Medical Affairs can use this study to explore critical strategies and tactics in communicating the value of their function and mitigating the negative effects of changing regulatory landscape.

$7680

Optimizing Key Opinion Leader Relationships: Best Practices in KOL Management (ID PSM-235)

This research explores the KOL management approaches at leading pharmaceutical companies. It examines the organizational structures, management strategies, activities, tools and tactics associated with KOL management excellence. Research findings provide industry metrics that can serve as a reference point for companies to improve their KOL management tactics.

$4500

Roles, Resourcing and Management of Medical Science Liaisons (ID PSM-234)

This research examines the growing roles and responsibilities of Medical Science Liaisons within leading healthcare organizations. The study captures critical insights across MSL operational, performance, and management fronts which includes the headcount, span of control, deployment factors, volume and mode of thought leader interactions, and medical science liaison performance measurement. Medical Affairs leaders can use this study as a benchmark for future strategic and resource planning and best-practice implementation for the medical science liaison function.

$5675

Patient-Focused Support: How Government Affairs & Public Policy Groups Support the Patient Journey (ID PSM-307)

This study captures insights on the level and type of support that Government Affairs and Public Policy functions provide to positively impact the patient journey. It includes leading insights and metrics around the activities, timing and funding contribution of Government Affairs and Public Policy groups towards patient advocacy and awareness.

$2500

Creating and Maintaining a Strategic KOL Management and Engagement System (ID POP-253)

This study identifies the most common and favored organizational structure for strategic TL management and engagement, understands the current state of TL management practices in the pharmaceutical industry. It also determines how TL management practices are evolving and identifies innovative practices that are driving TL management success at other organizations

$5200

The iPad: How MSLs Use It to Deliver Science and Data to HCPs (ID POP-252)

This study identifies the best practices and measures effectiveness for successful deployment of iPads to Medical Science Liaisons (MSLs). The study investigates how Medical Affairs functions in pharmaceutical companies are using iPads with their MSLs.

$2500

Shaping the Marketplace to Support Successful Diabetes Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers (ID SM-191)

This study explores the best practices in educating, informing and preparing the marketplace for new diabetes products – through Physician, Patient, and Payer education and publications, advocacy and communication strategies.

$7100

Building Best-in-Class Medical Affairs Capabilities In India – A Case Study For High-Growth Emerging Markets (ID POP-249)

This study illustrates how mature and Indian biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function particularly for Indian organizations.

$2000

Professional Medical Education Excellence: Benchmarking Critical Program Trends Transforming the Medical Device and Biopharmaceutical Marketplace (ID PSM-286)

This study informs Medical Education leaders on emerging trends regarding funding, program types, delivery channels, program effectiveness and value drivers.

$6450

Building Best-in-Class Capabilities for Medical Affairs (ID POP-228)

This study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.

$6250

Health Outcomes Liaison Excellence: How the HOL Function Drives Value Across the Healthcare Industry (ID PSM-287)

This study will help pharma and biotech executives and managers identify how leading companies deliver exceptional HOL services in an increasingly challenging business environment. The research also examines best practices in HOL management and identifies future trends expected to impact the HOL function.

$5250

Medical Science Liaison Services Excellence: Generating Value for Diverse Customer Groups Within the Medical Device Industry (ID PSM-281)

This study seeks to examine how MSLs can provide greater value through their work with internal stakeholders and with external decision-makers and leaders. Additionally, this new study will provide information on how the roles of MSLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the MSL landscape.

$4000

Best Practices in Advancing Customer Marketing: Innovations in Engaging and Communicating with Health Care Providers, Patients, Payers and KOLs (ID PSM-280)

This study identifies how companies structure, staff and organize to find, use and quickly incorporate innovative practices to improve marketing across all customer groups.

$5000

Medical Science Liaison Services Excellence: Generating Value for Diverse Customer Groups (ID PSM-279)

This study seeks to examine how MSLs can provide greater value through their work with internal stakeholders and with external decision-makers and leaders. Additionally, this new study will provide information on how the roles of MSLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the MSL landscape.

$6800

Professional Medical Education Excellence: Structures, Resources, Services & Performance Levels to Optimize Pharmaceutical Education Groups (ID PSM-268)

This study analyzes a broad range of medical education factors, and delivers qualitative and quantitative data on staffing, services, structures, investments and much more. Medical education leadership will benefit using this intelligence to evaluate their organization’s resource levels relative to other market leaders.

$4200

Professional Medical Education Excellence: Structures, Resources, Services & Performance Levels to Optimize Medical Device Education Groups (ID PSM-269)

This study was undertaken to inform medical education leaders on current approaches to medical education group size, service-levels, resources, and program development/deployment. The study - which provides segments for both pharmaceutical and medical device leaders - presents medical education leaders’ perspective on current and future trends for field-based medical educators, technological changes and spending changes.

$4200

Best Practices in Utilizing Health Outcomes Data (ID PSM-236)

This study aims to discover and collect best practices in how companies use and review the use of Health Outcomes data in promotional/commercial settings.

$4000

Advocacy Excellence: Optimizing Group Structure & Operations (ID PSM-253)

This study identifies the key trends, best practices, metrics and valuable insights into the evolution of advocacy groups. Also, the study covers areas such as group’s structure, service and staffing strategies to support its success with partners and internal customers.

$5100

Collaborating with Patient Advocacy Groups to Educate the Marketplace (ID PSM-242)

This study examines ideal structures and skill sets for pharma groups that deal with advocacy groups and emerging trends and challenges in patient advocacy.

$6500

Best Practices in Recruitment for Medical Education Programs (ID PSM-238)

This report identifies emerging trends in recruiting attendees for medical education in general and non-CME programs in particular. Additionally, this study seeks to understand industry norms for attendance goals versus actual attendance, average time for recruitment effort, effective recruiting methods and other operational activities.

$3895

Educating the Market: Creating Value Through Support of Continuing Medical Education (ID SM-180)

This study identifies the salient trends and likely directions of CME in the North American and European marketplaces practices. Marketing executives and managers can use the key benchmark metrics, executive insights and recommendations in this report to map a path to future success in support of CME.

$6995

NEW PRODUCT DEVELOPMENT click to expand contents

Launching New Biopharma Products in Competitive Markets: Critical Success Factors and Failure Points (ID PSM-369)

This benchmarking report highlights success factors and failure points in effectively launching a new biopharma product. The report also captures benchmarks and insights around value dimensions for stakeholders, thought leader engagement and education for market entry, and risk factors.

$6750

Launching New Biopharma Products in Competitive Oncology Markets: Critical Success Factors and Failure Points (ID PSM-395)

This benchmarking report explores the critical success factors and potential failure points in launching new oncology products in today’s highly competitive and complex landscape. It delivers benchmarks and insights on stakeholder value dimensions, thought leader engagement and education for market entry, and key risk factors.

$6750

Addyi (flibanserin): How an upstart biopharma used social media and policy tools to support its NDA approval - and a $1 billion payday (ID PSM-368)

Best Practices, LLC conducted extensive secondary research of government and company information to review how Sprout Pharma used social media, active lobbying and policy levers to win approval for its controversial therapy, Addyi® (flibanserin) in female hypoactive sexual desire disorder (HSDD) category.

$2900

Strategic Portfolio Planning for Successful New Product and Drug Platform Positioning (ID PSM-365)

Best Practices, LLC conducted “meta-analysis” of 22 of its primary and secondary benchmark studies to inform how drug platforms give rise to tech / MOA-enabled product portfolios and market leading franchises. This report also includes case studies of new product planning and market entry of many successful brands. It spotlights winning strategies, best practices and pitfalls to avoid for successful positioning of new products and drug platforms.

$7500

Leading in the Combination Product Space: Insights for Improving External Engagement, and Internal Development and Management (ID POP-298)

This benchmarking research is designed to help pharmaceutical, biotechnology and other healthcare companies improve the way they develop, manage and commercialize new combination products. The insights from this report will inform product and leadership teams about key external engagement approaches, staffing and investment, development phases and decision points, timing, partner management, and IP protection requisite to effectively develop and launch combination product assets.

$3990

Benchmarking R&D and Clinical Talent Development Initiatives (ID PHR-215)

This benchmarking report examines how leading pharma and tech companies align their Learning and Development function within R&D with corporate objectives, measure the success of their talent development initiatives, and identify ways to improve talent retention and development. It also explores current and future challenges for talent development.

$2100

Pharmaceutical New Product Planning Excellence: Structure & Activities that Drive Profitability & Growth (ID PSM-333)

This study was undertaken to examine the role and impact of New Product Planning function on pharma product commercialization. In particular, it delivers benchmarks on the structure, resources and activities of New Product Planning groups.

$8000

Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market (ID POP-232)

This study identifies the successful strategies on developing and commercializing FDC’s. Companies can use this study to understand and evaluate the benefits and avoid the pitfalls into conceptualizing a new FDC in the market.

$4100

Pharmaceutical New Product Planning: Role and Activities for Medical Affairs (ID PSM-249)

This study examines the role and impact of NPP groups on product commercialization efforts in pharmaceutical and biotech companies.

$4600

Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products (ID POP-226)

This study helps to better understand fixed-dose combination (containing two or more active pharmaceutical ingredients) product development strategies and timelines.

$5100

Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability (ID PSM-229)

This report identifies the structure and roles of NPP groups as well as the full set of activities that NPP groups perform across the development cycle and also examines the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolves as a company matures.

$9000

New Product Planning in Pharma: Preparing for the Market (ID PSM-227)

This report examines the winning strategies, structures, and best practices in early-stage product commercialization and portfolio management and also highlights the Global Product Strategy’s placement in the corporate organizational chart to determine a best fit for the organization to provide optimal support.

$4595

Pharmaceutical New Product Commercialization: Preparing for Market Success (ID SM-176)

This benchmarking report identifies the winning strategies, structures, and best practices in early-stage product commercialization and portfolio management for global pharmaceutical companies.

$5000

Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence (ID HR-63)

This benchmarking report highlights the following areas of cross-functional team management: Cross-Functional Team Structures; Collaboration and Productivity Processes; People Management; Decision-Making Processes; Communication and Collaboration; Resource Allocation.

$4015

From Genes to Giants: Best Practices in Early-Stage Product Commercialization (ID SM-162)

This report provides crucial insights and thorough analyses of how industry-leading companies develop successful early-stage commercialization (pre-clinical through Phase II) campaigns and portfolio management programs.

$5058

PATIENT FOCUSED SERVICES click to expand contents

KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History (ID PSM-392)

This case study reveals how Merck turned a near-failure into a cornerstone of cancer treatment through extensive clinical trials, innovative marketing, strategic collaborations, and unwavering investment. Despite entering the immuno-oncology market as a second-to-market product, KEYTRUDA not only caught up with its competitors but also became a dominant force in the field. The analysis provides insights into how Merck's efforts collectively propelled KEYTRUDA to the forefront of cancer treatment, establishing it as a blockbuster drug and a cornerstone of Merck’s oncology portfolio.

$3000

Patient-Focused Medical Affairs Excellence: Building Medical Patient Teams and Engaging Stakeholders with Patient Experience Insights (ID POP-368)

This benchmarking report examines how top biopharma companies are developing efficient Medical patient teams and engaging influential stakeholders with rich patient experience insights. It delivers an array of insights, exploring high-value activities and engagement strategies; influence of patient insights on KOL engagement; direct patient interactions; and Medical’s utilization of patient-reported outcomes.

$3900

Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease (ID PSM-389)

This case study reviews Tepezza’s trajectory to achieving blockbuster status in a rare disease autoimmune area for thyroid eye disease through Horizon Therapeutics’ launch and market entry strategies and execution.

$3900

Case Study: How argenx Broke into a Captive Market to Begin Dislodging an Entrenched Market Leader (ID PSM-388)

This case study reviews VYVGART’s trajectory to breaking into the captive generalized Myasthenia Gravis (gMG) market to begin dislodging an entrenched market leader. The study probes the development, launch, and market entry strategies executed by argenx to launch VYVGART as a first step in its rare disease franchise building.

$3900

Patient-Driven Growth: Maximizing Patient Journey Maps & Patient Co-Creation (ID POP-362)

This benchmarking report is designed to help biopharma leaders achieve patient-centric growth by examining innovative approaches, effective practices, and recommended vendors which are delivering high impact across patient journey mapping and patient co-creation. This research probes insights around patient journey mapping capabilities, structure, staffing, high-impact areas, sources, validation, updates, automation, vendors, innovation and KPIs – and overall leadership support of patient-centric initiatives. It also establishes benchmarks around patient co-creation programs, key design phases, engagement channels, high-impact areas, innovative trends.

$5900

Engaging Patients across Medical Affairs Activities and Functions (ID POP-351)

This benchmarking report highlights how Medical Affairs can amplify the patient voice within the biopharma organization. It delivers benchmarks around early-stage and late-stage patient support strategies, roles and responsibilities, and internal and external collaboration for patient engagement. The report also probes the critical lessons learned and pitfalls encountered in capturing and representing the patient voice through Medical Affairs.

$5700

Engaging Central Nervous System (CNS) Patients across Medical Affairs Activities and Functions (ID POP-402)

This benchmarking report delves into how Medical Affairs can amplify the voice of CNS patients within the biopharma industry. The report examines strategies for early-stage and late-stage patient support, roles and responsibilities, and effective internal and external collaboration with partners for CNS patient engagement. It also probes the critical lessons and pitfalls encountered in representing the patient voice in CNS segment.

$5700

Engaging Oncology Patients across Medical Affairs Activities and Functions (ID POP-403)

This benchmarking report focuses on how Medical Affairs can elevate the oncology patient voice within biopharma organizations. It examines early-stage and late-stage patient support strategies, roles and responsibilities, and the importance of internal and external collaboration to enhance oncology patient engagement. The report also delivers insights on critical lessons and challenges faced in representing the oncology patient voice.

$5700

Improving Patient Medication Adherence Metrics (ID PSM-381)

This report establishes industry benchmarks around patient medication adherence rates. It delivers benchmarks for basic metrics like Fill Rates, Time to Fill, and Reimbursement Rates as well as Complex Metrics like Adherence, Persistence, and Compliance Rates. The report also includes industry case studies around oral adherence.

$5000

How Pharma is Utilizing Social Media, Patient Groups and Virtual Formats for Delivering Medical Education (ID POP-343)

This benchmarking report is designed to help Medical Affairs leaders understand the latest medical education trends around use of social media platforms, patient programs, and sponsorships/corporate memberships.

$4900

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine (ID PSM-380)

This report probes successful practices for managing hostile stakeholders during the launch of a breakthrough new medicine. Best Practices, LLC engaged front-line executives at 11 companies across 9 therapeutic areas and conducted extensive secondary research on leading brand launches to identify winning strategies to soften stigma and hostile stakeholder responses during launch.

$3800

Healthcare Innovation Using Artificial Intelligence and Data Analytics: How “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth (ID PSM-379)

This Best Practices, LLC case study reviews how artificial intelligence and data analytics are being utilized to drive innovation in healthcare. Specifically, this case study probes how Colgate-Palmolive’s “Smart Toothbrushes” are establishing Health Outcomes and Real-World Data that drive growth.

$2400

Disease Awareness Program Excellence: Structure, Activities, and Resources Needed for Effective Pipeline Support (ID PSM-377)

This benchmarking report highlights effective practices around the timing, investment, and activities for disease awareness programs. It delivers insights, best practices, and pitfalls that participants have learned from many of their past disease awareness campaigns.

$5500

Benchmarking Meta-Analysis of New-Product Bridge and Fast-Start Patient Assistance Programs (ID POP-335)

This benchmarking report of over 300 companies spotlights current trends and future directions of bridge and fast start patient assistance / support programs supporting new biopharmaceutical product programs.

$1200

Patient Advocacy Internal Collaboration to Raise Awareness, Guide Research, and Improve Access (ID PSM-370)

This benchmarking report probes how biopharma companies’ advocacy teams work to improve coordination efforts with internal groups such as Marketing, Medical Affairs, R&D, and Government Affairs. The report spotlights winning strategies, best practices and pitfalls to avoid when working with these groups.

$5000

Building a World Class Medical Information and Patient Services Call Center (ID PCS-214)

This benchmarking report identifies performance benchmarks for building a world class medical information and patient services call center. It provides call center leaders with critical insights and metrics that can be used to evaluate and improve information and service call center effectiveness.

$3750

Pharma’s Digital Transformation Turning Point: Disruption, Challenges and Recommendations for Medical and Commercial Leaders (ID PSM-367)

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic. It probes the various approaches towards digital transformation adopted by forward-looking biopharma companies spanning critical areas including HCP and external engagement, advisory boards and speaker programs management, clinical trials management, patient engagement, performance measurement, and others.

$5500

Patient Support Excellence: Critical Programs, Tactics & Tools to Ensure Strong Advocacy & Access to Medicine during COVID-19 and Beyond (ID CM-6)

This benchmarking report highlights the evolution of advocacy group relationships and patient support programs during and post the COVID-19 era. It specifically identifies the impact of COVID-19 on patient support programs, implications of digital technology implementation for patient engagement, usage and effectiveness of performance metrics, key patient support tools, communication frequency and staffing.

$995

Health Info System Excellence: How Top Biopharmas Build Integrated Data Systems to Fulfill Patient-Centric Clinical & Commercial Objectives (ID POP-324)

This Best Practices, LLC research probes how biopharma companies can work with vendors to develop fully integrated and accessible databases for aggregated health insights, often referred to as health information systems. It identifies the strengths and weaknesses of six health information vendors, including IQVIA, Symphony Health, Accenture, Corrona, Optum Health, and Digital Reasoning Systems. This report will give an understanding of how peer pharma companies utilize a mix of vendors and data types when creating and maintaining their health information systems. It also provides insights into the typical roles of each function relative to data collection, storage, and analysis.

$3900

Meeting the Challenge of Copay Accumulator Programs: Effective Pharma Strategies & Tactics for Ensuring Patient Access (ID PSM-359)

This benchmarking report highlights the impact of payer-imposed copay accumulator programs on specialty pharma manufacturers and their patients. The research also delves into effective tactics and strategies employed by organizations for mitigating the impact of copay accumulator programs. Research findings and insights will help Market Access leaders create and deploy an effective copay accumulator mitigation strategy that meets the full scope of the threat and ensure patient-centric treatment and reimbursement solutions.

$5500

Meeting the Challenge of Copay Accumulator Programs: Effective Oncology Manufacturer Strategies & Tactics for Ensuring Patient Access (ID PSM-361)

This benchmarking report highlights the impact of payer-imposed “copay accumulator” programs on oncology and other specialty manufacturers and their patients. The research delves into effective tactics and strategies employed by specialty biopharma companies for mitigating the impact of copay accumulator programs. Research findings and insights will help Market Access leaders create and deploy an effective copay accumulator mitigation strategy that meets the full scope of the threat and ensure patient-centric treatment and reimbursement solutions.

$5800

Value-Driven Patient Support Programs: How Top Companies Engage, Educate and Ensure the Adherence of their Patients (ID PSM-360)

This benchmarking research was undertaken to examine the growing importance of establishing a patient centric organization and how it can positively impact patient outcomes and commercial results. This benchmarking report probes current trends in patient support group structure, effectiveness, activities and staffing / budget levels within the biopharmaceutical sector. It also probes the utilization of patient hub services, and the best practices and pitfalls / stumbling blocks encountered as part of the patient support organization.

$3500

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice Outside of the United States (ID PSM-357)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management outside of the United States. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice (ID PSM-353)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice in the United States (ID PSM-356)

This benchmarking report pinpoints effective practices in patient advocacy group collaboration and relationship management in the United States. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy.

$6000

Patient Advocacy: How Top Pharma Manufacturers Effectively Support Advocacy Groups Segmented by Reporting Function (ID PSM-358)

This benchmarking report highlights effective practices in patient advocacy group collaboration and relationship management. In particular, this research examines the winning strategies, best practices, preferred structures, responsibilities, collaboration approaches, resource levels, emerging trends, and challenges in patient advocacy. Research insights are segmented on the basis of reporting structure to offer a clear understanding of the impact of organizational decisions on patient advocacy trends.

$6000

Innovation in Combo Product Clinical Development – Harnessing Patient Insights from Reported Usability Outcomes (ID POP-308)

This benchmarking research provides current insights into how companies are integrating patient feedback into their clinical data and leveraging this data to address adherence and utilization issues. In particular, this report establishes benchmarks around clinical development team structure, roles, and operational standards. It also identifies the optimal measure targets, utilization, and deployment of patient and observer usability measures.

$2400

Connecting Pharma to Patients with Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets (ID PSM-354)

This benchmarking report probes the winning strategies, effective practices, and potential stumbling blocks encountered as a company shifts towards digital patient engagement in global, emerging and developed markets. Specifically, this report delivers digital patient engagement benchmarks around the tactics, tools and technologies employed for successful engagement; staffing drivers; investment trends; structure and reporting; processes and use of vendors; depth and scope of engagement; performance effectiveness; and critical lessons learned.

$5990

Gaining Support for Patient Adherence Programs and Effective Resource Allocation to Drive Adherence (ID PSM-349)

This benchmarking report delivers insights around the optimal resources and tactics for driving patient adherence. In particular, this report provides benchmarks around structure, staffing, vendor management, investment, leadership, process and program content for patient adherence programs. Additionally, this report highlights effective strategies for driving adherence.

$4000

Soliris: Translating Groundbreaking Science into a Successful Orphan Drug (ID PSM-342)

This case study reviews Soliris’ trajectory to achieving blockbuster orphan drug status – recording net product sales worth $2.8 billion in 2016 - through Alexion’s commercial expansion strategies, effective patient support programs and public relations campaigns. The study also highlights the numerous challenges encountered by the breakthrough therapy, most notably payer resistance to its hefty price tag and competition from upcoming biosimilars; and how Alexion is preparing to tackle these challenges.

$2500

Medical Affairs’ Role in Patient Engagement Activities (ID POP-280)

This benchmarking report delivers industry metrics and insights on key aspects of patient engagement programs including collaboration, activities, support, and involvement. Key benchmarks revolve around the role and responsibilities of the Medical Affairs function in different patient engagement activities like patient health outcomes, advocacy, education and medication adherence. Medical Affairs leaders can refer to this report to identify the patient engagement activities/strategies that work best for each group of stakeholders and gain insights into critical lessons learned and pitfalls.

$5800

Collaborating with Patient Advocacy Groups to Educate the Marketplace (ID PSM-330)

This benchmarking research identifies ways for bio-pharmaceutical companies to effectively collaborate and manage relationships with patient and professional advocacy groups. It also delivers benchmarks around the ideal structures and skill sets for pharma groups that deal with advocacy groups and evolving trends and challenges in patient advocacy.

$4000

Disease Awareness Program Excellence: Structure, Activities & Resources Needed for Effective Pipeline Support (ID PSM-328)

This study provides benchmarks on current disease state awareness program structure, spend, and activities that support pipeline products.

$6200

Patient Support Excellence: Structure, Activities and Resource Levels to Ensure Patient-Centric Products and Services (ID PSM-313)

This study explores the growing importance of establishing a patient centric organization and how it can positively impact patient outcomes and commercial results. It includes leading insights and metrics on current trends in Patient Support group structure, activities, alliances and resource/investment levels within the biopharmaceutical sector.

$7100

Patient-Focused Support: How Government Affairs & Public Policy Groups Support the Patient Journey (ID PSM-307)

This study captures insights on the level and type of support that Government Affairs and Public Policy functions provide to positively impact the patient journey. It includes leading insights and metrics around the activities, timing and funding contribution of Government Affairs and Public Policy groups towards patient advocacy and awareness.

$2500

Patient-Focused Marketing: Engagement Milestones Along the Patient Journey (ID PSM-306)

This study explores the growing influence of patients in the biopharmaceutical market and its impact on the activities and spends for marketing communications with patients.It also includes the current spending levels, key activities, and investment allocation patterns for marketing to and interacting with patients.

$8300

Shaping the Marketplace to Support Successful Diabetes Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers (ID SM-191)

This study explores the best practices in educating, informing and preparing the marketplace for new diabetes products – through Physician, Patient, and Payer education and publications, advocacy and communication strategies.

$7100

Best Practices in Advancing Customer Marketing: Innovations in Engaging and Communicating with Health Care Providers, Patients, Payers and KOLs (ID PSM-280)

This study identifies how companies structure, staff and organize to find, use and quickly incorporate innovative practices to improve marketing across all customer groups.

$5000

Online Patient Support Excellence: Using Brand Website Services to Grow Loyal Customers (ID PSM-258)

This study examined 10 leading biopharmaceutical products that treat chronic conditions, such as rheumatoid arthritis, osteoporosis and cancer, for which treatment is often expensive and patient education and long-term support are essential.

$3929

Advocacy Excellence: Optimizing Group Structure & Operations (ID PSM-253)

This study identifies the key trends, best practices, metrics and valuable insights into the evolution of advocacy groups. Also, the study covers areas such as group’s structure, service and staffing strategies to support its success with partners and internal customers.

$5100

Educating KOLs, Physicians, Patients and Payers to Support Successful Product Launches (ID PSM-248)

This benchmarking report was undertaken to assist launch executives at pharmaceutical, biotech and medical device companies with the most effective market education tactics and strategies for thought leaders, physicians, patients, and payers.

$8000

Collaborating with Patient Advocacy Groups to Educate the Marketplace (ID PSM-242)

This study examines ideal structures and skill sets for pharma groups that deal with advocacy groups and emerging trends and challenges in patient advocacy.

$6500

Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers (ID PSM-243)

This study will inform launch leaders on the most effective physician, payer and patient education practices conducted from clinical development through launch.

$8000

Innovations in Patient-Focused Initiatives: Case Studies in Reaching, Engaging and Supporting Patients (ID PSM-239)

As pharmaceutical, biotechnology and medical device companies seek new “go-to-market” strategies and tactics, they have explored new ways to approach and engage patient populations. This report examines the programs and initiatives aimed at directly affecting the lives and treatment of patients.

$4575

Using Institutional Patient Flow Maps to Optimize Psychiatric Treatment (ID SM-164)

This benchmarking report is designed to provide insights into the healthcare administered to psychiatric patients presenting with an episodic crisis. In particular, this report addresses issues such as communication gaps between patient and healthcare provider, patients more likely to fall through the cracks in the healthcare delivery process. Also, it looks at what decisions are made along the way and by whom and evaluates how healthcare could be improved for these critical patients.

$1892

Mapping Patient Flow to Better Manage Severe Hospital Infections and Sepsis (ID SM-165)

This report provides insights into the management of patients with severe infections, and specifically the infection response known as sepsis at six leading academic medical centers through 19 interviews with expert physicians within the disciplines of emergency care, internal medicine, infectious disease and critical care. It includes an integrated patient flow map, showing an illustrated view of patient movements through the common pathways that exist across each of the medical centers for each phase of care: Emergency Department, General Inpatient and Intensive Care Unit. This map highlights common points of decision-making and disease onset or progression.

$1891

PRODUCT LAUNCH click to expand contents

Achieving Launch Market Leadership: Resourcing the Next Generation of Blockbusters (ID PSM-393)

This benchmarking report provides comprehensive insights into pharmaceutical launch investment trends, with a focus on commercial and medical activity allocations during pre-launch and launch years. It also analyzes shifts in activity investments pre- and post-COVID, delivering actionable data on resourcing decisions by market archetype and Peak Year Sales Forecast (PYSF). Designed to support pharmaceutical and biotechnology organizations, the report offers key benchmarks and strategies to optimize launch budgets and activity timing, ensuring a competitive edge in today’s complex market environment.

$8000

Interweaving Medical Strategy to Maximize New Treatment Success: Linking Launch Strategies with Medical Operations Excellence and Competitive Resourcing Decisions (ID POP-405)

This benchmarking report explores the evolving role of Medical Affairs in new biopharma product launches. It provides insights on resource allocation, strategic development, and operational execution, with a focus on leveraging data, analytics, and digital tools for launch success. The report covers critical success factors, common challenges, and effective strategies used by leading biopharma organizations.

$4500

KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History (ID PSM-392)

This case study reveals how Merck turned a near-failure into a cornerstone of cancer treatment through extensive clinical trials, innovative marketing, strategic collaborations, and unwavering investment. Despite entering the immuno-oncology market as a second-to-market product, KEYTRUDA not only caught up with its competitors but also became a dominant force in the field. The analysis provides insights into how Merck's efforts collectively propelled KEYTRUDA to the forefront of cancer treatment, establishing it as a blockbuster drug and a cornerstone of Merck’s oncology portfolio.

$3000

Case Study: How Horizon Therapeutics Created an Ophthalmic Blockbuster in a Rare Disease Autoimmune Area for Thyroid Eye Disease (ID PSM-389)

This case study reviews Tepezza’s trajectory to achieving blockbuster status in a rare disease autoimmune area for thyroid eye disease through Horizon Therapeutics’ launch and market entry strategies and execution.

$3900

Case Study: How argenx Broke into a Captive Market to Begin Dislodging an Entrenched Market Leader (ID PSM-388)

This case study reviews VYVGART’s trajectory to breaking into the captive generalized Myasthenia Gravis (gMG) market to begin dislodging an entrenched market leader. The study probes the development, launch, and market entry strategies executed by argenx to launch VYVGART as a first step in its rare disease franchise building.

$3900

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine (ID PSM-380)

This report probes successful practices for managing hostile stakeholders during the launch of a breakthrough new medicine. Best Practices, LLC engaged front-line executives at 11 companies across 9 therapeutic areas and conducted extensive secondary research on leading brand launches to identify winning strategies to soften stigma and hostile stakeholder responses during launch.

$3800

Building More Effective Medical Affairs Product Launch Teams: Cardiology and Pulmonology Segment (ID POP-385)

This benchmarking report explores Medical’s role in cardiology and pulmonology product launches. The research probes digital tool utilization and launch tool deployment, roles and responsibilities, cross-functional alignment, and performance metrics. It further explores critical success factors for and major challenges to launch preparedness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Immunology Segment (ID POP-388)

This benchmarking report explores the critical role of Medical Affairs in launching immunology products. It analyzes the use of digital tools, role definitions, cross-functional alignment, and key performance indicators. Additionally, the report highlights success factors and major challenges impacting launch readiness.

$6000

Building More Effective Medical Affairs Product Launch Teams: CNS / Neurosciences Segment (ID POP-386)

This Best Practices, LLC report examines the role of Medical Affairs in CNS / Neurosciences product launches. The research investigates digital launch tool deployment, roles and responsibilities, cross-functional alignment, and performance metrics used to gauge success. Additionally, the report identifies key success factors and major challenges in achieving effective launch preparedness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Hematology Segment (ID POP-387)

This Best Practices, LLC report delves into the pivotal role of Medical Affairs in the launch of hematology products. It examines the deployment of digital tools, the delineation of roles and responsibilities, cross-functional collaboration, and key performance metrics. The report also identifies the success factors and significant challenges that influence launch readiness.

$6000

Building More Effective Medical Affairs Product Launch Teams: Metabolic Diseases Segment (ID POP-390)

This Best Practices, LLC report offers an in-depth analysis of how Medical Affairs can transform the launch of products for metabolic diseases. It explores the integration of digital tools, clear definition of roles, effective cross-functional collaboration, and essential performance metrics. The report also examines success factors and critical challenges that impact launch preparedness, equipping teams with actionable insights for achieving superior results.

$6000

Building More Effective Medical Affairs Product Launch Teams: Oncology Segment (ID POP-391)

This Best Practices, LLC report delves into optimizing Medical Affairs teams for successful oncology product launches. It covers the strategic use of digital tools, defines roles and responsibilities, and explores effective cross-functional collaboration. The report also highlights key success factors and common obstacles, providing actionable insights to enhance launch readiness in the competitive oncology landscape.

$6000

Building More Effective Medical Affairs Product Launch Teams: Respiratory Segment (ID POP-392)

This Best Practices, LLC report explores the vital contributions of Medical Affairs teams in launching respiratory products. It examines the implementation of digital tools, role management, and cross-departmental collaboration. The report identifies key success factors and common challenges, providing strategic guidance for optimizing launch readiness and effectively meeting patient needs in the respiratory therapeutic area.

$6000

Building More Effective Medical Affairs Product Launch Teams: Infectious Diseases Segment (ID POP-389)

This Best Practices, LLC report focuses on optimizing Medical Affairs in the context of infectious disease product launches. It provides a thorough analysis of digital tool integration, role clarity, and collaborative efforts. The report identifies key success drivers and challenges that Medical Affairs teams must navigate to ensure launch readiness in the rapidly evolving infectious diseases space.

$6000

Building More Effective Medical Affairs Product Launch Teams (ID POP-342)

This benchmarking report explores Medical Affairs’ role in product launch. The research explores roles and responsibilities, cross-functional alignment, performance metrics, resourcing, activities effectiveness, launch timeline, and digital launch tools deployment. It further explores the success factors and major challenges to Medical Affairs’ launch preparedness.

$6500

Best Practices Pharma Launch Playbook (ID PB-100)

This comprehensive Best Practices, LLC launch playbook provides the requisite insights for an effective new pharma product launch, right from the development stage to post-launch. The playbook delivers years of insights from successful launches, and showcases where exactly many of the prominent brands missed the mark - through our extensive primary benchmarking research studies and secondary research.

$79900

Disease Awareness Program Excellence: Structure, Activities, and Resources Needed for Effective Pipeline Support (ID PSM-377)

This benchmarking report highlights effective practices around the timing, investment, and activities for disease awareness programs. It delivers insights, best practices, and pitfalls that participants have learned from many of their past disease awareness campaigns.

$5500

Pharmaceutical Product Launch Evaluation Excellence: Processes and Measures to Evaluate Launch Success (ID PSM-376)

This benchmarking research was conducted by Best Practices, LLC to identify key performance measures used to evaluate launch success of pharmaceutical products. The report also reviews the role of forecasting in evaluating launch success. Additionally, the report probes the critical success factors and lessons learned in launching new pharmaceutical products.

$4500

Digital Trends in Biopharma Launch Strategy and Investment (ID PSM-375)

This benchmarking report spotlights the secondary and tertiary drivers behind the accelerated pace of using digital strategies to drive innovative biopharma launches. The report identifies the high-value digital activities, spotlights investment trends, and captures key lessons learned. It also benchmarks the tools and techniques used to get the most out of digital launches.

$3750

Pure Play Digital Launch: Launching a New Blockbuster Migraine Drug During a Global Pandemic (ID PSM-374)

This Best Practices, LLC case study probes how Biohaven used modern digital tools and technologies to successfully launch its ‘one dose’ migraine drug, Nurtec during the global COVID-19 pandemic.

$2500

Probing Best Practices for Successful Primary Care Launch & Physician Engagement (ID PSM-372)

This meta-analysis research assists biopharma launch planning in five critical areas spanning primary care targeting, launch uptake, promotion and messaging, primary care physician habits, and internal organization considerations.

$5000

Patent Protection: How AbbVie Builds Patent Fences to Extend Brand Life and Safeguard HUMIRA and Its Immunology Franchise (ID PSM-371)

Best Practices, LLC conducted extensive secondary research to review how HUMIRA used patent innovations as a source of competitive advantage to add value to its clinical assets and commercial operations. It highlights the lessons learned and winning strategies in HUMIRA’s journey to achieving blockbuster status.

$2500

Launching New Biopharma Products in Competitive Markets: Critical Success Factors and Failure Points (ID PSM-369)

This benchmarking report highlights success factors and failure points in effectively launching a new biopharma product. The report also captures benchmarks and insights around value dimensions for stakeholders, thought leader engagement and education for market entry, and risk factors.

$6750

Launching New Biopharma Products in Competitive Oncology Markets: Critical Success Factors and Failure Points (ID PSM-395)

This benchmarking report explores the critical success factors and potential failure points in launching new oncology products in today’s highly competitive and complex landscape. It delivers benchmarks and insights on stakeholder value dimensions, thought leader engagement and education for market entry, and key risk factors.

$6750

Addyi (flibanserin): How an upstart biopharma used social media and policy tools to support its NDA approval - and a $1 billion payday (ID PSM-368)

Best Practices, LLC conducted extensive secondary research of government and company information to review how Sprout Pharma used social media, active lobbying and policy levers to win approval for its controversial therapy, Addyi® (flibanserin) in female hypoactive sexual desire disorder (HSDD) category.

$2900

Strategic Portfolio Planning for Successful New Product and Drug Platform Positioning (ID PSM-365)

Best Practices, LLC conducted “meta-analysis” of 22 of its primary and secondary benchmark studies to inform how drug platforms give rise to tech / MOA-enabled product portfolios and market leading franchises. This report also includes case studies of new product planning and market entry of many successful brands. It spotlights winning strategies, best practices and pitfalls to avoid for successful positioning of new products and drug platforms.

$7500

COVID-19 Challenges for Product Launch Timelines and Activities (ID CM-3)

This benchmarking report explores how leading pharmaceutical and medical device companies are taking timeline decisions for their 2020 and Q1, 2021 product launches. It also probes the impact of COVID-19 across core commercial and medical pre-launch and launch activities. Additionally, it examines the launch staffing and investment adjustments made by organizations in response to COVID-19.

$995

Winning Necessary Resources for a Successful Product Launch (ID PSM-363)

Best Practices, LLC undertook benchmarking research to help biopharma leaders develop competitive launch and pre-launch activity budgets to ensure successful U.S. market entry for new products. Data in this report will support brand and marketing leaders in developing optimal total resourcing plans and fund allocations for their new brands based on Peak Year Sales Forecast, Market Archetype, Product Types, and Physician Types. This report also highlights the top success factors for effective product launches.

$10000

CAR-T & Cell Therapy Products: Next generation of oncology products create chance for boom or bust (ID PSM-362)

Best Practices, LLC conducted this extensive research project to examine the genesis, launch and market struggles of the first generation of chimeric antigen receptor T-cell (CAR-T) therapies - Novartis' Kymriah and Gilead's Yescarta - both based around using a patient's own re-engineered T-cells to attack their cancer. This report pulls together multiple sources of information across key issues affecting CAR-T development and launch to give new product development leaders and executives insights into the potential and challenges facing CAR-T development and launch.

$2500

What it Takes to Successfully Launch an Oncology Product in the U.S. Marketplace (ID PSM-341)

This comprehensive report is designed to inform oncology launch teams with critical investment, staffing and timing benchmarks required for a successful oncology product launch in the United States. This benchmarking report probes oncology product investment levels for 12 companies and 20 U.S. project launches across pre-launch, launch and post-launch periods. It includes staffing and budget benchmarks across key commercial and medical activities for various market-entry situations or market-entry archetypes: portfolios featuring multiple molecules which treat single or multiple indications, and portfolios using single molecules to treat individual cancer types. Also, this report outlines significant U.S. oncology market-entry trends and success factors and probes the synergy or franchise effects where multiple oncology products and indications create lift through shared infrastructure.

$10000

Growing Biopharma Digital Marketing Impact: Digitizing Launch, Developing Talent and Optimizing Service Alignment (ID PSM-334)

This research identifies the critical drivers of digital marketing performance excellence in the healthcare industry. It probes how savvy biopharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs, and optimizing insource vs. outsource mix.

$4450

Pharmaceutical New Product Planning Excellence: Structure & Activities that Drive Profitability & Growth (ID PSM-333)

This study was undertaken to examine the role and impact of New Product Planning function on pharma product commercialization. In particular, it delivers benchmarks on the structure, resources and activities of New Product Planning groups.

$8000

Medical Affairs Launch Excellence: Medical Affairs Role at Launch in Medical Device Companies (ID POP-274)

This study identifies the critical success factors for an effective medical affairs launch support, as well as highlights strategies for successful thought leader targeting and communication. Medical Affairs leaders at medical device companies can utilize this study to develop successful launch strategies.

$3900

Disease Awareness Program Excellence: Structure, Activities & Resources Needed for Effective Pipeline Support (ID PSM-328)

This study provides benchmarks on current disease state awareness program structure, spend, and activities that support pipeline products.

$6200

Launching A Specialty-Care Blockbuster Franchise in Hepatitis C: How Sovaldi & Harvoni Rewrote New Product Launch History (ID PSM-322)

This study reviews key aspects of Sovaldi’s launch, including prevalence of Hep C, Sovaldi’s method of action, key aspects of its product launch, results of launch, payers’ reaction to pricing, Gilead’s response to pricing criticism, patent challenges and the entrance of Harvoni.

$2500

Benchmarking Advisory Board Management At Large Pharmaceutical & Medical Device Organizations (ID PSM-319)

This study is designed to assist executives at large pharmaceutical and medical device organizations in identifying ways to best utilize the knowledge of advisory boards. It provides leading insights on the appropriate structure for different advisory boards, selection of advisory board participants, operational and cost benchmarks, top challenges and best practices for conducting advisory boards.

$4400

Optimizing Global Brand Website Launches (ID PSM-297)

Best Practices, LLC published this benchmarking report to highlight current and evolving approaches to brand website development and optimization used by leading pharmaceutical companies as part of their global launch. Also, the report delivers benchmarks on the important success factors for understanding and engaging key stakeholders, particularly physicians.

$1985

Best Practices in Launch Optimization: How Promotional Efficiency can be Leveraged to Support Multiple Products & Indications (ID PSM-293)

This study identifies evidence-based benchmarks on the pros and cons of managing multiple products via a franchise approach. The study focused on uncovering proven tactics for efficiently deploying Sales and Marketing resources to reduce the costliness of launching and promoting multiple products simultaneously.

$5260

Success Factors and Failure Points in Oncology Product Launches (ID PSM-267)

This study explores each aspect of this framework for launch success and provides an oncology segment as well as a data segment representing other therapeutic areas combined. This comprehensive launch study delivers qualitative and quantitative data on differentiation, pricing, physician and thought leader education, payer and formulary access, launch readiness, resource allocation and much more.

$8500

Educating the Market to Support Successful Product Launches in Oncology (ID SM-190)

This study explores the best practices in educating, informing and preparing the marketplace for new oncology products – through Physician, Patient, and Payer education and publications, advocacy and communication strategies.

$6800

Success Factors and Failure Points in Cardiovascular Product Launches (ID PSM-264)

This study presents launch leaders' perspective on the current and future risk levels for an array of pitfall factors that can affect a launch, from patient and payer to physician and regulatory.

$8500

Success Factors and Failure Points in Metabolic Product Launches (ID PSM-266)

This study explores each aspect of this framework for launch success and provides a metabolic/diabetes segment as well as a data segment representing other therapeutic areas combined. In addition, the study presents launch leaders' perspective on the current and future risk levels for an array of pitfall factors that can affect a launch, from patient and payer to physician and regulatory.

$8500

Success Factors and Failure Points in Biopharmaceutical Product Launches: An Updated Road Map for Strong Market Entry (ID PSM-261)

This study presents launch leaders' perspective on the current and future risk levels for an array of pitfall factors that can affect a launch, from patient and payer to physician and regulatory.

$8500

Educating KOLs, Physicians, Patients and Payers to Support Successful Product Launches (ID PSM-248)

This benchmarking report was undertaken to assist launch executives at pharmaceutical, biotech and medical device companies with the most effective market education tactics and strategies for thought leaders, physicians, patients, and payers.

$8000

Educating the Marketplace to Support Successful Diabetes Product Launches (ID PSM-246)

This study will inform launch leaders on the most effective physician, payer and patient education practices conducted from clinical development through launch.

$8000

Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers (ID PSM-243)

This study will inform launch leaders on the most effective physician, payer and patient education practices conducted from clinical development through launch.

$8000

Public Relations Excellence: Using PR to Launch, Grow and Extend Your Brands (ID PSM-231)

This study identifies what Public Relations activities are most effective at educating and informing consumers at different points in a product's lifecycle. The study also delivers insights into what Public Relations channels, tactics and calls-to-action are most effective for reaching consumers of pharmaceutical products. Three case studies of successful products are included in the study to highlight Public Relations tactics at different lifecycle stages.

$8000

Product Re-Launch Excellence: Transforming Lackluster Pharmaceutical Products Into Market Success Stories (ID SM-170)

This report probed best practices and lessons learned in successful product re-launches. It also includes two highly successful re-launch case studies: the history and lessons learned from Zithromax and Wellbutrin – two blockbuster products that nearly failed in the marketplace during their initial launches. This report serves as a guide to achieve an excellent product re-launch.

$4651

Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters (ID SM-124)

The findings in this study reveal the winning strategies, practices, team structures and investment patterns that distinguish successful new products. Additionally, the report includes case studies detailing the successful launches of 16 blockbuster products.

$7962

Driving Growth through New Product Planning and Strategic Alliances (ID SM-135)

Drive overall growth through a well-managed portfolio by addressing current and long-term needs in your company’s new product planning and strategic alliance systems.

$5622

QUALITY, COMPLIANCE AND REGULATORY click to expand contents

Navigating the Challenges and Costs of the New European Union Medical Device Regulation (EUMDR) (ID POP-345)

This benchmarking report probes the real-world costs and challenges that companies are experiencing during the transition from Medical Device Directive (MDD)/Active Implantable Medical Devices to new requirements in Medical Device Reporting (MDR). This report provides segment perspectives on product class types and company size.

$3750

Establishing a Promotion Review Editor to Oversee Advertising and Promotion Review Process (ID PSM-373)

This benchmarking report examines the utilization of the Promotion Review Editor role within biopharmaceutical companies. It probes the collaboration approaches, roles and responsibilities, importance and effectiveness of Promotion Review Editor within the company, involvement of Promotion Review Editors in electronic submissions and review process of promotional materials, functional location and reporting of Promotion Review Editors, and number of products supported by them. The report also highlights the best practices and challenges of having the Promotion Review Editor position in a company.

$2000

Patent Protection: How AbbVie Builds Patent Fences to Extend Brand Life and Safeguard HUMIRA and Its Immunology Franchise (ID PSM-371)

Best Practices, LLC conducted extensive secondary research to review how HUMIRA used patent innovations as a source of competitive advantage to add value to its clinical assets and commercial operations. It highlights the lessons learned and winning strategies in HUMIRA’s journey to achieving blockbuster status.

$2500

Developing Superior Global Quality, Regulatory, and Global-Trade Compliance Operations (ID POP-328)

This benchmarking report probes how leading pharmaceutical and medical device companies are improving the effectiveness of their Global Quality, Regulatory, and Trade Compliance functions to support their service and product portfolio. It benchmarks the structure, staffing, budget, process, development & design, and service levels of Global Quality, Regulatory, and Trade Compliance functions.

$6200

Overcoming Medical Device Resource & Competitive Demands in Quality Assurance, Regulatory Affairs and Post Market Surveillance (ID POP-299)

This benchmarking report establishes a broad range of operations and resource benchmarks for the Quality Assurance, Regulatory Affairs, and Post-Market Surveillance functions at medical device firms. It also highlights the number of CAPAs, NCEs, field actions, change requests, and complaints that medical device companies experience.

$3990

Best Practices in Postmarketing Surveillance and Complaint Resolution Management at Medical Device Firms (ID PCS-213)

This benchmarking report highlights the winning strategies used by top medical device companies to collect valuable insights from customer feedback and drive business improvements in the global marketplace, specifically the United States, European Union, Australia and Japan by streamlining their postmarketing surveillance and resolution systems.

$4800

Benchmarking Quality in the Biopharmaceutical & Medical Device Sector (ID POP-287)

This benchmarking report probes how Quality organizations can move beyond simply ensuring product safety and compliance and create enterprise value. Specifically, it establishes benchmarks around integrating quality into the organization’s strategic focus and priorities; structure of Quality groups; utilization of digital technology; management of quality for GLP, GCP, GMP and pharmacovigilance. It also delivers benchmarks around Quality staffing and spend levels; supplier management; audit and risk assessment; CAPA; and outsourcing.

$10000

Benchmarking Regulatory Affairs Staffing & Performance Excellence in Medical Devices (ID POP-272)

This study establishes benchmarks around performance levels, approaches and boundaries - as well as captures leading insights about high-performance in the Regulatory Affairs function at medical device companies. In particular, it identifies critical performance indicators for regulatory budget, staffing, submissions trends, management factors, critical regulatory roles, responsibilities and off-shoring/outsourcing trends. Also, it identifies current and future trends shaping the Medical Device Regulatory Affairs function.

$6800

REMS Excellence: Models & Trends in Supporting REMS Program Success (ID POP-270)

This study was conducted to identify how biopharmaceutical and medical device companies implement successful REMS plans for newly-approved products in the U.S. market. It provides insights around the structure and responsibilities of REMS teams, use of internal and external resources to support REMS programs, physician/ distributor compliance on ETASU, current challenges in REMS communication plans and innovative REMS approaches for new products.

$3000

Benchmarking BioPharma Quality and CAPA Processes (ID POP-261)

This study is designed to assist biopharmaceutical companies in achieving top-tier performance in three important areas critical to Quality: CAPA Process Management, CAPA Performance Benchmarks and Quality Resource Management. Research findings will serve as a benchmark for Quality leaders in building a strong CAPA system and thereby developing a robust quality function, within tight budgets.

$6200

Benchmarking Medical Device Quality 2014-15: Managing Cost While Ensuring Quality & Safety (ID POP-257)

This study seeks to explore how leading medical device companies are defining and allocating Quality spend, identifying factors that impact spending levels, and investing in future mission-critical Quality activities. Research findings provide evidence-based benchmarks for Quality spending, staffing, change request levels, outsourcing, software quality, inspections, lab testing, complaint management, trend insights and more.

$7500

Patient-Focused Support: How Government Affairs & Public Policy Groups Support the Patient Journey (ID PSM-307)

This study captures insights on the level and type of support that Government Affairs and Public Policy functions provide to positively impact the patient journey. It includes leading insights and metrics around the activities, timing and funding contribution of Government Affairs and Public Policy groups towards patient advocacy and awareness.

$2500

Benchmarking Quality: How Medical Device & Diagnostics Companies Manage Cost Effectiveness while Ensuring Quality & Safety (ID POP-247)

This study delivers comprehensive survey benchmarks on how medical device companies are defining and allocating Quality spend, identifying factors that impact spending levels, and investing in future mission-critical Quality activities.

$5675

Managing Healthcare Reform: Winning Strategies for Engaging the Government Ecosystem That Shapes Healthcare Policy (ID POP-246)

This study identifies current trends and future directions in structure, staffing, collaboration, resource allocations, and most-valued group activities across the biopharmaceutical and medical device sector. Also, the study examines performance excellence by probing how diverse groups such as Government Affairs, Policy, Managed Markets Marketing and other relevant stakeholders are staffed and organized to influence public policy and regulatory issues, particularly those flowing from CMS and other entities in the public sector healthcare system.

$6500

Risk Mitigation Excellence: Innovative Models & Trends in Supporting REMS & RMP Programs (ID POP-242)

This study examines how leading organizations build and execute successful Risk Evaluation & Mitigation Strategy (REMS) programs for products in the U.S. marketplace. The study also provides key insights into how market research groups support high-performing REMS teams, while highlighting collaboration opportunities with Risk Management Plan (RMP) teams working on European products.

$4450

Regulatory Affairs Excellence: Staffing & Performance in Medical Device Companies (ID POP-240)

This study establishes meaningful metrics and insights around the structure, activities, roles and responsibilities of Regulatory Affairs groups at medical device companies. The study also provides recent spend and staffing trends of regulatory affairs in medical device sector, including the use of outsourcing and off-shoring.

$6500

Corporate Affairs Excellence: Optimizing Group Structure & Operations (ID PSM-251)

This study help executives better understand the corporate affairs services and identify key benchmarks in corporate affairs structures and operations.

$3000

Government Affairs & Public Policy Excellence: Optimizing Group Structure & Operations (ID PSM-252)

This study will help executives’ government affairs functions to better support the entire business operation.

$5600

Best Practices for Post-Marketing Surveillance of Adverse Events within the U.S. (ID POP-230)

This study examines the best practices for post-marketing surveillance within the United States, as well as the processes for assessing reports of adverse events, follow-up activities and compliance training.

$2895

Building an Effective Regulatory Relationship with the FDA (ID OP-104)

This study delivers benchmarks and insights that identify approaches for understanding and effectively interacting with the FDA. The study also includes insights gleaned from interviews with 13 Regulatory executives who boast extensive experience with NDAs and the FDA.

$7000

Best Practices for Valuing Internal Consulting Organizations (ID POP-227)

This study identifies the practices that internal consulting groups can use effectively to measure their performance and to communicate their value to senior leadership.

$3700

Integrating Quality into Business Systems for High Performance (ID OP-103)

This benchmarking report offers practices, operational methods and performance metrics from over 30 quality organizations that have successfully integrated their quality function into day-to-day business operations drastically contributing to their bottom line efficiencies.

$4725

SALES LEADERSHIP click to expand contents

Developing the Best Hybrid Work Model for Your Commercial Biopharma Organization (ID PSM-387)

This benchmarking report examines the changing forms, features, conditions, and triggers for hybrid work models that are best suited for a flexible and resilient Commercial organization.

$3900

Best Practices for Managing Biopharma Sales Compensation During the COVID-19 Pandemic and Beyond (ID CM-8)

This benchmarking research explores how leading biopharma companies are refining their sales compensation and reward programs to ensure their sales force remains productive, motivated, and committed during and post the COVID-19 pandemic. It examines the changes in sales compensation and incentives, adjustments in staffing levels, and effective performance measurement metrics during the COVID-19 pandemic. This report also highlights the anticipated short-term and long-term challenges, and lessons learned around managing sales compensation and incentives plans during the COVID-19 pandemic.

$995

Factors That Drive Results for Biopharmaceutical Sales Training Programs (ID PSM-355)

This benchmarking report examines successful technologies, delivery approaches, performance measurement processes, resource levels, organizational structures and training venues that drive effectiveness in high-performing sales training departments within pharmaceutical and biotech companies.

$5000

Medical Device Sales Excellence: Training Field Professionals to Deliver Value-Based Solutions to Today’s Customers (ID PSM-344)

This benchmarking report is designed to help medical device sales leaders improve field sales performance through the use of a “value selling” approach. It examines the sales models, strategies, training approaches and key skill sets requisite for field sales representatives to succeed in selling valuable solutions across complex medical device product portfolios. This report will serve as a reference for sales leaders to benchmark their field sales performance against those of other leading medical device companies.

$5400

Assessing the Use of CSOs vs. Internal Hires (ID PSM-336)

This study evaluates the effectiveness of using Contract Sales Organizations (CSOs) vs. internal hires in various market conditions. It provides insights around the advantages and disadvantages of using CSOs, CSO competencies vs. internal hire competencies, and CSO vs. internal hire investment and team structure.

$2800

New & Effective Front-Line Management Training Practices to Optimize Performance & Grow Accountability at Launch (ID PSM-329)

This study identifies benchmarks around the ideal sales force training amount, optimal time to provide sales force launch training, assessment of different training platforms and measurement of district sales manager accountability.

$5400

Deploying the iPad or Android-Based Tablet to Sales and Managed Markets Teams: Benchmarking Training and Effectiveness (Updated 2014) (ID PSM-290)

This study identifies the best practices for deploying and measuring the effectiveness of the iPad as an innovative sales tool..

$5800

Pharmaceutical Sales Training Excellence: Tools, Processes & Resources That Drive Effectiveness (ID PSM-292)

This study identifies successful training venues, technologies, organizational structures, delivery approaches, performance measurement processes, and resource levels that drive effectiveness in high-performing Sales Training organizations..

$6075

Trends and Future Directions for the High Performing District Sales Manager: A Comparative View from 2007 and 2009 (ID PSM-247)

This study can help executives define the most important current and future roles of the district sales manager to drive superior sales productivity and growth.

$6500

The High Performing Pharmaceutical District Sales Manager: Current Trends & Future Directions (ID SM-178)

This report highlights the most important current and future roles of the DM in driving superior productivity and continued growth for their companies and also identifies the key trends impacting the DM function, examines the extent of change in current sales force models, investigates DM readiness for change and provides best practices companies are using to help DMs retain their effectiveness in the new marketplace.

$7895

U.S. Sales Communications Excellence: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications (ID PSM-225)

This report identifies the U.S. pharmaceutical sales communications groups impact and effectiveness and also highlights their thinking about the resources, skill-sets and tools needed for their communications group, and what practices and procedures can be used to maximize the impact (and minimize the time taken) on salespeople.

$2495

Rewarding & Recognizing Top-Sales People (ID PSM-224)

This report highlights the key benchmark metrics and executive insights to assess current trends and future directions of rewards and recognition programs targeting top-performing sales representatives.

$5995

Pharmaceutical Sales Training: Turning New Hires into Top Performers (ID SM-171)

The findings in this study provides a comprehensive look at sales training delivery, content, budgets and trends at leading pharmaceutical companies across the globe. Based on the perspectives of 24 sales training leaders at a diverse group of 19 pharmaceutical, biotechnology and medical device companies.

$4854

Increasing Sales Productivity Through Superior Performance Management (ID PSM-200)

This benchmarking report explores how leading pharmaceutical companies structure and deploy their global sales forces and measure the performance of their sales representatives to best increase sales productivity.

$1891

National Sales Director’s Roles & Responsibilities (ID PSM-206)

This benchmarking report highlights how nine pharmaceutical companies developed effective roles and responsibilities for their national sales directors to empower them to drive organizational growth.

$795

Coordinating People, Resources and Activities for Sales Team Effectiveness (ID PSM-209)

This report delivers benchmarks around the critical areas of sales team coordination and improvement. It will serve as a reference for pharmaceutical companies in coordinating people, resources and activities for superior sales team effectiveness.

$750

District Manager Performance Management: Recruiting, Career Path & Succession Planning (ID PSM-207)

This benchmarking report highlights the winning strategies used by top pharmaceutical companies to hire and manage district sales managers effectively. In particular, the report provides benchmarks around selecting and retaining the best managers, preparing sales managers for leadership, developing and training leaders, and managing the district manager's performance through both individual and corporate measurement.

$1798

Targeting Pharmaceutical Customers through Market Segmentation (ID SM-128)

This Best Practices, LLC report focused on market segmentation was undertaken to support the goal of developing world-class marketing capabilities that will drive demand and market growth. Insights in this report will enable companies to identify, review, evaluate and adapt the most effective and innovative segmentation strategies and practices implemented by other leading pharmaceutical companies.

$1654

Pharmaceutical Speaker Programs: Building the Business (ID SM-130)

Help sales reps develop strong, rewarding relationships through effective speaker program management. Impact doctor-rep relationships to build customer loyalty and drive market share.

$4219

BENCHMARKING REPORTS CATALOG

TABLE OF CONTENTS

Select All -- Deselect All

Select All -- Deselect All

Select All -- Deselect All

loading